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Abstract
The immunopathology of multiple sclerosis (MS), a disease of the central 
nervous system (CNS), is characterised by widespread inflammation, focal 
demyelination and axonal degeneration. As a result of early disturbances in the blood 
brain barrier (BBB), serum proteins, including fibrin(ogen) enter into the CNS. Up- 
regulation of components of the plasminogen activator (fibrinolytic) system correlates 
with onset of inflammation and migration of leucocytes into the brain parenchyma.
Significant upregulation of plasminogen and plasminogen activator inhibitor-1 
(PAI-1), and an accumulation of fibrin D-dimer was found during neuroinflammation, 
in the established mouse model of MS, chronic relapsing experimental allergic 
encephalomyelitis (CREAE) induced with spinal cord homogenate (SCH). Onset and 
progression of disease correlated with a reduction in dendritic markers, supporting 
evidence of early neuronal/axonal dysfunction. Furthermore an impairment of 
fibrinolysis in these mice ensured that fibrin entering the CNS was not effectively 
removed, suggesting a role for the PA system in the pathogenesis of CREAE.
Initially, using mice deficient in tissue-type plasminogen activator (tPA'A) and 
myelin oligodendrocyte glycoprotein (MOG)-induced EAE, animals displayed an early 
and a more severe acute disease characterised by incomplete recovery when compared 
to wild-type controls, with significantly higher CNS levels of PAI-1. This correlated 
with fibrin accumulation, which co-localised with non-phosphorylated neurofilament on 
thickened axons in EAE tissue. In contrast, urokinase plasminogen activator receptor 
knockout mice (uPAR_/) had a delayed, less acute disease reflected in delayed 
infiltration of inflammatory cells. However, these animals developed chronic disease as 
a result of steadily increasing inflammation, high levels of urokinase-type plasminogen 
activator (uPA) and greater degree of demyelination. Due to low rates of EAE 
susceptibility, mice deficient for PAI-1 were backcrossed onto the ABH strain for 4
generations. Induction of SCH-CREAE in PAI-1'7' mice resulted in a lower incidence 
of disease, with mice developing clinical signs of EAE significantly later than WT 
littermates. A delay in cellular entry into the CNS accompanied by a higher capacity for 
fibrinolysis resulted in a milder disease in PAI-1'7' mice with no clinical relapses and 
less axonal damage.
Thus, the plasminogen activator system can modulate both inflammatoiy and 
degenerative events in the CNS through the respective effects of tPA, PAI-1 and uPAR 
on fibrinolysis and cell adhesion/migration, manipulation of which may be of 
therapeutic importance in multiple sclerosis.
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1. Introduction.
1.1. Thesis introduction.
Serine proteases have a central role in the pathogenesis of multiple sclerosis 
(MS), both in the neuroinflammatory process and in demyelination. As a result of 
disturbances in the blood-brain barrier (BBB), serum proteins such as fibrin, together 
with leucocytes, enter the central nervous system (CNS) with resultant upregulation of 
the plasminogen activator (PA) cascade as one of the earliest pathological signs. 
Concentrations of free active tissue plasminogen activator (tPA), the key fibrinolytic 
enzyme, associated with a significant increase in its inhibitor PAI-1, ensure that fibrin 
entering the CNS is not efficiently removed. The proteolytic activity of urokinase PA 
(uPA), dependent on binding with its receptor uPAR, is involved in the migration and 
adhesion of inflammatory cells. Further investigation into the role and effects of the 
plasminogen activator system during inflammatory demyelination could lead to the 
development of more effective therapies, the need for which is great in patients with 
MS.
1.2. Multiple Sclerosis; an overview.
MS is thought to be an autoimmune disease of the CNS characterised by 
widespread inflammation, focal demyelination and a varying degree of axonal loss 
(Conlon et al., 1999). MS affects approximately 2.5 million people world wide, in 
countries of Caucasian prevalence. The disease onset usually occurs in young 
adulthood, ages 29-33, affecting twice as many women as men (Steinman, 1996). In the 
majority of cases, MS begins with a relapsing-remitting (RR) course. The time between 
the relapses can vary greatly however most patients will go on to develop a secondary 
progressive (SP) phase where the number of relapses decreases but a persistent 
accumulation of neurological deficits over time leads to an increase in disability 
(Bjartmar and Trapp, 2001). In approximately 10% of patients, MS begins with a
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primary progressive (PP) phase (Zamvil and Steinman, 2003) which, like SPMS, is 
characterised by less inflammation but acute neurodegeneration. Much research has 
been carried out into the genetics, immunology and neurobiology of MS in an attempt to 
uncover the mechanisms that underlie the disease cause, susceptibility, onset and 
progression.
1.2.1. Genetics and epidemiology.
There is a genetic association with MS as the concordance rate for disease 
among genetically identical twins is approximately 25% (Conlon et al., 1999). This 
observation prompted a large number of linkage studies to identity disease associated 
alleles (GAMES and Transatlantic Multiple Sclerosis Genetics Cooperative, 2003; 
Kellar-Wood et al., 1995). To date there is one key region of the genome that has been 
consistently shown to contain a gene conferring susceptibility to MS. This is the region 
of the major histocompatibility complex (MHC) located on chromosome 6, which 
contains the human leucocyte antigen (HLA) genes (Compston et al., 1998). The MHC 
gene products are involved in the processing and presentation of antigenic peptides to 
T-cells. However genetics are not solely responsible for the development of MS (Wilier 
et al., 2003). Environmental factors are also proposed to play a role as MS affects 
people predominantly in geographically restricted areas such as the northern hemisphere 
and it is a disease particularly of the western world. Studies have revealed that 
migration from a high risk to a low risk area before adolescence can reduce the risk of 
developing MS (Gale and Martyn, 1995). Although the cause of MS is still unknown, it 
is likely to be a number of factors, both genetic and environmental, which when 
combined act synergistically towards the manifestations and progression of MS 
(Hemmer et al, 2002).
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1.2.2. Diagnosis of MS.
The symptoms of MS are notoriously variable but in general reflect the 
involvement of those parts of the CNS that are demyelinated (Compston et al, 1998). 
The most common presenting symptoms include weakness of one or more limbs, optic 
neuritis, paraesthesiae, diplopia, vertigo and disturbance of micturition (Compston and 
Coles, 2002). There are many additional symptoms of MS that have been documented; 
however problems arise with diagnosis due to the overlapping nature of many of these 
signs with other primary, neurological and systemic autoimmune diseases. The disease 
usually manifests itself in either two or more episodes each lasting more than 24h and at 
least one month apart or as a stepwise progression over a minimum of six months 
(Compston et al, 1998). Oligoclonal immunoglobulin G bands in the CSF are found in 
>95% of patients with clinically definite MS (Andersson et al, 1994) and the absence 
of these bands in a patient with suspected MS should lead to a careful reassessment of 
the diagnosis (Compston and Coles, 2002). The introduction of magnetic resonance 
imaging (MRI) in the 1980’s (Young et al, 1981) has greatly improved the diagnosis of 
MS. MRI is a highly sensitive technique which can detect changes in the white matter 
with respect to the identification of the development of lesions in space and time. 
However MRI also aids detection of CNS abnormalities and changes associated with 
many other disorders, many of which have similarities with the MRI of MS patients. 
Thus MRI can be used as a tool to confirm the diagnosis of MS, which is supported by 
other clinical and laboratory investigations. Once a diagnosis is confirmed, a decision is 
made on how to manage and possibly treat the MS patient.
1.2.3. Pathology of MS.
Early studies on the macroscopic pathology of MS were carried out by Carswell 
and Cruveilhier in the mid 19th century (Compston et al, 1998), however Jean Martin
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Charcot, in the late 19th century, gathered together many clinical and pathological 
observations and identified the destruction of myelin sheaths as the key pathological 
feature of MS (Compston et al, 1998). Today the pathology of MS is well documented. 
On a macroscopic level, plaques or lesions are seen in the white matter of the brain and 
spinal cord of MS patients. These lesions tend to occur around blood vessels and 
correspond to areas of focal myelin destruction or demyelination (Conlon et al., 1999). 
Microscopically there is complete loss of the myelin sheaths surrounding axons in the 
lesion and infiltration of inflammatory lymphocytes and macrophages (Adams, 1989). 
Characteristic of demyelinating lesions is the presence of macrophages and activated 
microglial containing lipid filled vesicles of myelin debris followed by the development 
of a dense astrocytic scar (Adams, 1989); lesions are sharply demarcated with evident 
inflammation and relative axonal preservation. Also observed are shadow plaques, 
areas of previously demyelinated white matter which are spontaneously partially 
remyelinated by oligodendrocytes, the specialised myelinating cells of the CNS 
(Compston et al., 1998). However with PP or SPMS, inflammation becomes less 
evident and axonal degeneration more apparent (Lassmann, 1998). There is a great deal 
of heterogeneity of multiple sclerosis lesions, suggesting that MS may be a disease with 
heterogeneous pathogenetic mechanisms. A detailed pathological study of MS lesions 
by Lucchinetti et al., (2000) assessed extent of demyelination, plaque geography and 
extension, oligodendrocyte destruction and evidence of complement activation and 
found that most lesions can be categorised into two large groups. One in which lesions 
are of a typical nature, with a high number of inflammatory cells including macrophages 
and microglia (Li et al., 1993), and the other in which lesions have features of primary 
oligodendrocyte loss rather than of autoimmunity. Furthermore, recent findings of 
widespread oligodendrocyte apoptosis in the absence of a clear cellular immune 
response (Barnett and Prineas, 2004) suggest a mechanism of pathogenesis that has not
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yet been fully explored. Oligodendrocyte apoptosis as a result of a viral infection or 
excitotoxicity could contribute to the inflammatory response in MS.
1.2.4. Current treatment of MS.
Although the pathogenesis of MS is not yet fully understood, the evidence that 
immunological mechanisms are involved has prompted the development of 
immunological therapies acting on the inflammatory stages of disease. Drug treatments 
which alter the duration and frequency of relapse in MS include oral and intravenous 
(i.v.) steroids, Interferon beta (IFN-(3), Glatiramer acetate and mitoxantrone (Compston 
and Coles, 2002). These therapies are more beneficial in patients with relapsing 
remitting MS rather than in progressive MS as they act on the inflammatory elements of 
disease. The therapeutic mechanism of IFN-p is unknown (Amason et al, 1997). It has 
an anti-inflammatory action, reduces evidence of BBB dysfunction and is thought to act 
by restoring suppressor T cell functioning and also by inhibiting the release of the pro- 
inflammatory cytokines; lymphotoxin, TNF and IFN-y, which are all cytotoxic to 
oligodendrocytes (Amason et al, 1997). Glatiramer acetate, a synthetic mixture of four 
amino acid copolymers ranging from 40 to 90 amino acids in length, was originally 
synthesised to evoke a model of MS in animals, as it resembles the structure of myelin 
basic protein (Dhib-Jalbut, 2003). However it was actually found to have anti­
inflammatory properties and in addition to actions on the immune system, Glatiramer 
acetate is also neuroprotective (Gilgun-Sherki et al, 2003a). Mitoxantrone suppresses 
T and B cell immunity by intercalating with DNA and inhibiting DNA and RNA 
synthesis, thus preventing cell replication and inducing immunosuppression (Compston 
et al, 1998). More recently two humanised antibodies, Natalizumab and Campath-IH, 
which target the antigens 0C4 integrins and CD52 respectively, have been in clinical trials 
for the treatment of MS. These surface antigens have a central role in lymphocyte
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adhesion and migration mto the CNS, and in MS patients both antibodies reduce 
relapses and formation of new lesions (Coles et al., 2005; Miller et al., 2003). 
However, natalizumab has now been withdrawn after three cases of progressive 
multifocal leukoencephalopathy in MS patients taking the drug (Engelhardt and 
Ransohoff, 2005). Additionally, campath-lH causes prolonged immunosupression, and 
in patients with SPMS failed to prevent sustained accumulation of disability attributable 
to ongoing axonal loss (Coles et al, 2005).
No existing therapy is ideal and although all these drugs have some beneficial 
actions, there are still a large number of MS patients who don’t respond to these 
treatments and/or whose disease is too advanced. Furthermore, despite inhibition of 
new MRI lesion formation and inhibition of relapses, secondary progressive disease 
continues. With the increasing recognition of MS as a neurodegenerative disorder 
future therapies are likely to focus on neuroprotection in addition to anti-inflammatory 
strategies.
1.3. Myelin and autoimmunity.
Although the autoimmune nature of MS has not yet been proven, the importance 
of immunopathological events is extensively documented (Hemmer et al., 2002; 
Lassmann, 1998; Neumann et al., 2002). The presence of blood-derived myelin 
specific T cells, and B cells that secrete antibodies to myelin components in MS lesions 
(Martino et al., 2002), may contribute to the autoimmune hypothesis, although these are 
also found in normal individuals (Steinman, 1996). Although the primary event leading 
to the manifestation of MS is still unknown, a pro-inflammatory environment leads to 
an antigen driven immune response whereby CNS antigens are released (Hemmer et al., 
2002). The main candidate CNS autoantigens are thought to be myelin proteins 
(Zamvil and Steinman, 2003). The myelin sheath is a lipid rich multilamellar
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membrane, which both inculates and enhances conduction in nerve axons (Cuzner and 
Norton, 1996). It is synthesised by specialised myelinating glial cells called 
oligodendrocytes. Myelin is composed of many proteins, the main ones proteolipid 
protein (PLP) and myelin basic protein (MBP), and smaller proteins including myelin 
oligodendrocyte glycoprotein (MOG), are highly susceptible to proteolytic activity and 
are exceptionally encephalitogenic (Cuzner and Norton, 1996). T-lymphocytes with 
receptors for CNS myelin components recognise their antigen presented by the MHC on 
antigen presenting cells, notably dendritic cells, and enter tissues, including the brain in 
search of their target antigen. Additionally, in the complete collection of proteins 
extracted from MS-affected myelin, there was one protein that appeared to be a 
dominant antigen for CD4+ T cells, which was a small heat-shock protein, called aB- 
crystallin (van Noort et al, 1995). aB-crystallin is present at enhanced levels in the 
cytosol of oligodendrocytes and astrocytes in MS lesions, and increased expression is 
closely correlate with immunological activity of the lesion (Bajramovic et al, 1997). 
Thus aB-crystallin is a potential autoantigen in MS.
Entry of T cells into the brain is an active process requiring the breakdown of 
BBB components, the surrounding extracellular matrix (ECM) (Owens, 2003) and 
endothelial cell remodelling (Etienne-Manneville et al, 2000). On re-encountering 
their antigen, T-cells can activate and undergo further clonal expansion thus targeting 
local cells and triggering an inflammatory cascade (Compston et al, 1998). One 
hypothesis states that MS is a disease which is initially targeted against one myelin 
antigen (Lehmann et al, 1992). T cells specific for the antigen are activated upon 
recognition of the antigenic peptides presented on MHC class II and release cytokines to 
recruit non-specific circulating lymphocytes, microglia and astrocytes. As the disease 
progresses and demyelination occurs, new myelin epitopes are thought to appear, which 
recruit more T cells, leading to an exacerbation of inflammation (Figure 1.1). This is
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known as the Epitope spread theory by which “diversification of epitope specificity 
from the initial focused, dominant epitope-specific immune response spreads to 
subdominant (cryptic) epitopes on that protein” (Vanderlugt and Miller, 2002). Another 
hypothesis describing possible mechanisms of the pathogenesis of MS is the molecular 
mimicry theory. This postulates that there is an infectious aspect involved which 
triggers the autoimmune response leading to MS. This is based on structural similarities 
in protein sequence between infectious pathogens and self-antigens (Conlon et al., 
1999).
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Figure 1.1. Onset o f  neuroinflammation and the epitope spread hypothesis. A Presentation o f the 
primary epitope by the MHC class II on antigen presenting cells (APC) in the peripheral lymphoid tissue 
(self antigen, or viral/bacterial antigen mimicking self). B Upon presentation to a T-cell with the correct 
T-cell receptor (TCR), these Thl autoreactive T cells undergo activation and differentiation and enter the 
vasculature to circulate through the tissues. C Entry into the target tissue, in this case the CNS, requires 
adhesion and migration through the BBB endothelium. D Upon re-encountering the antigen presented on 
resident APC, T-cells release a host o f cytokines and chemokines, E, which leads to further recruitment of 
additional mononuclear phagocytes and T-cells from the periphery. F Locally produced cytokines are 
capable o f activating macrophages and microglia leading to, G, myelin phagocytosis and the release of 
cytotoxic substances. H Resulting tissue debris is, I, processed and presented on peripheral and resident 
APCs, leading to activation and differentiation of a second wave of Thl cells, J, which can re-enter the 
CNS and cause additional tissue destruction. Adapted from Vanderlugt and Miller, (2002).
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1.4. Animal models of MS.
A number of animal models have been developed, which over the years have 
aided understanding of neuroimmunology and allowed investigation into the 
pathogenesis of inflammatory demyelination, in addition to providing models for 
preclinical analysis of new drug compounds. It is important to note that no existing 
model exactly mimics all the features of MS, but that each model represents specific 
features of inflammation and/or demyelination, which aid in the attempt to investigate 
the underlying mechanisms involved in the onset and progression of the disease. These 
models are grouped into three main categories according to their aetiology and include; 
immune-mediated, viral-induced and toxic demyelinative disorders (Glabinski et al,
1997). There are a number of viruses that can induce demyelinating syndromes in 
mammals, the most commonly studied are Theiler’s murine encephalomyelitis viruses 
(TMEV) and Semliki forest virus (SFV), which can induce demyelination and 
encephalitis in susceptible mouse strains (Fazakerley, 2004; Lipton and Dal Canto, 
1979). TMEV are single stranded RNA picornaviruses and are natural mouse 
pathogens. There are two main groups of TMEV viruses characterised by the degree of 
CNS infection in which they cause (Dal Canto et al., 1996). One group produces a fatal 
encephalomyelitis whilst the other produces a chronic persistent infection, which is 
more reminiscent of MS, thus virus strains from the second group are more commonly 
used in experimental demyelination. Onset of disease occurs typically 4 weeks after 
infection and clinical signs include waddling gait, spasm and incontinence and upon 
histological analysis, perivascular inflammatory cell infiltrates and primary 
demyelination are evident in the spinal cord (Lehrich et al, 1976). SFV inoculation in 
mice leads to infection of neurons and oligodendrcotyes, with resulting variable mild -  
fatal encephalitis, with a predominantly CD8+ T-cell response (Fazakerley, 2004). In 
both TMEV and SFV, viral-induced demyelination seems to be immune-mediated. The
28
disease course and susceptibility depends on the ability of the mouse to mount a 
delayed-type hypersensitivity response to the viral antigens. The method of toxic 
demyelination is particularly useful when investigating a precise area of the CNS and 
requires a focal area or lesion of demyelination to study. It can be induced by 
intracerebral or intraspinal injection of lysolecithin or ethidium bromide and by dietary 
administration of cuprizone (Blakemore, 1973; Blakemore, 1978; Blakemore, 1982). 
Mechanisms of demyelination are due to toxic effects on oligodendrocytes and are not 
related to inflammatory attack, although there is macrophage recruitment which remove 
myelin debris. This model can provide a useful method for studying the mechanisms 
involved in the process of remyelination (Woodruff and Franklin, 1999).
1.4.1 Experimental Allergic Encephalomyelitis.
EAE is the most commonly used immune-mediated model and is also the 
leading model of MS. It was first developed at the end of the 19th century after 
complications were observed with the rabies vaccination in man (Compston et al,
1998). The inactivated virus was cultured in rabbit CNS tissue and inoculation 
occasionally and unpredictably resulted in fever, paralysis, and even death. Post­
mortem tissue of these patients showed perivenular demyelination and acute 
inflammation reminiscent of MS (Compston et al, 1998). This lead to the conclusion 
that autoimmunity targeted against nervous tissue elements can induce brain 
inflammation. Rivers et al, (1933) formally proved this theory by immunising 
monkeys with brain tissue to induce inflammatory demyelination. EAE can be induced 
in virtually all mammalian species, including man; the most commonly used include 
mice, rats, guinea pigs and primates. Active induction of EAE involves immunisation 
with nervous tissue from an animal of the same or different species. Spinal cord is 
usually employed for disease induction as it is more encephalitogenic, as it contains
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more myelin than brain tissue, mixed with Freund’s adjuvant and injected 
subcutaneously (Mullay-Eberhard and Miescher, 1976). Injection in this way ensures 
that encephalitogenic antigen plus adjuvant are delivered to draining lymph nodes to 
initiate an immune response. Freund’s adjuvant, which contains killed mycobacterium, 
paraffin oil and emulsifier is important for manifestation of EAE (Lee and Schneider, 
1962). In addition to killed Mycobacterium tuberculosis, other bacteria, for example 
Bordetella pertussis vaccine, can be substituted or given in addition to the other 
adjuvants (Goverman et al., 1993). B. pertussis has a potentiating effect on EAE 
possibly by increasing BBB permeability to cell trafficking, enhancing the production 
of cytokines by T cells and by induction of lymphocytosis (Hofstetter et al., 2002). 
EAE onset usually occurs 10-20 days after injection in rodents, and clinical signs 
include tail paralysis, ataxic gait and paresis or paralysis of hind limbs (Mullay- 
Eberhard and Miescher, 1976). Histopathologically there are many similarities with 
MS. EAE is characterised by BBB breakdown/damage, subsequent entry of plasma 
proteins, namely fibrinogen, followed by infiltration of inflammatory mononuclear 
cells. There are varying degrees of demyelination and axonal damage depending on the 
particular model used but the presence of macrophages and activated microglia are 
common of most forms of EAE (Kornek et al., 2000). The type and dose of 
encephalitogenic antigen, type of adjuvant, route of sensitisation, and species and strain 
of animal all influence the onset and course of disease in EAE (Mullay-Eberhard and 
Miescher, 1976). Studies with various inbred and outbred strains of rodents showed 
that the susceptibility to EAE varied greatly (Levine and Sowinski, 1973). Through 
extensive backcrossing experiments it became clear that resistance or susceptibility to 
myelin protein induced EAE in inbred rodent strains of mice, rats and guinea pigs was 
primarily associated with their MHC-class II antigen haplotypes (Fritz and McFarlin, 
1989). This can account for the differences in disease course observed with different
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strains and species, for example immunisation of the Lewis rat with MBP induces a 
monophasic EAE characterised by acute inflammation but notably little demyelination 
or axonal damage (Stepaniak et al, 1995). After injection of spinal cord into the DA 
rat, they develop a relapsing remitting disease which is more reminiscent of MS with 
evident axonal pathology and demyelination (Lorentzen et al., 1995). In addition 
chronic relapsing EAE (CREAE) can be induced in strain 13 guinea pigs and in 
susceptible mouse strains such as SJL and ABH (Baker et al., 1990; Fallis et al., 1989). 
However, the differences in clinical course observed are not solely due to differences in 
genetics. Chronic disease in mouse EAE, characterised by axonal loss, is associated 
with CD8+ MOG specific T cell activation (Sun et al., 2001), described in detail in 
section 1.5, whereas classic-remitting EAE is mediated by CD4+ T cells (O'Neill et al., 
1993). Different strains of mice are susceptible to induction of EAE with different 
proteins (summarised in Table 1.1) (Levine and Sowinski, 1973). C57BL/6 mice, the 
strain commonly used for making genetic knockouts, are amongst the most resistant to 
MBP or whole myelin induced disease, are only susceptible to EAE induced with MOG 
whilst SJL mice are susceptible to all antigenic peptides (Levine and Sowinski, 1973; 
Tuohy et al., 1988).
Strain
EAE inducing antigen
MBP1 PLP2 MOG3 SCH4
C57BL/6 - - + -
BALB/c - - - -
SJL + + + +
ABH - + + +
Table 1.1. The su scep tib ility  o f  differen t m ouse stra in s to  ac tive ly  in du ced  E A E  w ith  differen t an tigens. 
M yelin basic protein (M B P ), proteolipid protein (PLP), m yelin oligodendrocyte glycoprotein  (M O G ) or 
w hole spinal cord hom ogenate (SC H ). 1 (Bernard and Carnegie, 1 9 7 5 ) ,2 (Tuohy et al., 1 9 8 8 ) ,3 (M endel 
e ta l.,  1995); (A m or et al., 1 9 9 4 ) ,4 (Raine e t al., 1980).
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As it is widely accepted that the incidence of MS in females is twice that of 
males, it is understandably of importance and interest to determine whether the same is 
true for EAE. While it was thought that sex hormones play a role in the susceptibility 
of humans to MS (Soldan et al., 2003) and animals to EAE, the mechanisms by which 
this occurs are poorly understood (Voskuhl et al., 1996). Several reports have shown 
that female SJL mice are more susceptible to induction of EAE with either MBP (Cua et 
al., 1995) or PLP (Bebo et al., 1998; Papenfuss et al., 2004). However little work has 
been carried out on gender differences in MOG-induced EAE. One recent study 
demonstrated no differences in EAE development between male and female C57BL/6 
when the mice were immunised with MOG35.55 peptide (Okuda et al., 2002). This 
highlights that the gender difference influencing susceptibility of mice to EAE depends 
on the strain of animals used and/or the encephalitogenic substance employed for 
disease induction (Okuda et al., 2002).
EAE can also be induced by a procedure known as “adoptive transfer” in which 
activated encephalitogenic T cells, obtained from sensitised animals or propagated in 
vitro, are injected intravenously into immunologically compromised or naive recipients, 
with resulting disease that is similar to actively induced EAE (Lafaille et al., 1997). 
Adoptive transfer in the rat was the first demonstration that EAE was mediated by T 
cells and that the response was initiated and generated in the lymph nodes (Paterson, 
1960). Many people categorise EAE as a delayed, type IV, hypersensitivity reaction. 
Reactions of this type are mediated by T cells in response to soluble or cell-associated 
antigens. Injected cells then migrate to the CNS where they initiate an immune 
response resulting in the recruitment of additional lymphocytes and monocytes from the 
blood. Monocyte recruitment is an essential step in EAE as disease development is 
suppressed in animals after elimination of monocytes/macrophages (Brosnan et al., 
1981; Huitinga et al., 1990). As with MS, perivascular accumulation of leucocytes is
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evident. More recently, aided by molecular biology techniques, transgenic mice which 
can spontaneously develop autoimmunity in the CNS have been developed. Mice that 
express a MBP-specific TCR spontaneously develop EAE when kept in a non-sterile 
animal housing facility (Goverman et al, 1993). Additionally, TCR transgenic mice for 
PLP 139.151 also spontaneously develop CNS inflammation, and are also highly 
susceptible to EAE induction with PLP peptide indicating that these T cells were not 
tolerised in the thymus (Waldner et al, 2000).
Whilst no single EAE model exactly mimics MS it is important to note that there 
are models which give a better representation of the underlying pathological 
mechanisms involved in MS than others. It may be useful to use a MOG-induced or 
chronic relapsing EAE model in mice when investigating neurodegeneration, in which 
neurological damage is evident, as opposed to MBP induced acute Lewis rat EAE, 
which is a monophasic disease with no axonal pathology. However this monophasic 
EAE may be more suitable to investigate earlier stages of the disease.
1.5. Neuroinflammation and neurodegneration.
There are varying degrees of axonal loss in MS lesions, correlating to the 
permanent disability characterising the chronic progressive stage of the disease 
(Bjartmar et al, 2003; Siva et al, 1999). Damage to CNS axons has important clinical 
consequences because they are normally unable to regenerate (Neumann, 2003). Focal 
damage to axons leads to Wallerian degeneration of the distal segment, and possible 
death of the cell body due to lack of connections with other neurons (Coleman and 
Perry, 2002). It is increasingly evident that neuronal and axonal damage and 
degeneration takes place early on in MS (Bjartmar et al, 2003). Studies into axonal 
pathology in MS have used various markers to assess axonal damage and degeneration. 
Work by Trapp et al, (1998) using an antibody against nonphosphorylated
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neurofilaments (SMI32), found that although rarely detected in normal white matter 
from control patients, a large increase in SMI32 immunoreactivity was found within 
areas of demyelination in MS patients. The pattern of staining depended on the activity 
of the lesion, as in active lesions, axonal swellings and ovoids were found throughout 
the plagues consistent with axonal transaction. Additionally, antibodies directed to 
neurofilaments are detected in the CSF of MS patients, which could aid in 
neurodegeneration through the guidance of macrophages to their targets. Ferguson et 
al, (1997) studied the immunoreactivity of amyloid precursor protein (APP), a marker 
for axonal injury, in acute, active chronic and chronic MS lesions. The study revealed 
that axonal damage was evident in areas coinciding with inflammation and 
demyelination. Axonal loss appears to remain clinically silent for many years, and 
irreversible neurological disability develops when a threshold of axonal loss is reached 
and compensatory CNS resources are exhausted (Bjartmar et al., 2003). In the EAE 
model of MS axonal degeneration is also an early pathological feature of disease, which 
increases in severity with relapses (Onuki et al., 2001; Wujek et al., 2002). Ultimately 
the degree of axonal loss in mice with EAE determines the permanent neurological 
disability (Wujek et al, 2002). The actual mechanisms of axonal injury are not known, 
and whether axons degenerate purely in response to demyelination, or together with 
other factors involved is still the focus of much research (Summarised in Figure 1.2). 
Axonal injury correlates with the number of macrophages and CD8 positive T-cells but 
not with the expression of tumour necrosis factor-alpha (TNF-a) or inducible nitric 
oxide synthase (iNOS), two potential mediators of demyelination (Bitsch et al, 2000). 
This suggests that axonal damage is closely associated with inflammation and 
demyelination (Ferguson et al, 1997) but can also occur independently of 
demyelination.
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Due to their unusual shape and high level of metabolic activity, axons are highly 
vulnerable to toxic inflammatory mediators, oxidative stress and changes in protein 
turnover (Neumann, 2003). There is evidence to suggest that excitotoxicity may play a 
role in neuronal and oligodendrocyte damage and degeneration in MS and EAE (Groom 
et al, 2003; Matute et al, 2001; Smith et al., 2000; Werner et al, 2000; Werner et al,
2001). Macrophages and activated microglia produce glutamate in large quantities 
(Werner et al, 2001). Furthermore alterations in glutamate transporters on glia (Werner 
et al, 2000) affects cellular glutamate/glutamine homeostasis leading to overactivation 
of the glutamate receptors, N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl- 
4-isoxazolepropionic acid (NMDA, AMPA) and Kainate. This in turn produces an 
increase in the cell’s permeability to calcium. Excessive calcium influx via this route 
can lead to free radical formation (Traynelis and Lipton, 2001) and ultimately injury and 
death to axons and oligodendrocytes (Matute et al, 2001). Using magnetic resonance 
spectroscopy techniques levels of glutamate are found to be significantly higher in acute 
MS lesions and in NAWM when compared to control subjects (Srinivasan et al, 2005). 
Antagonists to glutamate receptors NMDA and AMPA/kainate ameliorate EAE disease 
(Achiron et al, 2000; Bolton and Paul, 1997; Pitt et al, 2000; Smith et al, 2000) with 
increased oligodendrocyte survival and reduced axonal damage. Furthermore, the 
NMDA antagonists, MK801 and memantine are capable of modulating the neurological 
course of EAE disease, and are particularly effective in reducing BBB breakdown 
(Bolton and Paul, 1997; Paul and Bolton, 2002). Additionally, Riluzole, a glutamate 
receptor antagonist and sodium channel blocker suppresses inflammation and 
demyelination in EAE (Gilgun-Sherki et al, 2003b) and appears to slow the progression 
of CNS atrophy in PPMS (Killestein et al., 2005).
There has also been much interest in the role of nitric oxide (NO) in MS and its 
contribution to axonal injury and degeneration. In MS lesions, levels of NO are
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increased due to upregulation of iNOS by cytokines and production by activated 
macrophages/microglia and reactive astrocytes (Oleszak et al, 1998). NO alone is 
capable of causing vasodilation in the cerebral vessels which may aid in the migration 
of lymphocytes into the CNS by reducing the velocity of the surrounding blood flow 
(Smith and Lassmann, 2002). As NO is a highly reactive molecule, it readily combines 
with other molecules to form several related compounds including peroxynitrite 
(ONOCT). This reactive nitrogen species is potentially capable of exacerbating 
demyelination through damage of oligodendrocytes (Mitrovic et al, 1996) and 
contributing to neuronal degeneration by impairment of mitochondrial energy 
metabolism and depletion of ATP (Bolanos et al, 1995). Axons exposed to NO in vivo 
can undergo persistent conduction block, particularly if they are electrically active 
during NO exposure, due to axonal degeneration (Smith et al, 2001). Sodium and 
calcium channel blockers are effective in ameliorating EAE (Bechtold et al, 2004) and 
preventing NO- mediated axonal degeneration (Kapoor et al, 2003). These effects are 
thought to be mediated by blocking deleterious accumulations of Na+ and Ca2+ at sites 
of inflammation as a result of Na+ / K+ ATPase failure and reversal of the Na+ / Ca2+ 
exchanger (Bechtold et al, 2004; Kapoor et al, 2003). It is possible that detrimental 
accumulation of these ions is due to NO-mediated impairment of mitochondrial ATP 
generation. Therapies limiting Na+ and Ca2+ entry into axons might have beneficial 
effects treating axonal injury and degeneration associated with MS.
The presence of cytotoxic lymphocytes with a CD8 positive phenotype in MS 
lesions has been recently indicated in the pathogenesis of axonal injury. Inflammatory 
infiltrates into the brains of MS patients include both CD4+ and CD8+ T cells 
(Steinman, 2001). Much research has focused on the role of CD4+ T cells in MS since 
the observation that the genetic susceptibility to MS lies within the region encoding for 
the MHC class II molecules (Haines et al, 1996). The MHC class II molecules are
36
expressed in the CNS by microglia, and infiltrating macrophages and B cells and are 
recognised by CD4+ T cells. In contrast, all CNS cells including neurons and 
oligodendrocytes can express MHC class I molecules (Neumann et al, 2002), which are 
recognised by CD8+ T cells (Janeway et al., 2001). In MBP and MOG induced EAE 
there is a consistently higher activation of CD8+ than CD4+ T cells (Huseby et al, 2001; 
Sun et al, 2001). When these cells were adoptively transferred they induced a much 
more severe and permanent disease characterised by more progressive and destructive 
lesions (Sun et al, 2001). In addition, demyelination and inflammation are reduced in 
MOG induced EAE in CD8_/‘ mice (Abdul-Majid et al, 2003). The degree of axonal 
injury correlates with the number of macrophages and CD8+ T-cells (Bitsch et al, 
2000). It is therefore a possible theory that CD8+ T cells are contributing to the 
destruction of axons in MS. Possible mechanisms include release of proteases 
contained in cytotoxic granules by CD8+ cells and/or activation of the Fas (CD95) 
receptors both leading to apoptosis of the target cells (Neumann et al, 2002) which 
could include neurons and oligodendrocytes, thus having an effect on remyelination in 
addition to neurodegeneration.
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Figure 1.2. Putative mechanisms o f neurodegeneration during neuroinflammation. T-cells re- 
encountering their antigen in the CNS activate local cells triggering an inflammatory cascade, releasing 
cytokines into the parenchyma. Activation o f microglia and recruitment o f monocytes/macrophages leads 
to myelin phagocytosis, thus promoting demyelination. Microglia and macrophages are also capable of 
releasing a number o f other potentially cytotoxic substances, and demyelinated axons are particularly at 
risk from these molecules. Proteolytic enzymes are capable of further degrading the myelin sheath, in 
addition to causing further microglial activation, and promoting leucocyte migration into the CNS. 
Furthermore, NO can cause axonal conduction block, and excessive glutamate can potentially cause 
excitotoxic cell death to oligodendrocytes and neurons.
1.5.1. Neurofilaments.
Neurofilaments are one of the major protein components of the neuronal 
cytoskeleton. They are classified as intermediate filaments (~10nm in diameter) and are 
responsible for maintaining the calibre of axons (Al-Chalabi and Miller, 2003). This is 
important as the speed of conductivity of an impulse down the axon is proportional to 
its calibre (Miller et al., 2002). As neurofilaments are CNS cell-type specific proteins 
they can qualify as potential surrogate markers of axonal and neuronal damage (Petzold, 
2005). Neurofilaments are heteropolymers and are composed of three subunits termed 
light (NfL), medium (NfM) and heavy (NfH) chain which are 68, 150 and 200 kDa 
respectively (Petzold, 2005). Each subunit is composed of a head, rod and a 
hypervariable C-terminal tail domain. These three subunits form heterodimeric 
tetramers, combine into protofilaments, eight of which join together, resulting in 
neurofilament formation (Petzold, 2005). NfL is essential for correct assembly of 
neurofilaments as each tetramer contains at least two NfL subunits (Al-Chalabi and 
Miller, 2003). These filamentous structures can run the entire distance of axons which 
can be over a metre in length. Diversity in NF subunits resides primarily in the length 
and sequence of the tail domain, with NfH exhibiting the longest (Grant and Pant, 
2000). The most distinct feature of this domain is a number of lysine-serine-proline 
(KSP) repeats which are highly phosphorylated. The function of neurofilaments is 
intimately related to their phosphorylation state and phosphorylation of the C-terminal 
tail domain is thought to occur at the side arms protruding from the assembled filaments 
(Grant and Pant, 2000). The side arm domains of NfM and NfH form cross bridges 
which stabilises the filament network by interacting with neighbouring structures and 
other filaments. Additionally, neurofilaments are also phosphorylated at the amino- 
terminal head domain, which is a possible mechanism by which neurofilament assembly 
is regulated (Miller et al, 2002).
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Neurofilaments are synthesised in neuronal cell bodies and transported down the 
axon. It was originally thought that this was by slow axonal transport processes, at a 
rate of between 0.1 and 3mm per day, much slower than fast transport by molecular 
motors such as kynesin and dynein (Miller et al., 2002). However more recent studies 
suggest that neurofilaments are transported by conventional fast rates of movement 
which is interrupted by periods of extended pausing, giving the appearance of slow 
movement (Wang et al., 2000). This intermittent movement points to a mechanism by 
which neurofilaments are capable of controlling their attachment and release to motor 
proteins (Miller et al., 2002). Side arm phosphorylation of NfM and NfH may be a 
regulating factor in this process, as degree of phosphorylation correlates inversely with 
the velocity of axonal transport (Grant and Pant, 2000).
Disruption of neurofilament phosphorylation and transport are common features 
of many neurodegenerative conditions. Staining for phosphorylated neurofilaments 
(SMI34 or SMI35) is increased in Alzheimer’s disease (AD), amyotrophic lateral 
sclerosis (ALS) and MS (Petzold, 2005). However, increased staining for non- 
phosphorylated neurofilaments have also been related to axonal injury in MS (Trapp et 
al., 1998), and neurofilament dephosphorylation has been shown to precede 
excitotoxicity in a cell culture model of ALS (Vartiainen et al., 1999).
1.5.2. Synaptic and dendritic proteins.
Neuronal dendrites are basic but essential functional units, which integrate 
neuronal circuits and are sites of structural and functional synaptic plasticity. More than 
90% of dendrites in the mammalian CNS are contacted by excitatory synapses (Harris 
and Kater, 1994), which renders them highly vulnerable and sensitive to excitotoxic 
insult. Following NMDA or kainate treatment, cultured neurons show dramatic 
dendritic beading, however dendrites recover and pre- and post-synaptic elements
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remain in physical proximity, suggesting that dendritic beading is not necessarily 
associated with loss of synaptic contacts (Hasbani et al, 2001). By using markers for 
synapses and dendrites, it is possible to detect early changes in these structures 
following insult to the nervous system, as a possible indication of underlying 
excitotoxicity. Recently the localisation and expression of microtubule-associated 
protein (MAP)-2, synaptophysin, postsynaptic density protein (PSD)-95 and synapsin I 
was investigated in EAE to assess synaptic and dendritic pathology (Zhu et al., 2003). 
MAP-2 is the most abundant MAP in the brain where it is expressed in the neuronal 
somata and dendrites (Johnson and Jope, 1992). It has dynamic functions in the growth, 
differentiation and plasticity of neurons and has key roles in neuronal responses to 
growth factors, neurotransmitters, synaptic activity and neurotoxins (Johnson and Jope, 
1992). Loss of MAP-2 is an early feature of neuronal dysfunction following transient 
ischaemia in a guinea pig model of stroke, indicating that this is an important marker of 
changes in dendritic pathology and that dendritic breakdown may be a first sign of 
neurodegeneration (Matesic and Lin, 1994). In the normal rat spinal cord, antibodies 
against MAP-2 stain large motomeurons and the intricate dendritic network in the grey 
matter (GM), which extends heavily into the white matter (WM) (Zhu et al, 2003). At 
peak of disease in EAE, most dendrites in the WM show a beaded morphology, which 
return to normal following clinical recovery from EAE (Zhu et al., 2003). From this the 
authors concluded that MAP-2 loss may be induced by excitotoxicity, however other 
inflammatory components may contribute including reactive oxygen species, cytokines 
and/or proteases. Thus, it appears that MAP-2 represents a sensitive marker for early 
changes in dendritic pathology, however it does not provide a marker for permanent 
neurological damage.
Synaptophysin is a pre-synaptic protein, which is localised in the membrane of 
synaptic vesicles where it is thought to have a role in neurotransmitter vesicle
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exocytosis (Valtorta et al, 2004). In AD, early progression correlates with alterations 
synaptophysin and growth associated protein (GAP)-43 (Masliah et al, 2001). 
Additionally, synaptophysin loss in the midfrontal cortex is associated with a reduction 
in local glutamate uptake (Masliah et al, 1996). Post-synaptic density protein (PSD)-95 
is an important protein which is associated with NMDA glutamate receptors at 
excitatory synapses. It contributes to both synaptic targeting of receptors and to their 
signalling functions (Kim and Sheng, 2004). Disruption of PSD-95/NMDA receptor 
interactions attenuates NMDA receptor-mediated neurotoxicity (Aarts and Tymianski, 
2003). Although PSD-95 is continuously turned over as a result of synaptic activity, 
NMDA receptor activation leads to PSD-95 degradation by the calcium-dependent 
protease, calpain (Lu et al, 2000), thus PSD-95 can be used as a marker of excessive 
NMDA receptor activation as occurs under excitotoxic conditions. In control rat spinal 
cord, the GM matter showed punctuated staining for synaptophysin and PSD-95 which 
encircled large motomeurons. At the peak of EAE disease, staining for synaptophysin 
and PSD95 were greatly reduced, although levels partially recovered following EAE 
remission (Zhu et al, 2003).
GAP-43 is an axonal phosphoprotein which is involved in regulating the growth 
state of axon terminals, in combination with other molecules, including c-jun (Benowitz 
and Routtenberg, 1997). GAP-43 is expressed at high levels during development and is 
re-induced by regeneration in the PNS (Benowitz and Routtenberg, 1997). However, 
injury to the CNS does not result in significant regeneration and this has been suggested 
to correlate with a failure of central neurons to up-regulate GAP-43 after axotomy 
(Kerschensteiner et al, 2004). Following a targeted EAE lesion, GAP-43 staining is 
decreased, and only a small proportion of c-jun positive cells also express GAP43 and 
are thus unlikely to initiate growth (Kerschensteiner et al, 2004). However a negative 
correlation exists between levels of GAP-43 and myelination in the adult CNS, thus in
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animals with a targeted EAE lesion, resulting in extensive demyelination, it would be 
expected to lead to a reduced effect of myelin inhibition on neurite outgrowth in and 
around the lesion area.
Investigating different synaptic and dendritic proteins in disease states, including 
EAE and MS, could provide clues about the degree of axonal pathology, and point to 
early changes that precede neurodegeneration.
1.6. Immunology of Neuroinflammation.
All tissues in the body contain a resident population of immune cells, namely 
macrophages and dendritic cells, which play key roles in a variety of immune responses. 
Macrophages are part of the innate immune repertoire and are responsible for pathogen 
recognition, clearance and phagocytosis (Janeway et al., 2001). Dendritic cells have the 
ability to capture antigen, migrate to lymphoid tissue and present it to T cells, initiating 
T cell responses (Janeway et al., 2001). The CNS has evolved to protect its functioning 
from damaging immune-mediated inflammation by shielding itself with the BBB 
(Aloisi, 2001). The BBB is a dynamic, complex cellular system capable of rapid 
modulation, comprising of cerebral endothelial cells (EC) resting on the basal lamina 
(Huber et al., 2001). These specialised EC line the cerebral capillaries containing tight 
intercellular junctions, which seclude the CNS parenchyma. The function of these cells 
is to regulate the entry of blood-borne molecules into the brain and to preserve 
metabolic and immunoregulatory homeostasis within the brain microenvironment 
(Tepass, 2003). The cerebral capillaries are also surrounded by astrocytic foot 
processes and perivascular macrophages/microglia that exert a regulatory effect on BBB 
tightness (Aloisi, 2001). Small lipophilic molecules such as oxygen can freely diffuse 
across the lipid membranes of the endothelial cells whereas small polar molecules, such 
as glucose, require special transporters. The CNS lacks any obvious lymphatic vessels
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and the BBB prevents entry of any plasma proteins or immune cells into the nervous 
tissue. However the CNS is routinely and efficiently surveyed by the immune system 
(Hickey, 2001) by perivascular microglial and astrocytic cells which scrutinise all 
portals of entry for blood-derived pathogens and immune cells (Aloisi, 2001). MS is 
associated with a disruption to the BBB, and opening of the BBB is necessary but not 
sufficient for establishing the cascade of events which culminates in demyelination 
(Compston et al., 1998). Inflammatory changes of the BBB are characterised by 
increased permeability to serum proteins (Kwon and Prineas, 1994) and infiltration of 
mononuclear cells into the perivascular space and brain parenchyma. Breakdown of the 
BBB and subsequent lymphocyte entry into the CNS depends on a variety of 
mechanisms including increases in the expression components of the plasminogen 
activator (PA) - matrix metalloproteinases (MMPs) cascade, adhesion molecules, 
cytokines and chemokines (Cuzner and Woodroofe, 2002). Perivascular astrocytes and 
microglial cells, as well as the cerebral ECs, are thought to locally produce 
inflammatory cytokines that increase BBB permeability which subsequently increase 
the expression of adhesion molecules (Chavarria and Alcocer-Varela, 2004).
1.6.1. Migration of lymphocytes across the BBB.
Trafficking of inflammatory T-cells into the CNS is a crucial step during 
neuroinflammation and begins with weak adhesion and rolling of cells on the 
endothelium of the BBB, followed by firm arrest on the luminal side of the endothelium 
and subsequent diapedesis across the BBB, cells then finally penetrate the basement 
membrane (Languino et al., 1995; van-Horssen et al., 2005). Cell migration is a 
complex process which is regulated by cytokines, chemokines and growth factors acting 
through multiple pathways (Brown, 2001). Much of the work carried out to investigate 
how lymphocytes cross the BBB has been carried out in an animal model of MS, EAE.
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A distinct feature of MS and EAE is the presence of cuffs of lymphocytes around small 
blood vessels. Infiltrating T lymphocytes can be CD4+ and CD8+, and the CD4+ cells 
mostly express the phenotype of Thl lymphocytes in that they produce pro- 
inflammatory cytokines, in contrast to Th2 cells which secrete anti-inflammatory and B 
lymphocyte differentiation cytokines (Janeway et al., 2001). The leucocyte migration 
patterns observed in EAE are thought to also be relevant to the pathogenesis of MS. 
Lymphocyte binding to blood vessel walls depends upon the interaction of adhesion 
molecules, expressed on its surface, with corresponding ligands on ECs, as migration 
does not occur without adhesion (Pryce et al, 1997). Integrins, intracellular adhesion 
molecule 1 (ICAM-1/CD54) and vascular cell adhesion molecule-1 (VCAM-1/CD106) 
are thought to be involved in the passage of lymphocytes though the BBB prior to 
demyelination. VCAM-1 is expressed on endothelial cells and is a ligand for the 
integrin ct4pi, also called very late antigen 4 (VLA-4), which is expressed on the surface 
of activated leucocytes. It plays a crucial role in adhesion of leucocytes to the vascular 
endothelium and migration into the parenchyma (Miller et al., 2003). ICAM-1 is 
constitutively expressed at low levels on BBB endothelial cells however, in the presence 
of pro-inflammatory cytokines, specifically tumour necrosis factor alpha (TNF-a) 
(Brown, 2001; Cannella and Raine, 1995; Zameer and Hoffman, 2003), the expression 
of ICAM-1 is rapidly increased on the luminal surface. Levels of ICAM-1 are increased 
in EAE and in active MS lesions (Ahmed et al., 2003; Cannella and Raine, 1995), 
indicating that ICAM-1 plays an important role in leucocyte infiltration into the CNS 
(Pryce et al., 1997). There are two receptors for ICAM-1, namely the integrin leucocyte 
function-associated antigen-1 (LFA-1 or CDlla/CD18, a Lp2) and also Mac-1 
(CDllb/CD18, a Mp2) (Lee and Benveniste, 1999). It was initially though that cell 
migration of leucocytes occurs through the tight junctions (Bianchi et al., 1997), 
however it has become evident that this migration could in fact occur through the
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endothelial cells, keeping the tight junction “tight” (Figure 1.3) (Wolburg et al, 2005). 
To enable leucocytes to migrate through endothelial cells, a rearrangement of the actin 
cytoskeleton is required. ICAM-1 cross-linking induces calcium signalling which, via 
protein kinase C, mediates phosphorylation of actin associated proteins, activation of 
Rho and cytoskeletal rearrangement in brain endothelial cell lines (Etienne-Manneville 
et al, 2000; Walters et al, 2002; Wolburg et al, 2005).
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Figure 1.3. T-lymphocyte migration through the BBB and into the CNS during inflammatory 
demyelination. Following activation o f Thl T cells in the peripheral lymphoid tissue, they enter the blood 
stream and circulate through the tissues in search o f their target antigen. Increased levels o f cytokines 
and chemokines, released from activated microglia, macrophages, APCs and T cells, leads to the 
upregulation o f adhesion molecules such as ICAM-1 and VCAM-1 on the endothelial cell surface. 
Adhesion of the T-lymphocytes to the endothelium occurs when ICAM-1 or VCAM-1 bind to their 
corresponding receptors on the T-cells, leucocyte function associated antigen-1 (LFA-1) and very late 
antigen-4 (VLA-4). This brings about ICAM-1 cross-linking, ultimately leading to activation o f Rho and 
cytoskeletal rearrangement, enabling migration through the endothelial cell by a transcellular pathway. 
Cells must then degrade the basement membrane to enter into the CNS parenchyma.
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1.6.2. BBB Tight junctions.
Tight and adheren junctions together form the junction complex between 
adjacent endothelial cells, which line the vascular walls. Tight junctions (TJs) are 
located in the most apical section of the plasma membrane of adjacent cells where they 
form a seal to prevent solutes from diffusing through the intracellular (paracellular) 
space (Tepass, 2003), thus mediating the gate function of the BBB. Tight junctions at 
the BBB are composed of an intricate combination of transmembrane and cytoplasmic 
proteins, linked to an actin cytoskeleton, which allows the junction to form a seal 
(Figure 1.4) (Huber et al, 2001). Claudins are considered to be the core components of 
the TJ strands as they can mediate adhesion between opposing plasma membranes. 
Claudins are small proteins about 20-22 kDa that span the membrane four times (Petty 
and Lo, 2002). They form dimers and bind to claudins on adjacent cells to form the 
primary junction seal. In mice deficient for claudin 5 the development and morphology 
of brain blood vessels were not altered (Nitta et al., 2003). However, the BBB TJs in 
these knockouts showed a peculiar abnormality. Tracer experiments and MRI have 
revealed that the BBB permeability is severely affected against small molecules (< 800 
D), but not larger molecules, thus concluding that there is a size-selective loosening of 
the tight junctions in these mice. Additionally it is possible that removal of claudin 5 
would be harmful to CNS activity as claudin-5 knockout mice died within 10 hours of 
birth (Nitta et al., 2003). Another integral protein of TJs is occludin. Occludin is a -60 
kDa protein with four transmembrane segments. Its presence at the BBB is correlated 
with increased electrical resistance across the barrier and decreased permeability 
(McCarthy et al, 1996). In mice deficient for occludin, most tissues bear TJ 
morphologically indistinguishable from those of the wild type controls (Saitou et al,
2002), indicating that occludin is not required for the formation of TJs. However 
occludin knockout mice do bear some puzzling phenotypes. Their sexual behaviour is
48
affected, and they suffer severe postnatal growth retardation. Furthermore, histological 
abnormalities are found in several tissue including chronic inflammation and 
hyperplasia in the gastric epithelium and progressive accumulation of mineral deposits 
in the cerebellum and basal ganglia (Saitou et al, 2000). These deposits were 
composed almost entirely of calcium suggesting that lack of occludin does in fact alter 
some aspect of TJs and that this barrier dysfunction could affect the absorption of 
calcium.
Alterations in the permeability of the BBB are thought to precede or accompany 
inflammation in the CNS during MS. As demonstrated by gadolinium-enhanced MRI, 
BBB breakdown is characteristic of new and expanding lesions; however the anatomical 
route of leakage has not been established. It is possible that brain endothelial TJs play a 
role in increasing the permeability of the BBB and that increased leucocyte migration 
alters the molecular organisation of the junctional complex (Bolton et al., 1998). By 
examining TJ proteins in blood vessels in MS lesions using immunofluorescence, 
Plumb et al., (2000) discovered changes in staining for occludin and a junctional 
cytoplasmic accessory protein called zona occludens 1 (ZO-1). Tight junction 
abnormalities manifested as beading, interruption or diffuse cytoplasmic localisation of 
immunofluorescent staining, and were most common in active MS lesions with 
perivascular inflammation and microglial activation. The absence of these disruptions 
in chronic plaques suggests a mechanism of reversible junction disturbance, related to 
the involvement of such vessels in the diapedesis of inflammatory cells (Plumb et al,
2000). Using fibrinogen as a marker of BBB leakage, further work revealed that blood 
vessels with the highest degree of TJ alterations showed severe fibrinogen leakage (Kirk 
et al, 2003). Additionally, Kirk et al, (2003) discovered that TJ abnormalities were 
independent of blood vessel size and lesion activity. Had changes in tight junctions 
resulted solely from infiltration of inflammatory cells, post-capillary venules and veins
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would have been expected to bear the brunt of pathological changes (Kirk et al, 2003), 
however the involvement of all blood vessels suggests that TJ alterations are partly 
mediated by alterations within the CNS.
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Figure 1.4. Proposed interactions o f the major proteins associated with BBB endothelial tight junctions. 
Claudins are the proposed backbone o f the junctions which form dimers by binding to claudins on 
adjacent cells. Claudins 1 and 5 have been identified at BBB TJs. Claudins can also bind to occludins 
which act as regulatory proteins. The presence o f occludins at the BBB TJ is associated with increased 
electrical resistance across the membrane and decreased permeability. Junctional adhesion molecule 
(JAM) is involved in cell-cell adhesion, and also contributes to permeability control. There are several 
cytoplasmic accessory proteins, such as the zono occludens (ZO) and cingulin which anchor the proteins 
to the actin cytoskeleton and aid in signal transduction. Adapted from Petty and Lo, (2002).
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1.6.3. Basement membrane penetration and BBB disruption.
Once past the EC barrier, leucocytes are faced with the complex hurdle of the 
basement membrane (BM) (van-Horssen et al, 2005). The BM is a subendothelial 3D 
network of ECM proteins, e.g. laminins, collagens and proteoglycans, and underlying 
connective tissue. Given the complexity of the BM it is likely that there are many 
different proteolytic systems involved in the degradation of matrix components. It is 
possible that the cytokines TNF-a, interleukins (IL) -1(3 (IL-1(3) and IL-6, released from 
activated microglia and astrocytes, lead to the early disruption of the BBB via release of 
prostaglandins (De Vries et al., 1996). In addition, microglia and astrocytes have been 
shown to release elevated levels of MMPs in response to inflammation (Rosenberg, 
2002). MMPs are a group of tightly regulated neutral proteases which have important 
functions in the CNS including remodelling of the ECM. They are generally secreted as 
inactive pro-forms, or zymogens, that are extracellularly activated by other MMPs or 
other proteinases such as plasmin (Lo et al, 2002). The synthesis and activity of MMPs 
is tightly regulated at several levels by transcription, secretion, activation or by 
endogenous tissue inhibitors of MPs (TIMPs) and by ot2-macrogloblin (Rosenberg,
2002). The balance of these processes prevents excessive proteolysis or inhibition. 
However under neuroinflammatory conditions where excessive amounts of MMPs are 
produced, the balance is disrupted and increased ECM breakdown occurs. There are 
four main categories of MMPs, several of which are upregulated in MS (Bar-Or et al.,
2003). The expression of MMP-9 or gelatinase B, so called because it breaks down 
gelatin, is markedly increased during inflammation and is thought to have a critical 
destructive role during the multiple phases of neuroinflammation. MMP-9 is elevated 
in the cerebrospinal fluid (CSF) of MS patients (Gijbels et al, 1992; Leppert et al,
2003) and in lesions and normal appearing white matter (NAWM) of MS tissue (Cuzner 
et al, 1996; Lindberg et al, 2001). MMPs 2, 3 and 7 have also been linked to
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inflammation (Rosenberg, 2002). Activated T cells and monocytes express MMPs at a 
higher levels which facilitates their entry into the CNS through breakdown of the 
basement membrane ECM (Leppert et al., 1992). In addition to BBB breakdown, 
MMPs have a number of other potentially harmful actions which could play a role in the 
pathogenesis of MS. Myelin proteins, such as MBP, and ECM molecules are 
vulnerable to proteolysis by MMP-9 and plasmin which could be implicated with 
demyelination (Cammer et al., 1978). That cleavage of MBP by MMP-9 can release 
encephalitogenic peptides (Gijbels et al., 1993) has lead to the “remnant epitopes 
generate autoimmunity” (REGA) theory. This postulates that myelin proteins, after 
proteolysis, can take on a very different conformations and additional alterations in the 
local CNS environment may render these peptides immune to degradation thus 
increasing the opportunity for MHC presentation (Cuzner and Opdenakker, 1999; 
Descamps et al., 2003). Investigations into MMPs in EAE has had varied results. A 
number of MMPs and their inhibitors are upregulated in EAE correlating with disease 
progression (Nygardas and Hinkkanen, 2002) and synthetic inhibitors of MMPs can 
alleviate and suppress severity of EAE (Hewson et al., 1995). Treatment of mice with 
minocycline, an inhibitor of MMP activity, reduces disease severity in both mild and 
severe EAE (Brundula et al., 2002). Young MMP-9 knockout mice are less susceptible 
to the onset of EAE (Dubois et al., 2002), however knockout mice older than 4 weeks 
were equally susceptible as wild types. More dramatic were the effects of a combined 
MMP and TNF-a inhibitor which markedly suppressed EAE signs in the Lewis rat and 
dramatically reversed the weight loss characteristic of this disease (Clements et al.,
1997)
In addition to the action of MMPs, there is a unique mechanism by which 
leucocytes can focally degrade the ECM proteins of the BM. This is via the urokinase 
plasminogen activator (uPA) system. This is discussed in detail in section 1.7.3.
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1.6.4. Microglia and macrophages -  effector cells of neuroinflammation.
Microglia constitute 5-15% of the total brain cell population (Carson, 2002) and 
are the resident macrophages and primary immune cells of the central nervous system. 
In their resting state microglia are present in a ramified, downregulated form 
characterised by a small elongated cell body and highly branched processes which 
extend along myelinated nerve fibres. Their exact role in the normal CNS is still 
unknown but they are involved in glial-neuron signalling and supporting neuronal 
survival (Cuzner and Woodroofe, 2002). They are the first cells to respond to neural 
insults sensing changes in their microenvironment and rapidly migrate to sites of injury 
where they undergo a series of changes that characterise their activation (Kreutzberg, 
1996). They become more amoeboid in morphology and begin to express a number of 
cell surface markers, including CD45 (and F4/80 in mice), which are key to induce the 
macrophage-like functions and phagocytic capabilities. Activated microglia are known 
to release a number of substances that contribute to both neuroprotection and 
neurotoxicity (Zhang and Fedoroff, 1996) and whether they exert cytotoxic or protective 
effects depends on the nature of the tissue and the presence or absence of other immune 
cells (Diemel et al., 1998). Activated microglia accumulate in many CNS diseases and 
are thought to be involved in the pathogenesis of MS. In addition to microglia-derived 
macrophages, blood-borne monocyte-derived macrophages are also identified in MS 
lesions, they both play a role in myelin phagocytosis and debris clearance and are an 
indicator of lesion activity (Li et al., 1996). Upregulation of MHC class I and II 
molecule expression and therefore the acquisition of antigen presenting properties are 
also features of microglial activation (Bo et al., 1994; Matsumoto et al., 1992). 
Activated microglia are thought to aid in the initiation of demyelination following 
phagocytosis of myelin by presenting the autoantigen to T cells. Macrophages and 
microglia are thought to contribute to demyelination by secreting a variety of soluble
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factors, including cytokines, proteolytic enzymes, reactive oxygen species and nitric 
oxide, which can be cytotoxic to oligodendrocytes and neurons (Cuzner and 
Woodroofe, 2002; Diemel et al., 1998). Cytokines are key regulators of immune 
responses and are released by tissue infiltrating immune cells, CNS-associated 
macrophages, microglia and astrocytes in conditions of CNS inflammation (Imitola et 
al., 2005). To maintain homeostasis, a dynamic balance between pro- and anti­
inflammatory cytokines is required. Microglia are a major source of the pro- 
inflammatory cytokines TNF-a and IL-1 which in turn have been implicated in the 
facilitation of leucocyte entry into the CNS via upregulation of adhesion molecules and 
chemokines (Sedgewick et al., 2000). Other cytokines considered to have an active role 
in demyelination include Interferon gamma (IFN-y), IL-2 and IL-12. Additionally, 
chemokines, released from microglia and macrophages also play a central role in the 
inflammatory recruitment of leucocytes and other cell types. Chemokines induce and 
activate leucocyte adhesion molecules and establish a chemotactic gradient that results 
in their migration across the endothelial barrier (Sellebjerg and Sorensen, 2003). Whilst 
past research has focused on glial-derived pro-inflammatory cytokines it is becoming 
increasing evident that microglia also secrete cytokines with anti-inflammatory 
properties such as TGF-p and IL-10 which are thought to be potential mediators of 
remyelination or MS disease remission (Diemel et al., 1998; Ledeen and Chakraborty,
1998).
1.7. The fibrinolytic system.
1.7.1. Plasminogen and fibrinolysis.
The final stage in the blood clotting cascade is the activation of thrombin by 
factor Xa, thus enabling thrombin to convert soluble fibrinogen into the insoluble mesh­
like substance fibrin (Adams et al., 2004). In order to breakdown fibrin, another
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cascade or series of enzymes is involved. The central component of the fibrinolytic 
system is the glycoprotein plasminogen, which is a 92 kDa proenzyme. It is composed 
of 5 kringle-like domains which facilitate binding to fibrin, with a C-terminal domain 
that is homologous to other trypsin-like proteases (Dobrovolsky and Titaeva, 2002). 
Plasminogen is secreted by the liver in its inactive form, which circulates in the 
vasculature and is converted into the active two-chain structure of plasmin by 
proteolytic cleavage of a single peptide bond (Castellino and Ploplis, 2005). There are 
two main plasminogen activators (PA) namely tissue-type and urokinase-type (tPA and 
uPA). Proteolytic cleavage of plasminogen can result in different conformations, Glu- 
plasminogen and Lys-plasminogen, and dramatic differences exist in these 
conformations that are highly influential to their functions (Castellino and Ploplis, 
2005). Lys-plasminogen has a more open conformation that is highly activatable 
compared to Glu-plasminogen, which is severely attenuated in its activation (Castellino 
and Ploplis, 2005). The main plasmin inhibitor is ot2-antiplasmin (0C2-AP), but its 
activity can also be inhibited by ot2-macroglobulin (ot2-MG) and by thrombin-activated 
fibrinolysis inhibitor (TAFI) (Lijnen H.R., 2002). Although the primary target of 
plasmin is fibrin, it is also capable of binding to and degrading several other 
constituents of the extracellular matrix, such as laminin and fibronectin (Dobrovolsky 
and Titaeva, 2002), and activating cytokine precursors and other proteolytic enzymes 
into their active forms (Liu et al., 2005). The generation of plasmin occurs 
preferentially on the fibrin surface, which offers binding sites for plasminogen and its 
main activator tPA (Kamath and Lip, 2003). Localisation of plasmin to sites of fibrin 
formation promotes efficient clot lysis where fibrin is digested into soluble degradation 
products (FDP) (Figure 1.5). Fibrinogen has a symmetrical structure formed by three 
pairs of non-identical polypeptide chains called Aa, Bp and y chains. When
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fibrin(ogen) is sequentially digested by plasmin, the resulting degredation products are 
designated as X-, Y-, D - and E- fragments (Kamath and Lip, 2003).
Endothelium
Plasm in inhibitor
P l a s m i n
Inhibition
PAI-1 I  tPA A ctivation q  0 o 0 FDP
Degradation
Plasminogen Plasm in
Figure 1.5. Illustration o f  fibrinolysis in the vasculature. The key plasminogen activator, tPA is released 
from the endothelium into the blood stream where it can bind to plasminogen, converting it to the active 
enzyme plasmin. The proteolytic activity o f tPA is greatly increased in the presence o f fibrin. Plasmin 
catalysed digestion of fibrin leads to the release o f soluble fibrin degradation products (FDP). tPA 
activity is inhibited by plasminogen activator inhibitor-1 (PAI-1) and plasmin can be inhibited by a 2- 
antiplasmin or by a 2-macroglobulin. Adapted from www.chromogenix.com.
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1.7.2. Plasminogen activators - structure and function.
Tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) 
are the major proteins in the group of plasminogen activators (Castellino and Ploplis, 
2005). The primary action of tPA is in the periphery where it is responsible for the 
dissolution of fibrin at sites of vascular injury via the conversion of the zymogen 
plasminogen to its active protease form plasmin to release soluble fibrin products. tPA 
is synthesised and secreted by ECs as a single chain active enzyme of 70 kDa (Lijnen
H.R., 2002). It is composed of 5 domains and bears distinct homology to trypsin like 
proteases, plasminogen, epidermal growth factor (EGF) and fibronectin (Dobrovolsky 
and Titaeva, 2002) (Figure 1.6). In physiological conditions tPA activates plasminogen 
at a very low rate, however in the presence of fibrin, a ternary complex of plasminogen, 
tPA and fibrin is formed which increases the catalytic activity of tPA by 1000 fold 
(Dobrovolsky and Titaeva, 2002). Whilst tPA can act in a single form, formation of 
two chain tPA by plasmin, kallikrein or factor Xa increases its activity (Lijnen H.R., 
2002). The main site of clearance for tPA is in the liver, where it binds to one of its 
many receptors, low density lipoprotein (LDL) receptor-related protein (LRP) 
(Dobrovolsky and Titaeva, 2002). LRP is a multifunctional receptor that binds to 
several structurally and functionally unrelated ligands and endocytoses them.
uPA is a 53 kDa trypsin-like protease which is secreted by many cells in the 
body (Lijnen, 2002). It is produced as an inactive single chain that is activated into two 
chain uPA by plasmin, cathepsin, plasma kallikrein or mast cell tryptase (Lijnen, 2002). 
It is composed of three domains and like tPA has homology to EGF (Figure 1.6). It is 
found at much lower plasma concentrations than tPA, although synthesis is highly 
upregulated during inflammation (Gabay and Kushner, 1999). Urokinase PA requires 
binding to a cell surface receptor (uPAR) via its EGF-like domain before it can initiate 
activation of plasmin (Dobrovolsky and Titaeva, 2002), and due to this receptor bound
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nature of uPA, its major role is in cell-mediated proteolysis (Blasi and Carmeliet P., 
2002). The specific receptor for uPA, uPAR, is expressed on many cell types as a 65 
kDa cell surface bound glycosyl phosphatidylinositol (GPI)-linked protein (Lijnen H.R.,
2002). It consists of three domains (Dl, D2 and D3) and cleavage of the GPI anchor 
can release soluble uPAR (suPAR) from the plasma membrane (Castellino and Ploplis, 
2005) (Figure 1.6). The amino terminal fragment of uPA, is essential and sufficient for 
uPAR binding (Bu et al, 1994). This results in the exposure of the catalytic, carboxy- 
terminal domain and subsequent plasminogen activation. Binding of uPA to uPAR 
controls uPA activity through endocytosis (Section 1.7.3.) and also activates local 
proteolysis and intracellular signalling transduction, which is as a result of uPAR 
interactions with neighbouring integrins (Myohanen and Vaheri, 2004). Recycling and 
endocytosis of the uPA:uPAR complex also involves intereaction with LRP and the key 
PA inhibitor, PAI-1 (Binder et al., 2002).
Endogenous inhibitors of PA’s exist, which form part of the family of the serine 
protease inhibitors (SERPINS). This family includes plasminogen activator inhibitor-1 
(PAI-1), 2 and 3, ct2-antiplasmin and antithrombin III. PAI-1, a 45-50 kDa protein, is 
the major inhibitor of tPA and uPA (Figure 1.6), thus is capable of inhibiting vascular 
fibrinolysis and cell-associated proteolysis (Lijnen H.R., 2002). PAI-1 is produced by 
ECs, smooth muscle cells, macrophages and in liver, spleen and adipose tissue (Huber,
2001), however 90% of the inhibitor is stored in platelets from where it can be released 
locally at sights of thrombus formation (Dobrovolsky and Titaeva, 2002). In plasma, 
PAI-1 is present in 2 forms; active and latent. The active form specifically interacts 
with vitronectin, an extracellular matrix protein which stabilises PAI-1 in its active 
conformation (Loskutoff et al., 1999). The involvement of PAI-1, vitronectin, uPAR, 
uPA and LRP is given in more detail in section 1.7.3. The synthesis of PAI-1 is 
markedly increased by a large number of substances including pro-inflammatory
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cytokines, insulin, TGF-|3 and thrombin. PAI-1 is regarded as an acute phase protein, as 
it is rapidly increased several fold during the acute phase of disease (Dobrovolsky and 
Titaeva, 2002) and thus may be regarded as a marker for an ongoing inflammatory 
process (Binder et al, 2002). Interaction of tPA, uPA, uPAR and PAI-1 is illustrated in 
Figure 1.7, which also depicts the link between the PA and MMP cascades.
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Figure 1.6. A schematic representation o f the structure o f  tPA, uPA, uPAR and PAI-1. (a) tPA protein is 
composed o f a fibronectin-like domain, an epidermal growth factor (EGF)-like domain, 2 kringle domains 
and a catalytic C-terminal domain. The fibrin binding sites are located in the fibronectin-like domain and 
the second o f the kringle domains. PAI-1 binding also occurs at two sites in the second kringle domain 
and at the catalytic domain, (b) uPA, a smaller protein than tPA, also has an EGF-like domain, only one 
kringle domain and a C-terminal catalytic domain. uPAR binding occurs at the N-terminal EGF domain 
and PAI-1 interaction occurs in the catalytic domain indicating that interaction o f uPA with its receptor 
and inhibitor can occur at the same time, (c) uPAR protein is composed o f three domains. The 
chemotactic region (Ch) is activated upon splicing o f the protein between domains 1 and 2. Domain 1 
contains the uPA binding site, domain 2, the vitronectin binding region and domain 3, the interaction site 
for integrins. (d) PAI-1 protein has a region for vitronectin interaction at the C-terminus and interactions 
with uPA and tPA occur near the N-terminal domain o f the protein.
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Figure 1.7. Schematic representation o f  the PA cascade; functions and interactions. A number of 
effects, both beneficial and deleterious, can occur as a result o f the activation o f these systems. Active 
enzymes and their interactions are indicated in blue, inhibitors are indicated in red and enzymes 
precursors in bold text.
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Plasminogen activators are not solely expressed in tissues that are associated 
with fibrinolysis suggesting that this group of proteins have additional roles. The 
expression of tPA has been described both in the developing and 4he adult mouse brain 
where it plays a role in development, synaptic plasticity and remodelling (Sappino et 
al, 1993). High levels are found particularly in the thalamus, amygdala and 
hippocampal pyramidal neurons (Teesalu et al., 2002), an area associated with learning 
and memory. Neurons and glial cells are the key tPA producing cells in the CNS where 
it is stored intracellularly and released upon depolarisation of the neuronal cell 
membrane in a calcium dependent manner (Gualandris et al., 1996). In line with this, a 
brain specific inhibitor of tPA, neuroserpin has been identified (Hastings et al, 1997). 
Unlike other PA inhibitors, neuroserpin is a more effective inhibitor of tPA than uPA 
(Yepes and Lawrence, 2004). It is a 44kDa protein which is expressed primarily in 
neuronal cells in areas of the brain also associated with tPA expression, such as the 
hippocampus (Hastings et al, 1997).
In the last decade the introduction of methods of gene inactivation have enabled 
in depth study of the components of the fibrinolytic system. Disruption of the tPA gene 
involved the replacement of a section of the gene encoding for the kringle 2 domain and 
part of the proteolytic domain with a neomycin-resistance gene (Carmeliet P. et al, 
1994). Litter size, frequency of birth and body weights are normal in these homozygous 
knockout animals. Mice deficient for tPA suffer impaired clot lysis (Carmeliet P. et al, 
1994) although no histological or macroscopic abnormalities are observed in mice aged 
up to 14 months (Ploplis and Castellino, 2002). Mice deficient for uPAR were created 
by replacing a large part of the genomic sequence, exons 2-5, with the neomycin 
resistance gene (Dewerchin et al, 1996). None of the homozygous knockout offspring 
demonstrate abnormal growth or fertility, and histologically there are no pathological 
lesions or fibrin deposits (Ploplis and Castellino, 2002). Clot lysis in these animals is
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normal, although uPA mediated plasminogen activation is reduced (Dewerchin et al., 
1996). PAI-1 deficient mice were generated by homologous recombination in 
embryonic stem cells resulting in the deletion of the entire coding region of PAI-1 
(Carmeliet P. et al., 1993). PAI-1 knockout mice are viable, litter and offspring sizes 
are similar to wild type animals, with no apparent macroscopic or microscopic 
histological abnormalities. Use of these knockouts in a wide variety of experiments has 
enabled in-depth exploration into the roles of the components of the PA system in a 
number of pathological models.
1.7.3. uPAR, PAI-1 and cell migration.
Binding of the serine protease enzyme uPA to its cell surface bound receptor, 
uPAR, activates local proteolysis via the conversion of the zymogen plasminogen to 
plasmin. However, the role of uPAR is not limited to cell associated proteolysis, as 
interaction of uPAR with uPA, PAI-1, LRP, vitronectin and integrins provide a novel 
mechanism for cell chemotaxis, adhesion and migration (Binder et al., 2002). 
Leucocytes including monocytes, macrophages and activated T-cells all constitutively 
express uPAR (Garcia-Monco et al., 2002) which plays an important role in adhesion 
and migration to sites of inflammation via interactions with vitronectin and numerous 
integrins (Chapman, 1997; May et al., 1998; Tarui et al., 2001). The function of PAI-1 
in modulating cell adhesion and migration is somewhat complex. The key modulatory 
effect of PAI-1 occurs through its capacity to bind to vitronectin (Hertig and Rondeau, 
2004). Vitronectin (VN) is an adhesive glycoprotein present in plasma and tissues 
which, once deposited, binds many ligands including uPAR, PAI-1 and integrins. 
Binding of PAI-1 to VN stabilises the inhibitor in its active conformation thus enabling 
PAI-1 to competitively inhibit the uPAR-dependent attachment of cell to VN (Waltz et 
al, 1997). In this way PAI-1 acts as a molecular switch interfering with the uPAR-VN
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link, leading to detachment of cells from the substrate (Deng et al, 1996). Binding of 
PAI-1 to VN not only directly blocks uPAR mediated adhesion, but also sterically 
hinders ctvfh integrin binding to VN (Loskutoff et al, 1999). Waltz et al., (1997) 
discovered that by promoting detachment of uPAR bearing cells from VN, PAI-1 
increased cellular migration on this matrix. The effect of PAI-1 on cell migration is 
particularly evident in cancer whereby high levels of this inhibitor are associated with 
tumour metastasis and a poor prognosis (Dellas and Loskutoff, 2005). A summary of 
the molecules capable of interacting with components of the PA system and their effects 
on cell migration/ adhesion is given in Table 1.2.
uPAR bound uPA is polarised at the leading edge of migrating leucocytes 
(Estreicher et al, 1990) where it can remain for some time, unless complexed with an 
inhibitor (PAI), whilst also increasing the affinity of uPAR for association with 
integrins (Blasi, 1997). In addition to competitively binding to VN, PAI-1 can also 
complex with uPAR bound uPA, and the inhibitor-proteinase-receptor complex are 
removed from the cell surface via members of the scavenger receptor family such LRP 
(Nykjaer et al, 1997). In this case the complex is then endocytosed and the uPA-PAI-1 
complex is targeted for lysosomal degradation whilst uPAR is recycled and reappears at 
the cell surface (Figure 1.8). This unique tool enables the cell to recycle uPAR in a 
ligand-free form promoting the adhesion/chemotaxis state of the cell in favour of the 
proteolytic state (Bianchi et al, 1997). uPAR also interacts with integrins, cell surface 
receptors that anchor cells to the ECM, and this model provides the attachment, 
detachment and reattachment of integrins necessary for cell migration.
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PA components Interacting molecules Adhesive/deadhesive | 
funtions
uPAR VN Adhesion
uPAR + PAI-1 VN Detachment
uPAR + uPA VN, FN, otvP3, (X5P1, ctvPi Adhesion
uPAR + uPA + PAI-1 VN, FN, 0CvP3, ctvPi Detachment
uPAR + uPA + PAI-1 VN, FN, otvP3, ayPi LRP Detachment, integrin
inactivation, endocytosis
uPAR (uPA?) a 4Pi, a vP3, CC9P1 Cell-cell adhesion
uPA uPAR, Lmp2 Adhesion
Table 1.2. Components o f the PA cascade, their interactions and functions. VN = vitronectin, FN = 
fibronectin. From Myohanen and Vaheri, (2004).
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Figure 1.8. Schematic to illustrate the interactions between uPAR, uPA, PAI-1, LRP and integrins. The 
interaction of uPAR, uPA and PAI-1 with LRP is inhibited by receptor associated protein (RAP) which 
will prevent the recycling of uPAR back to the cell surface. The interaction of uPA with its receptor 
promotes local proteolysis whilst PAI-1 forms the bridging element between the uPA:uPAR complex and 
LRP, promoting cell migration. Endocytosis of the uPAR is thought to lead to intracellular signalling 
events via the Janus-kinase and signal transducer and activator of transcription (JAK-STAT) pathway, 
Src-like protein-tyrosine kinases and extracellular signal-regulated protein kinases (ERKs). uPA 
interaction with uPAR increases the affinity of the receptor for vitronectin and a variety of integrins also 
promoting cell adhesion and migration. Adapted from Binder et al., (2002).
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Generation of uPAR deficient mice (Dewerchin et al, 1996) has enabled 
detailed study of the role of uPAR on cell adhesion / migration in response to infection, 
injury and inflammation (Busso et al., 1998; Gyetko et al, 2001; Ploplis and Castellino, 
2002). Mice deficient for uPAR have impaired neutrophil recruitment in response to 
Pseudomonas aeruginosa pneumonia when compared to the wild type (Gyetko et al, 
2000). In addition, this mechanism appears to be dependent on p2 integrins confirming 
the required interaction of uPAR with integrins for cell migration. Increase in uPAR 
expression has been linked to numerous human diseases (Blasi and Carmeliet P., 2002), 
including cancer where increased levels of uPAR are strongly correlated with tumour 
invasiveness and metastasis and poor prognosis (Blasi and Carmeliet P., 2002). Several 
approaches at inhibiting the uPA:uPAR interaction in preclinical studies of cancer 
treatment with small peptide molecules, monoclonal antibodies or using antisense 
technology have shown promising results (Choong and Nadesapillai, 2003). In 
addition, amplified uPAR expression has also been indicated in cerebral malaria (Fauser 
et al, 2000), traumatic brain injury and focal cerebral ischaemia (Beschomer et al, 
2000). Although uPAR is found in the serum and CSF of patients with various 
neurological diseases (Garcia-Monco et al, 2002), little research has been carried out 
into the roles of uPAR in inflammatory diseases of the CNS.
1.7.4. PAs and Neuropathology.
Over the last decade much interest has been invested into exploring the role of 
the PAs, particularly tPA, in various neuropathologies (summarise in Table 1.2). tPA 
was found to be expressed as an early gene induced after seizures (Qian et al, 1993). 
Following on from this discovery, Tsirka et al, (1995) discovered that tPA knockout 
mice were less susceptible to pharmacologically induced seizures. In addition, they also 
observed that tPA deficient mice, and plasminogen deficient mice, were resistant to
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excitotoxin-induced neuronal degeneration following intracerebral administration of 
NMDA, AMPA or kainate into the hippocampus, indicating that the tPA/plasmin 
cascade is in involved in the mechanisms underlying excitotoxic cell death (Tsirka et 
al., 1997b). Further work revealed that the critical event in this cascade appeared to be 
plasmin mediated degradation of laminin matrix in the hippocampus which precedes the 
onset of neuronal death (Chen and Strickland, 1997; Tsirka et al., 1997a). Mechanisms 
of excitotoxicty are thought to be involved in the underlying pathology of many 
conditions such as AD and stroke (Hynd et al., 2004), thus these findings 
understandably led to the investigation of the role of the PA cascade in ischaemia. This 
was of particular interest as tPA is used as a clot busting drug clinically, administered to 
people who have suffered an acute stroke. The expression of all components of the PA 
system are increased in response to ischaemia and traumatic brain injury (Dietzmann et 
al., 2000). Investigating the role of tPA in various animal models of stroke has however 
led to conflicting results and these differences appear generally due to the model of 
ischaemia employed in the studies. Using a permanent middle cerebral artery occlusion 
(MCAO) model of stroke, Wang et al., (1998) discovered that tPA deficient mice had 
50% smaller infarcts that the wild type. In addition, intravenous injection of tPA 
increase the infarct size in tPA /_ and wild type mice indicating that tPA can increase 
stroke-induced injury. In the same model it has also been shown that transgenic mice 
over-expressing neuroserpin, the brain specific tPA inhibitor, have smaller infarcts after 
MCAO (Cinelli et al., 2001). Injection of neuroserpin directly into the brain of rats 
shortly after MCAO reduced stroke volume by 64% at 72h compared with untreated 
animals (Yepes et al., 2000). In both of these studies, the thrombolytic effect of tPA is 
not assessed as the model used does not involve microvascular thrombus formation. 
Experiments using a transient model of ischaemia by MCAO with an unsiliconised 
thread, leading to cerebrovascular thrombosis indicate that tPA has beneficial effects
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where tPA'7' mice suffer exacerbated ischaemic insult (Tabrizi et al., 1999). In 
conclusion, it is still not entirely clear of the role of tPA in ischaemia, however it is 
clear that differences in experimental design can yield different results and that tPA can 
have beneficial and deleterious effects within the same and different neuropathologies.
More recently the PA system has been linked to AD. AD is a common form of 
dementia in aged individuals, the cause of which is unknown. A characteristic 
pathology includes plaques in the brains of AD patients largely composed of amyloid-|3 
(Ap) peptide (Hynd et al., 2004). It has been documented that the activation of plasmin 
by tPA can degrade Ap (Tucker et al., 2000), as can uPA (Tucker et al., 2002), however 
neither of the PA enzymes can degrade Ap in culture without the presence of 
plasminogen. Ap peptide injected into the brains of mice deficient for either tPA or 
plasminogen revealed persistent Ap immunoreactivity which completely disappeared in 
the wild type (Melchor et al., 2003). Increases in uPAR expression have also been 
documented in the post mortem tissue from the brains of AD patients (Walker et al.,
2002). It is becoming increasingly evident that AD has an inflammatory component to 
the pathology, and here, uPAR upregulation is a marker of microglia and macrophage 
activation.
The actions of tPA and the PA cascade in the CNS led to investigations of their 
effects in models of peripheral nervous system injury. Axonal outgrowth during 
peripheral nerve regeneration relies on the ability of growth cones to migrate through 
ECM components utilising the actions of the PA proteases (Seeds et al., 1996). After 
peripheral nerve injury, expression of the PA system is rapidly induced (Siconolfi and 
Seeds, 2001a), thus to investigate the functional consequences of the absence of various 
components of the PA system on peripheral nerve regeneration, a model of sciatic nerve 
crush was employed in mice deficient for tPA, uPA or plasminogen (Siconolfi and 
Seeds, 2001b). The results indicated that the PA system facilitates recovery after sciatic
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nerve injury. Knockout animals suffered delayed recovery of sensor and motor 
functions in the hindlimb after injury, possibly due to impaired nerve outgrowth. 
Another study of sciatic nerve injury also showed a protective role for tPA and 
plasminogen in this model and, focusing on the mechanisms behind this particular 
effect, demonstrated that fibrin deposition on axons correlates to the degree of nerve 
damage observed (Akassoglou et al., 2000). Mice deficient for tPA or plasminogen 
showed exacerbated axonal loss after injury and pharmacological depletion of fibrin 
ameliorated the axonal degeneration in the knockout animals (Akassoglou et al, 2000). 
In addition, double knockout mice for plasminogen and fibrinogen showed similar 
levels of axonal loss and demyelination to wild type (Akassoglou et al., 2000). This 
was the first example of how the fibrinolytic capacity of tPA can have beneficial effects 
other than its role in the vascular system.
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Neuropathology Findings References
Normal CNS tissue
Human tPA expressed in neurones and microglia, high 
levels in the hippocampus. Involved in axonal 
growth cone migration and neurite outgrowth.
(Seeds et al., 1996)
Rodent
Traumatic brain injury and ischaemia
Mouse model o f 
TBI
tPA amplified cortical brain damage and oedema 
in TBI (Mori etal., 2001)
Acute stoke - 
humans
tPA used as a treatment because of its 
thrombolytic activity.
M ouse model o f  
focal ischaemia
tPA can increase stroke-induced injury. (Wang et al, 1998)
Inflammatory demyelinating disease
M ultiple sclerosis
tPA activity increased in CSF of MS patients and 
correlates with disease progression. 
Decreased tPA activity in MS brains due to 
increased PAI-1. Increased uPAR expression on 
inflammatory cells in lesions.
(Akenami et al., 1996) 
(Gveric et al., 2001)
EAE Increased severity of EAE and delayed recovery in tPA ko mice. (Lu et al., 2002)
Neurodegenerative disease
Excitotoxin-
induced
neurodegeneration
tPA ko mice resistant to neurodegeneration after 
injection of excitotoxin. (Tsirka et al., 1995)
A lzheim er’s disease Increased uPAR expression in AD brain. (Walker et al., 2002)
M ouse model o f  
AD
tPA-plasmin proteolytic system accelerates AP 
degeneration. (Melchor et al., 2003)
Spinal cord and peripheral nerve injury
Sciatic nerve crush tPA and uPA aid recovery and peripheral nerve regeneration after SNC.
(Akassoglou et al., 2000) 
(Siconolfi and Seeds, 
2001b)
Spinal cord 
contusion
tPA increases secondary injury after spinal cord 
contusion and is involved in the activation of 
microglia and macrophages after injury.
(Abe et al., 2003) |
Table 1.3. Alterations/involvement o f the PA system in different neuropathological conditions.
1.7.5. tPA and microglia.
Microglial activation is known to have an important role in the progression of 
neuroinflammation via release of a number of neurotrophic and particularly neurotoxic 
substances, which are thought to promote disease development (Kreutzberg, 1996). In 
recent years activation of microglia has been documented in a number of 
neuropathologies, including stroke, MS and AD. As tPA is stored and released from
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microglia, it was of some interest to investigate its role in their activation. As 
previously discussed, tPAv' mice are resistant to excitotoxin induced neuronal 
degeneration, in addition the same study revealed that microglia in these animals 
showed attenuated activation (Tsirka et al, 1995). Microglia isolated from tPA 7' mice 
show attenuated activation in response to lipopolysaccharide (LPS) in culture, 
determined by morphological changes and upregulated expression of the surface antigen 
F4/80, and this effect of tPA on microglia appears to be independent of its proteolytic 
action (Rogove et al, 1999). LPS-activated microglia produce conditioned medium 
which results in neuronal death, in vitro. This effect is inhibited by PAI-1 or by 
incubation with an anti-tPA antibody (Flavin et al., 2000), suggesting that microglial 
tPA contributes significantly to hippocampal neuronal death. Under pathological 
conditions in vivo, it appears that injured neurones are the primary source of tPA, which 
acts as a cytokine to activate microglia, that in turn secrete additional tPA, promoting 
ECM degradation and neurodegeneration (Siao et al., 2003). In EAE, although tPA '' 
mice suffered worse clinical disease, they showed delayed and attenuated microglial 
activation when compared to the wild type (Lu et al., 2002), indicating that in this 
situation microglia are releasing potentially beneficial substances such as growth factors 
and anti-inflammatory cytokines (Diemel et al., 1998). High levels of NO are 
considered to be toxic to neurons and oligodendrocytes and are thought to play a role in 
a number of diseases, including MS. It has been shown that tPA derived from 
astrocytes can inhibit NO produced from activated microglia (Vincent et al., 1998) 
providing a possible beneficial mechanism for tPA.
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1.7.6. Plasminogen activators and Neuroinflammation.
Activation of serine proteases in inflammatory CNS lesions in MS is considered 
to play a major role in the disturbance of the BBB and subsequent leucocyte entry 
leading to inflammation and demyelination (Lo et al, 2002; Teesalu et al., 2001). 
Studies on human brain tissue homogenates (Gveric et al, 2001) has revealed that 
antigen levels of uPA, uPAR and PAI-1 are significantly increased in normal appearing 
white matter (NAWM) and MS lesions compared to control brains. However, tPA, 
although being the most abundant plasminogen activator in normal control brains, was 
reduced in both MS white (WM) and grey matter (GM). tPA is immunolocalised on 
thick and damaged axons in active MS lesion borders but was confined to blood vessel 
walls in chronic lesions. In contrast, in a relapsing model of EAE in the Lewis rat 
induced by IL-12, tPA antigen and activity levels were found to rise during the acute 
phase and subsequent two relapses and the enzyme was primarily localised in 
inflammatory cells in perivascular infiltrates (Ahmed et al., 2001). However, during the 
third relapse, a small decrease in tPA antigen levels was coupled with tPA 
immunolocalisation on axons overlapping with the areas of axonal death. Levels of 
PAI-1 and particularly tPA are increased in the CSF of MS patients (Akenami et al, 
1996; Akenami et al, 1997). Although levels of tPA antigen have been shown to 
decrease in MS tissue, other studies have suggested expression levels are actually 
increased (Cuzner et al, 1996). Akenami et al, (1999) demonstrated an increase in tPA 
mRNA, particularly in neuronal cells, however whether tissue damage in MS is the 
cause or effect of increased tPA is not known.
Fibrin(ogen), a protein of the extracellular matrix with a broad range of 
biological functions, is not present physiologically in the nervous tissue. However in 
neuroinflammatory disease such as MS, there is evidence of fibrin exudation through a 
damaged BBB (Claudio et al, 1995) followed by deposition on axons, which precedes
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clinical symptoms of MS (Kermode et al., 1990) and occurs prior to demyelination 
(Wakefield et al., 1994). Co-localisation of tPA on demyelinated damaged axons 
stained with non-phosphorylated neurofilament and fibrin may indicate a role for tPA in 
axonal damage (Gveric et al., 2001), paradoxically it may also indicate a protective role 
for tPA, via fibrin removal. Significant upregulation of the tPA inhibitor PAI-1 in MS 
tissue decreases the amount of enzyme thus affecting fibrin removal and axonal 
integrity (Gveric et al., 2003). Fibrin deposition has been shown to hinder axonal 
regeneration in a model of peripheral nerve damage, (Akassaglou et al 2000), thus it is 
possible that the same applies in the CNS. Indeed more recently it has been proven that 
MS tissue, and in part NAWM, has impaired fibrinolytic capacity, leading to 
accumulation of fibrin products on axons (Gveric et al., 2003). Under conditions of 
neuroinflammation it also appears that there are conflicting data proving an unclear 
message as to whether tPA is harmful or protective in this situation. A recent 
experiment investigated the role of tPA in EAE by using mice tPA knockout mice (Lu 
et al., 2002). In these animals, the disease progression of EAE was significantly 
different to the wild type, and knockout mice had a delayed onset of disease which was 
more severe than the wild type. In addition, axonal degeneration and demyelination 
were delayed, but prolonged in the tPA A mice.
The role of fibrin in EAE has previously been investigated in the rat. Early 
studies by Paterson, (1976) demonstrated that perivascular fibrin deposits correlated to 
the occurrence of clinical paralytic signs, however neither paralytic signs nor fibrin 
deposition related to the development of perivascular cellular infiltrates. In addition, 
rats treated with ancrod, a defibrinogenating agent, showed a marked inhibition of fibrin 
deposits and exhibited no paralytic signs (Paterson, 1976). It has been shown more 
recently that increased BBB permeability and activation of the coagulation cascade 
occur one day before clinical signs of EAE and maximal fibrin deposition (Koh et al.,
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1993). Recovery of BBB permeability and return of fibrin deposition to normal levels 
were demonstrated prior to complete remission of neurological signs (Koh et al, 1993). 
Defibrination with batroxobin suppresses cell transferred EAE in Lewis rats (Inoue et 
al, 1996) and in TMEV-induced demyelinating disease (Inoue et al, 1997). Fibrin 
entry into the CNS during neuroinflammation occurs as a result of increased BBB 
permeability. Although the role of tPA on BBB breakdown has not been investigated in 
neuroinflammation, in a model of cerebral ischaemia tPA has been shown to induce 
increases in vascular permeability and opening of the BBB, via plasminogen and MMP- 
9 independent mechanisms, through LRP (Yepes et al, 2003). This occurs possibly by 
a receptor-mediated cell signalling event although the exact mechanism has not yet been 
elucidated (Yepes et al, 2003).
Although uPAR is largely undetectable in the normal brain, a significant 
increase in its expression is seen in MS tissue and NAWM. uPA-uPAR complexes are 
immunolocalised on inflammatory cells (monocytes and foamy macrophages) in the 
perivascular zone of evolving lesions (Gveric et al, 2001), suggesting that uPAR may 
facilitate cellular infiltration into the CNS via proteolysis and ECM breakdown. This 
increase in uPAR may also initiate adhesion of inflammatory cells to blood vessel walls, 
thus amplifying focal uPA activity (Gveric et al, 2001). uPAR expression on 
monocytes is increased in patients with CPMS and SPMS and also moderately in 
RRMS (Balabanov et al, 2001). Expression of uPAR on peripheral monocytes 
markedly increases prior to onset of an exacerbation, and subsequently decreases 
(Balabanov et al, 2001) suggesting that uPAR+ cells are migrating into the CNS. 
Microglia isolated from MS patients display an increase in uPAR on the cell surface 
(Washington et al, 1996) as uPAR is a marker for microglial activation (Beschomer et 
al, 2000).
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1.8. Aims of the thesis
Tissue plasminogen activator is thought to play a role in contributing to 
increased BBB permeability and neurodegeneration during the course of MS. 
Paradoxically, it can also promote neuronal survival through removal of fibrin deposits. 
Therefore, depending on the stimulus and surrounding microenvironment, tPA has the 
potential to be either a destructive or a beneficial agent in CNS injury and disease. In 
addition to roles in fibrinolysis, uPAR and PAI-1 are involved in cell migration and 
adhesion.
The aims of this project were to determine the role of the PA system on 
fibrinolysis and cell migration in an established chronic relapsing model of MS. 
Furthermore, these studies aimed to shed light on the endogenous fibrinolytic pathway 
as a potential therapeutic target by examining the disease pathology in a mouse model 
of MS, in the absence of this system. By developing EAE in tPA, uPAR and PAI-1 
knockout mice, characterising inflammation, and investigating demyelination and 
axonal pathology, the functions of these molecules could be determined. Finally, in 
order to explain the variations observed in the different knockout genotypes of mice, the 
known functions of the PA molecules were studied to uncover how they act during 
neuroinflammation and neurodegeneration. Enzyme-linked immunosorbant assays 
(ELISAs) for tPA, PAI-1 and uPA, and Western blotting for plasminogen and fibrin, in 
addition to in vitro and in situ assays, were used to analyse the fibrinolytic capactity of 
control and diseased CNS tissue.
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Materials and methods.
2.1. Mice.
tPA'7', uPAR'7', PAI-1'7' mice (Carmeliet P. et al., 1993; Carmeliet P. et al., 1994; 
Carmeliet P. et al., 1995; Dewerchin et al., 1996) and their respective wild type 
littermates (C57BL/6 x 129) (obtained from Professor H.R. Lijnen, Centre for 
Molecular and Vascular Biology, University of Leuven, Belgium) were bred in-house at 
the Institute of Neurology and screened by polymerase chain reaction (PCR). Biozzi 
ABH mice (Baker et al., 1990) were from stock bred in-house. All mice were fed RM- 
1(E) diet and water ad libitum. All experiments were ethically performed according to 
the UK Animals (Scientific Procedures) Act (1984).
2.1.1 ABH Backcrosses.
Induction of MOG-EAE in PAI-1'7' and PAI-1 WT littermate mice on the 
C57BL/6 background revealed a very low incidence of disease (36 % and 25 % 
respectively). As it is important to have a true comparison of knockouts with WT 
littermates, mice deficient for PAI-1 were backcrossed for 4 generations into the ABH 
strain of mice. This yielded PAI-1 heterozygote (PAI-1'/+) mice. By backcrossing the 
mice susceptibility rates are increased, as the C57BL/6 background is relatively 
resistant to EAE induction (Levine and Sowinski, 1973). Heterozygote animals were 
then paired up and resulting offspring produced PAI-1'7', PAI-1'/+ and PAI-1+/+ mice. 
The genotypes of mice were assessed using PCR to establish correct mice for breeding. 
To produce both knockout and WT littermate counterparts PAI-1'7' x PAI-1'7' and PAI- 
l +7+ x PAI-1+7+ breeding pairs were established. Following on from the homozygous 
breeding pairs, mice were routinely screened by PCR to confirm the integrity of the 
strain.
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2.2. Polymerase Chain Reaction (PCR).
In order to ascertain the correct genotype of the mice, it was necessary to set up 
polymerase chain reaction (PCR) methods, which could be routinely performed on 
DNA extracted from tail snip samples. PCR is a technique for amplifying areas of 
DNA using complimentary fragments of DNA flanking the region of interest 
(oligonucleotide primers). Primer design requires knowledge of the DNA sequence of a 
gene. Complementary sequences are chosen at sites on the DNA, which are most 
unique to reduce the chance of primers binding to other regions on the template DNA. 
A primer length of 17-28 bp is required to ensure uniqueness and is usually composed 
of 50-60% G + C content. The first stage in PCR is whereby the DNA double helix is 
separated to single strand segments using a high temperature, usually between 91 and 
97°C for 1 min, following which primers anneal to the single stranded DNA at specific 
temperatures related to their basic structure. The melting temperature (Tm) of primers 
depends on their length and composition of bases. The annealing temperature (Ta) is 
directly related to the Tm. These parameters are calculated by the following formulae:
Tm = 4 (G + C) + 2 (A + T) °C 
Ta = Tm- 4 ° C
Most annealing temperature are in the range of about 50-65 °C. A higher 
temperature means the reaction is more stringent, with less chance of primer mismatch, 
however if the temperature is too high, then less product will be made. When using a 
combination of primers, the annealing temperature should be optimised to ensure the 
formation of non-specific low molecular weight products are minimised. After the 
annealing stage the temperature is then changed to allow activation of a heat-tolerant 
DNA polymerase, which extends the primer in a 5’ to 3’ direction using surplus free
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deoxyribonucleoside triphosphates (dNTPs). A third temperature change denatures the 
DNA strands and the cycle can repeat, allowing the number of cycles to determine the 
degree of DNA amplification. The amplification is exponential up to a point then 
plateaus out, with DNA polymerase being the rate limiting factor. Taq DNA 
polymerase (from Thermus aquaticus bacteria) is heat stable and therefore ideal for this 
application. It has a half life of 30 min at 95 °C thus the number of amplification cycles 
shouldn’t exceed 30 cycles without reducing the denaturation time. Taq polymerase 
requires the presence of free magnesium ions to function, with the magnesium acting as 
a cofactor. Lower concentrations of magnesium chloride (MgCL) increase the 
stringency of the reaction, thus MgCL titrations should be performed with each new 
primer combination.
2.2.1. DNA Extraction.
Genomic DNA was prepared from the tails of mice that required screening. Tail 
snips (0.5 cm) were taken using Ethyl Chloride local anaesthetic (Roche, Ireland) and 
were digested by incubation overnight in 50pl 2mg/ml proteinase K (Invitrogen, 
Paisley, UK) and 450pl lysis buffer (400mM Tris/HCl, 60mM EDTA, 150mM NaCl 
and 1% sodium dodecyl sulphate (SDS), adjusted to pH 8 with 40% NaOH) in a heating 
block at 60°C (Techne-Dri block DB-2B, Cambridge, UK). The following day 188pl 
5M sodium perchlorate was added and samples were incubated for a further 30min at 
60°C. 750pl chloroform (VWR, Lutterworth, Leicestershire, UK), was then added and 
samples vortexed and centrifuged at 15,000 g (Eppendorf centrifuge 5425R, Eppendorf 
UK Ltd, Cambridge, UK) for 5 min. The upper aqueous phase was removed and 
transferred to fresh tubes containing 1ml absolute ethanol (VWR). These samples were 
incubated at 4°C overnight to precipitate the DNA. The following day samples were 
spun at 15,000 g in a centrifuge (Eppendorf) to pellet the DNA, the ethanol was
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removed and the DNA was resuspended in 50jil diethyl pyrocarbonate -treated water 
(DEPC; Sigma, Poole, Dorset, UK).
2.2.2. PCR protocol.
PCR was set up in sterile PCR reaction tubes (Perkin-Elmer Applied 
Biosystems, Norwalk, USA; 8 tubes per strip) using a mastermix consisting of; 10 x 
PCR reaction buffer (200mM Tris-HCL pH 8.4, 500mM KC1; Invitrogen) 2mM dNTPs,
1.5 — 2mM MgCE final concentration, 2.5 units of Taq DNA polymerase (Invitrogen) 
and ImM forward and reverse primers. 4jnl DNA was added per sample and the total 
volume made up to 50jnl with DEPC-treated water. Primers were custom made 
(Qiagen, Crawley, Sussex, UK) (Table 2.1); and samples were cycled in PCR machine 
(GeneAmp 9700, Applied Biosystems) according to the protocols indicated in Table
2 .2 .
Primer name Sequence
tPAfwd 5 ’-c g c t g t g t a a c t c t t g c c c a t g a g g a c -3 ’
tPArev 5 ’-g g a a a g g t g t g a c t t a c c g t g g c a c c c a c -3 ’
PAIfwd 5 ’-g a g t g g c c t g c t a  g g a a a t t c a t t c -3 ’
PAIrev 5 ’-g a c c t t g c c a a g g t g a t g c t t g g c a a c -3 ’
uPARko 5 ’-t t g a t g a g a c g c c t c t t c g g a g g a a c -3 ’
uPARwtfwd 5 ’-GTTACCTCGAGTGTGCGTCCT GCAC-3 ’
uPARwtrev 5 ’ -CCACCATTGCAGTGGGTGTAGTTGC-3 ’
insert PgKpA cassette 5 * -AATGTGTC AGTTTC ATAGCC-3 ’
Table 2.1. Oligonucleotide primers and their sequences used for genotyping knockout mice by PCR.
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Stage tPA genotyping PAI-1 genotyping uPAR genotyping
Denaturing 94°C -  4 min 94°C -  4 min 94°C -  4 min
Denaturing 94°C -  1 min 94°C -  1 min 94°C -  1 min
Annealing ^  x 30 55°C -  1 min 57°C -  1 min 57°C -  1 min
Extension ^ 72°C -  1 min 72°C -  1 min 72°C -  1 min
Extension 72°C -  10 min 72°C -  10 min 72°C -  10 min
HOLD 4°C 4°C 4°C
Table 2.2. Cycling programs for genotyping o f tPA", uPAR" and PAI-1'' mice.
Magnesium chloride titrations were performed to determine to optimum 
concentration for each reaction (Figure 2.1 A - C). Lower concentrations of MgCE 
increase the stringency of the reaction. Following this it was found that 1.5 mM MgCE 
most favourable for tPA primers, whilst 2 mM MgCb was optimal for PAI-1 and uPAR 
primers. Primer annealing temperatures were used according to the melting 
temperatures of individual primer pairs.
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MgCh titrations for tPA primers.
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Figure 2.1. Magnesium chloride titrations for tPA, PAI-1 and uPAR primers. Various concentrations of 
MgCl2 (between 0.5 and 2.5 mM) were tested to investigate which were optimal for each set of primers. 
Optimal MgCl2 concentrations were found to be 1.5mM for tPA primers and 2mM for PAI-1 and uPAR 
primers.
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For tPA and PAI-1 reactions a multiplex system was used whereby three primers 
were added in one reaction to detect knockout and wild type DNA samples (Figure 2.2 
and 2.3). For uPAR, two separate reactions were carried out, one to detect the knockout 
gene and the other to detect the wild type gene (Figure 2.4).
2.2.3. Analysis of PCR products by 1% agarose gel electrophoresis.
Separation of DNA fragments was performed on a 1% agarose gel, and 
visualised under ultra violet light using ethidium bromide. The sizes of PCR products 
were determined by comparison with a DNA ladder. Agarose (Sigma) in 1 x Tris-boric 
acid-EDTA (TBE) buffer (10 x solution; 1M tris, 0.1M boric acid, 0.01M EDTA; 
Invitrogen) with 0.5pg/ml ethidium bromide was prepared and poured into a gel box 
with well-forming combs, and allowed to set for 45 min. Once set, the combs and 
barriers were removed, and the gel was mounted in an electrophoresis box and 
immersed in 1 x TBE buffer. Samples and a 100 base pair DNA ladder (Promega, 
Southampton, UK) were prepared by diluting 5 pi of PCR product/ladder with 5 pi dfUO 
and 2pl loading dye (Promega). Samples were loaded into separate wells, flanked by 
wells containing DNA ladder, and the gel was run at 110 volts for 1 hr and 30 min. 
After running, the gel was destained in dP^O under agitation for 15 min, photographed 
using dedicated CoolSnapPro-cf monochrome camera and analysed using the GelPro 
image analysis package (Media Cybemectics, Berkshire, UK).
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Figure 2.2. PCR for tPA homozygous knockouts, heterozygotes and homozygous wild types. DNA was 
extracted from tail snips samples with proteinase K and lysis buffer. Chloroform extracted DNA was 
precipitated in ethanol and resuspended in water. The DNA was amplified using PCR and subject to 
agarose gel electrophoresis. Lane one indicates a heterozygote, with two bands present at 200 and 100 
base pairs (bp). Lane 2 shows a homozygote tPA wild type with one band at 1 OObp and lane 7 shows a 
homozygote tPA knockout with one band at 200bp.
Figure 2.3. PCR for PAI-1 homozygous knockouts, heterozygotes and homozygous wild types. DNA was 
extracted as described above. The DNA was amplified using PCR and subject to agarose gel 
electrophoresis. Lane 1 indicates a PAI-1 homozygous knockout with one band at 190bp and lane 6 
shows a PAI-1 homozygous wild type with one band at 400bp. This gel shows no heterozygous DNA, 
but this would be seen as two bands in the same lane, one at 190bp and the other at 400bp.
Illm
Figure 2.4. PCR for uPAR homozygous knockouts, heterozygotes and homozygous wild types. DNA was 
extracted as described above. The DNA was amplified using PCR and subject to agarose gel 
electrophoresis. Lane 4 indicates a uPAR homozygous knockout with one band at 970bp and lane 10 
show a uPAR homozygous wild type with one band at 780bp.
2.3. Myelin Oligodendrocyte Glycoprotein (MOG) induced EAE.
Mice (6-8 weeks) received 300pg MOG peptide 3 5 . 5 5  (Met -Glu -Val -Gly -Trp 
-Tyr -Arg -Ser -Pro -Phe -Ser -Arg -Val -Val -His -Leu -Tyr -  Arg -  Asn -Gly - 
Lys; Advanced Biotechnology Centre, Imperial College, London) (Bernard et al., 1997) 
injected into the flanks on day 0 and day 7. The peptide was emulsified in 300pl 
Incomplete Freund’s adjuvant (IFA) (Difco, Beckton Dickenson, Oxford, UK) 
supplemented with 4mg/ml of Mycobacterium tuberculosis (H37Ra) (Difco). Mice 
were injected intraperitoneally with 300ng of reconstituted lyophilised Bordetella 
pertussis toxin (Sigma) in 200pl PBS on day 0. The pertussis toxin injection was 
repeated after 48 h. Mice were monitored and weighed daily.
2.4. Spinal cord homogenate induced EAE.
2.4.1. Making of spinal cord homogenate.
Spinal cords were removed from ABH mice under hydrostatic pressure. This 
involved decapitation of the mouse followed by an incision into the lumbar spinal 
column in the pelvic region. A syringe filled with 1 x PBS with a 20 gauge needle was 
wedged into the spinal column and the spinal cord expelled from the cervical column 
using hydrostatic pressure. Spinal cords were homogenised by hand using a glass 
homogeniser. The container was covered with parafilm with small holes in the top to 
allow water to sublimate. This was frozen overnight at -20°C, and freeze dried for 48 
hours (Edwards Freeze drier, Crawley, Sussex, UK). Finally, the spinal cord 
homogenate was diced into a fine powder with a single edged razor blade and stored at - 
20°C until used.
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2.4.2. EAE induction.
ABH and backcrossed ABH/PAI-1'7' and ABH/PAI-1+/+ mice each received lmg 
freeze dried spinal cord homogenate injected into the flanks on day 0 and day 7. The 
homogenate was emulsified in 300pl IFA (Difco) supplemented with 4mg/ml of M. 
tuberculosis (H37Ra) (Difco) and 1 mg/ml M. butyricum (Difco). Mice were monitored 
and weighed daily.
2.5 Assessment of functional deficit in EAE mice.
2.5.1. Clinical scoring of mice.
Clinical disease was assessed and scored: 0 = normal, 1 = limp tail, 2 = impaired 
righting reflex, 3 = partial paralysis of hindlimbs, 4 = complete paralysis of hindlimbs 
and 5 = moribund/death. In addition, intermediate scores were given when appropriate. 
0.5 = loss of tail tonicity, 1.5 = slower than normal righting reflex, 2.5 = hindlimb 
weakness, 3.5 = paralysis of one hindlimb and paresis in the other. The mean day of 
onset, mean maximal score, mean score at experiment termination and the incidence of 
relapse were calculated from the data. Accompanying these signs in ABH and ABH 
backcrossed mice, weight loss occurred 1 -  2 days prior to onset of disease and is an 
accurate predictor of changes in disease, with animals regaining weight prior to 
recovery in remission (Baker et al., 1990). Weight loss in the C57BL/6 strain of mice is 
not that apparent therefore not used as a predictor of disease onset. Signs of tail 
spasticity included stiffness, curling and flicking and was visually assessed as being 
either present or absent. For specimen collection, mice were killed with carbon dioxide 
and immediately perfused intracardially with PBS. Spinal cords were removed under 
hydrostatic pressure and brains were dissected out. Once removed, the tissue was 
immediately snap frozen on dry ice, wrapped in foil and stored at -70°C until used.
Clinical Score
0 - Normal
1 - Limp tail u (1) -  Remission
2 -  Impaired 
righting reflex
3 -  Partial 
paralysis
4 -  Hindlimb 
paralysis
5 -  Moribund
Figure 2.5. The clinical scoring criteria in MOG3S_55 or spinal cord homogenate induced EAE. Signs 
become more severe as the disease course progresses. Used with permission of David Baker.
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2.5.2. Movement in an open-field activity chamber.
Movement activity of mice was carried out to investigate motor dysfunction and 
the degree of neurological impairment, which was found in previous studies to be 
closely correlated with axonal damage (Pryce et al, 2003). Mice were placed in a 27 x 
27 cm open-field activity chamber (Med Associates, Georgia, VT, USA) at 35 days post 
EAE induction (dpi) for all groups of mice and at 60 dpi for MOG-induced EAE. The 
movement around the chamber was recorded over a 5 min period and the total distance 
travelled (cm) per mouse was noted. Non-injected mice of each genotype were used as 
controls as mice injected with MOG or SCH which developed no EAE disease had 
comparable levels of activity to non-injected mice. Control tPA '' mice were 
significantly more active than control WT mice thus all data for EAE mice was 
normalised to the appropriate control and expressed as a percentage of that control.
2.6. Immunohistochemistry.
2.6.1. Slide preparation.
Super premium twin frost glass slides (VWR) for immunocytochemical staining 
were coated with Vectabond reagent (Vector Laboratories, Peterborough, UK) 
according to manufacturer’s instruction. Briefly, 2% Vectabond solution was prepared 
by mixing 7ml of Vectabond with 350ml of acetone (VWR). Slides were thoroughly 
washed in soapy water followed by distilled water, before being left to air dry. Slides 
were then immersed in acetone for 5 min. A coating solution of 2% Vectabond in 
acetone was applied for another 5 min. Slides were briefly washed in distilled water 
and dried at 37°C overnight.
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2.6.2. Haematoxylin and eosin staining.
Haematoxylin and eosin (H & E) staining was used to assess the extent of 
inflammatory infiltration and cellularity in EAE sections. Unfixed sections mounted on 
glass slides were placed in Harris haemotoxylin (Sigma) for 3 min and then blued 
briefly with running tap water. Slides were dipped into acid alcohol (1% v/v HC1 in 
70% ethanol) 10 times and then washed again for 2 min in cold running water. Finally, 
slides were counterstained in eosin (VWR) for 30 s, dehydrated through graded ethanol 
solutions (95% followed by 2 x 100% solution) and xylene (VWR) for 45 sec each, 
followed by a further 3 min in xylene. Finally slides were mounted in DPX (VWR) and 
left to dry overnight.
2.6.3. Histopathological evaluation.
To assess the extent and degree of infiltration of inflammatory mononuclear 
cells into the spinal cord during EAE, the total number of perivascular cuffs was 
counted in a spinal cord longitudinal section area of 4cm2. Each cuff was given a score 
according to the degree of cellular infiltration, to gain a semi-quantitative measure of 
inflammation as follows; 1, perivascular inflammation three or fewer cells deep; 2, more 
than three cells deep; 3, parenchymal infiltrate. The average cuff count and score was 
taken from a total of three slides from different mice per time point.
2.6.4. Preparative techniques: choice of tissue fixative and antibody titration.
Adequate and complete fixation forms the foundation of all good histological 
preparations and its aim is to preserve the tissue antigens as far as possible in their 
native structure. Four protocols were tested to assess the effects of different fixatives on 
antigen-antibody reaction. Each reagent was initially tested under three different 
temperature conditions with antibody markers for neurofilament, and MBP as internal
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controls (Table 2.3). Based on the clarity of cellular staining, tissue structure 
preservation, low background signal and suitability for both single and double 
immunocytochemisty, methanol at -20°C for 5 min was adopted as the protocol of 
choice. Aldehydes were typically not used as they are known to reduce antibody 
detection of many antigens (Baker et al, 1990).
Fixative RT 4°C -20°C
Ethanol ++ + _
Methanol ++ +++ +++
Acetone - + -
Table 2.3. Assessment o f different fixation protocols. Key: - poor, + good, ++ satisfactory and +++ 
excellent.
Optimal binding conditions for primary antibodies were established by applying 
a range of dilutions to sections of normal and EAE CNS tissue. Initial dilutions for 
monoclonal antibodies were 1:20, 1:50, 1:100 and 1:200 and for polyclonal antibodies 
1:200, 1:500, 1:1000 and 1:2000. Further titrations after these initial dilutions were 
carried out if necessary. The optimum dilution was considered to be the antibody 
concentration which gives a clear staining pattern and a low background signal (Table
2.4).
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Antibody Cell specificity Isotype Dilution Source and reference
mAb SMI-35
Phosphorylated
neurofilament
IgGl 1 in 10000 Sternberger monoclonals
mAb SMI-32
Non-phosphorylated
neurofilament
IgGl 1 in 2000 Sternberger monoclonals
Rabbit oc-MBP Myelin basic protein Polyclonal 1 in 2000
Chemicon (Chandlers 
Ford, Hampshire, UK)
Rat <x-CD45
All haemopoietic cells, 
leucocyte common antigen
IgG2b 1 in 2000
Serotec (Kidlington, 
Oxford, UK)
Rat oc-CD8
Cytotoxic T cells and 
macrophages
IgG2b 1 in 500 (Cobbold etal., 1984)
Rat oc-CD4 Thl and Th2 cells IgG2b 1 in 1000 (Cobbold etal., 1984)
Rat oc-F4/80 Microglia and macrophages IgG2b 1 in 50 Serotec
Goat oc- 
Fibrinogen
Fibrin(ogen) Polyclonal 1 in 10000 Sigma
Rabbit oc-uPA
Urokinase plasminogen 
activator
Polyclonal 1 in 1000 Prof. H.R. Lijnen
mAb oc-PAI
Plasminogen activator 
inhibitor
IgG 1 in 100 (Declerck etal, 1995)
mAb oc-uPAR
Urokinase plasminogen 
activator receptor
IgGl 1 in 100
Axis Shield Diagnostics 
(Dundee, UK)
Rabbit oc- 
GAP43
Growth-associated protein IgG 1 in 5000 Abeam (Cambridge, UK)
Rabbit oc- 
MAP2
Microtubule-associated
protein
Polyclonal 1 in 1000
Santa Cruz (Insight 
Biotech, Wembley, UK)
Goat oc-PSD- 
95
Post-synaptic density 
protein -95
Polyclonal 1 in 100 Santa Cruz
mAb <x- 
synaptophysin
Synaptophysin IgGl 1 in 200 Sigma
Table 2.4. Characteristics and source o f antibodies used in immunohistochemistry.
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2.6.5. Single immunocytochemical staining.
A three step peroxidase method was employed for single immunohistochemical 
staining. Cryostat sections (10-pm) cut onto Vectabond-coated slides, were fixed in 
methanol (-20°C, 5 min) and blocked with 2.5% normal serum diluted in phosphate 
buffered saline (PBS, 0.15M NaCl, lOOmM K2HP04.3H20  and 20mM KH2P 0 4, pH
7.4) for 1 hour at room temperature (RT). The blocking serum used was dependent on 
the animal in which the secondary antibody was raised. Blocking serum was tipped off 
and sections were incubated overnight at 4°C with primary antibodies in PBS. The 
following day slides were washed 3 x 5  min in PBS on a magnetic stirrer and sections 
were incubated with biotinylated secondary antibodies (1:100, Vector) for 1 h at RT. 
Peroxidase-labelled avidin and biotin reagents (ABC; Vector) were mixed at 1:100 in 
PBS and pre-incubated for 30 min according to the manufacturer’s instructions to 
ensure formation of complexes. After a further three washes in PBS, the avidin-biotin 
solution was incubated on slides for 1 h at RT. The peroxidase substrate was prepared 
by mixing 0.05% (w/v) 3,3’-diaminobenzidine tetrahydrochloride (DAB, Sigma), 
0.04% (w/v) NiCl2 and 0.02% (v/v) hydrogen peroxide in 400 ml PBS immediately 
before use. Sections were incubated in the nickel-enhanced peroxidase substrate for 5 
min giving a black colour where antigen was immunolocalised. Slides were washed in 
tap water for 5 min, dehydrated through graded ethanol solutions (95% followed by 2 x 
100% solution) and xylene for 45 s each, followed by a further 3 min in xylene. Finally 
slides were mounted in DPX (VWR) and left to dry overnight. Omission of primary 
antibody, secondary antibody or ABC complex was routinely used as controls. Isotype 
matched controls were also used as controls and failed to show any staining, as 
previously shown by (Baker et al, 1990).
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2.6.6. Semi-quantitative analysis of demyelination and axonal pathology.
For semi-quantitative analysis of demyelination, sections stained with anti-MBP 
antibody were examined using a Quantimet 500 image analyzer (Leica Microsystems 
Imaging Solutions Ltd, Cambridge, UK) attached to a Zeiss microscope (Zeiss, 
Hertfordshire, UK). Four random fields per section were studied with three or four 
sections per group. The results were expressed as the amount of light transmittance 
through a stained portion of section normalized to a non-stained area of the slide. 
Axonal pathology was assessed by counting the number of SMI32 positive axons in 
randomly selected areas of spinal cord white matter from control and EAE mice at x 
400 magnification. Four areas were counted by two independent observers per section 
with three sections per group. In all instances the results were consistent between the 
different observers.
2.6.7. Single immunocytochemistry for CD45, CD8, CD4 and F4/80.
For immunohistochemical staining for CD45, CD8, CD4 and F4/80 a slightly 
different method was employed (Baker et al., 1990). Primary antibodies were diluted in 
5% normal mouse serum to eliminate the blocking stage, and incubated on the sections 
for 1 h at RT. Following 3 x 5  min in PBS, a rabbit oc rat biotinylated secondary 
antibody was diluted 1 in 100 in 5% normal mouse serum and incubated on the sections 
for 1 h at RT. Peroxidase-labelled avidin and biotin elite reagents (Vector) were mixed 
at 1:50 in 5% normal mouse serum and pre-incubated for 30 min according to the 
manufacturer’s instructions to ensure formation of complexes. After a further three 
washes in PBS, the avidin-biotin solution was incubated on slides for 30 min at RT. 
Finally a swine oc rabbit horse radish peroxidase (HRP) labelled antibody was diluted 1 
in 50 in 5% normal mouse serum and incubated on the sections for 30 min at RT. This 
was used to enhance and amplify the signal from the primary antibody. The peroxidase
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substrate was prepared as described above, however DAB substrate without nickel was 
used for CD45, CD8, CD4 and F4/80 staining and slides were counterstained in 
Mayer’s haematoxylin (HD scientific supplies, Aylesbury, UK) for 30 s. Slides were 
dehydrated and mounted as described in section 2.6.5.
2.6.8. Double immunocytochemical staining.
Double immunocytochemical staining was performed using 
immunofluorescence. Sections were fixed in the same way as described for single 
staining and blocked with 2.5% normal horse serum for 1 h at RT. A mixture of two 
antibodies (SMI32, 1:2000 and goat oc fibrinogen, 1:5000) in PBS were added to the 
sections and incubated overnight at 4°C. The following day after 3 x 5min wash in 
PBS, sections were incubated with horse oc mouse biotinylated secondary antibody 
(1:200, Vector) in PBS for lh at RT. Following another washing stage a mixture of 
fluorescent antibodies were added to the sections for lh at RT, avidin fluorescein 
isothiocyanate (FITC) DCS (1:200, Vector) and rabbit oc goat IgG 
tetramethylrhodamine isothiocyanate (TRITC) (1:20, Sigma) in sodium bicarbonate 
buffer (lOOmM N a^CCb, pH 8.5). After a final wash sections were mounted in 
Citifluor® anti-fade reagent (Citifluor Ltd, London, UK). Sections were examined 
under a fluorescent microscope. Single fluorescent staining with each primary antibody 
was carried out as a control. Omissions of primary, secondary and fluorescent 
antibodies were also routinely employed as controls.
2.6.9. Immunofluorescent staining for tight junction proteins.
Double staining for tight junction proteins using immunofluorescence was 
performed by Dr. Arie Reijerkerk of the Department of Molecular Biology and 
Immunology, VU medical Centre, Amsterdam, to investigate changes in the BBB
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before and during EAE onset. Cryostat sections (10-|Lim) cut onto Vectabond-coated 
slides, were fixed in acetone (RT, 15 min) and blocked with 20% normal goat serum 
diluted in 1 x PBS containing 1% bovine serum albumin (BSA) for 20 min at room 
temperature (RT). Primary antibodies, mouse oc claudin-5 (Zymed, Sam Fransisco, CA, 
USA), or mouse oc occludin (Zymed) were diluted 1 in 100 in PBS-1% BSA, and 
incubated on the sections overnight at 4°C. Following 3 x 5  min washes in PBS-1% 
BSA a biotinylated goat oc mouse secondary antibody was diluted 1 in 500 in PBS-1% 
BSA and incubated for 1 h at RT. Following another washing stage, a 1 in 500 dilution 
of the fluorescent antibody oc goat Alexa 546 (Molecular Probes, Leiden, Netherlands) 
was added to the sections for 1 h at RT. Following 3 x 5  min washes in PBS-1% BSA a 
rabbit oc laminin antibody (MP Biochemical Inc., Eschwege, Germany) was diluted 1 in 
100 in PBS-1% BSA and incubated on sections for 1 h at RT. After a further washing 
stage, a 1 in 500 dilution of a second fluorescent antibody, oc rabbit Alexa 488 
(Molecular Probes) was added to the sections for 1 h at RT. After a final washing stage, 
slides were mounted in Citifluor and examined under a fluorescent microscope.
2.7. Protein Extraction.
Snap frozen samples of spinal cord from EAE and control mice were weighed, 
finely cut and resuspended at 1:1 Og wet weight/ml in Tris-HCl buffer pH7.4 (lOOmM 
Tris, 5mM EDTA, 150mM NaCl, with 1% Triton X-100). Samples were homogenised 
using a high-intensity ultrasonic processor (Jencons Scientific Ltd, Leighton Buzzard, 
UK) and incubated on ice for 30 min. The tissue suspensions were spun at 15,000 g in 
an Eppendorf centrifuge for 60 min at 4°C and the supernatants collected at stored in 
aliquots at -70°C.
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2.7.1. Protein measurement.
The total protein concentration of spinal cord homogenates was determined by 
the Folin phenol method (Lowry et al, 1951), which is based on a two-step colour 
reaction. In an alkaline solution copper associates with protein and subsequently 
reduces the Folin reagent to form a blue coloured product. To maximise the colour 
resulting from the reduction, 0.4M sodium hydroxide is present to neutralise any acid 
released on addition of the Folin’s solution and sodium carbonate is added to buffer the 
reagents to an optimal pH of 10. The optical density, read at 750nm, is proportional to 
the copper bound protein.
For protein analysis an aliquot of each sample was thawed on ice and diluted to 
1 in 30 using 0.05M NaOH. Standards of bovine serum albumin (BSA) fraction V 
(Sigma) were prepared (0, 5, 10, 15, 20 and 30 pg/ml) in a volume of 150pl. Samples 
and standards were assayed in duplicate. 50pl of each diluted sample was placed in a 
10ml conical tube (Fisher Scientific, Loughborough, UK) with lOOpl distilled water. 
50pl 0.4M NaOH was added to each tube (standards and samples), followed by 1ml of 
freshly prepared solution X (2% Na2C03, 0.02% K2 Tartrate in 0.1M NaOH added to 
1% CuS04.5H20  in a ratio of 99:1). All tubes were vortexed, and left for 15min. lOOpl 
of Folin and Ciocalteu’s reagent (Lowry et al., 1951) (diluted 1:1 with water; VWR) 
was added to each tube. After vortex mixing the tubes, they were incubated in the dark 
for a further 30 min. The absorbance of each sample was read on an Ultraspec 2000 
spectrophotometer (Amersham Pharmacia Biotech UK Ltd., Little Chalfont, 
Buckinghamshire, UK), with water as a reference reading repeated in between samples. 
The generation of a linear standard curve allowed conversion of optical density to pg of 
protein per sample, any samples with concentrations above the level of the standard 
curve were re-assayed with a 1:50 dilution.
98
2.8. Western blotting.
Western blotting is a technique for quantifying specific protein levels in a given 
sample. This technique entails running the protein in a sample through a gel under high 
electrical current to separate protein by molecular weight -  smaller proteins will travel 
further than large proteins in a given time. These are then transferred on to a membrane 
and probed with antibodies raised against the protein of interest. Bands on an 
autoradiograph can then be quantified using computer imaging techniques.
40pg of supernatant proteins (3-6 pi) were diluted in reducing or non-reducing 
sample buffer (Reducing; 2% sodium dodecyl sulphate (SDS), 10% glycerol, 2.5% (3- 
mercaptoethanol, 125M Tris-HCl pH 6.8, 0.02% bromophenol blue, Non-reducing; 
same as before, expect without p-mercaptoethanol), denatured at 100°C and loaded onto 
a 5% stack, 5 or 10% resolve sodium dodecyl sulphate-polyacrilamide gel (Bio-Rad, 
Hemel Hempstead, Hertfordshire, UK) which were placed in a Biorad Mini-Protean 3 
gel-electrophoresis tank. The chamber and wells were filled with 1 x running buffer 
(0.25M Tris base, 1.92M glycine, 1% SDS). The gel was then run at 180 volts for ~ 
45min until the bromophenol blue dye front had reached the bottom of the gel. 
Following removal of the gel, it was equilibrated in transfer buffer (0.25M Tris base, 
1.92M glycine, 20% methanol and 0.1% SDS) for 20 min along with a piece of 
Immobilon-P polyvinylidene difluoride membrane (Millipore, Bedford, UK) which had 
previously been activated in ice cold methanol for 1 min. Mini Protean 3 fibre pads and 
3mm blotting paper were also soaked in transfer buffer. The transfer sandwich was 
constructed according to the manufacturer’s instructions, and loaded into the transfer 
block. This was then immersed in transfer buffer in the Mini Protean 3 chamber and 
proteins transferred to the membrane for 1 hour at 80 volts for 5 % gels or overnight at 
22 volts for 10 % gels. When using an overnight transfer, an ice block was added into 
the transfer chamber to reduce heat production from the electric current. Following
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removal of the membrane and a 1 x 10 minute wash in Tris-buffered saline with Tween- 
20 (T-TBS; 0.01M Tris-HCl, pH 7.4, 0.15M sodium chloride, 0.05% tween-20 
(Sigma)), non specific binding sites on the membrane were blocked with 5% Marvel ® 
dried fat free milk (Premier International Food (UK) Ltd, Lincolnshire, UK) dissolved 
in T-TBS for 1 h at RT. Following 1 x 1 0  min wash in T-TBS, the primary antibody of 
interest was diluted in 5% Marvel in T-TBS and incubated with the membrane for 2 h at 
RT (Table 2.5). After washing 3 x 1 0  min in T-TBS, the membrane was incubated with 
the secondary antibody which was coupled to horseradish peroxidase (HRP); oc mouse 
IgG HRP (1:1000, Affinity Bioreagents, Cambridge, UK), oc rabbit IgG HRP (1:1000; 
Amersham Biosciences) or oc goat IgG HRP (1:1000, Santa Cruz) for 1 h at RT. After 3 
x 10 min washes in T-TBS, the blots were developed by enhanced chemiluminescence 
(ECL, Amersham Biosciences) for 1 min according to the manufacturers instructions. 
The blot was the visualised using ECL x-ray film (Amersham Biosciences) with 
exposures of 1, 2, 5, 8 or 10 min. Film was placed in Kodak developer solution (Sigma) 
until there was a good contrast between the bands and the background (~2 min), and 
fixed in Kodak reagent (Sigma) for 5 min. Blots were analysed using the GelPro 
software package and the density measured in arbitrary units. Blots probed with 
secondary antibody only were used as control to check for non-specific binding (Figure 
2 .6).
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Antibody Specificity Dilution Source Conditions I
mAb oc fibrinogen 
Clone 85D4
Fibrinogen, fibrin 
monomers, D-dimer and 
D-fragment.
1 in 1000 Sigma
Non-reducing 
5 % gel
Rabbit oc-Plasminogen
Plasminogen, pre­
activation.
1 in 1000 Dako
Non-reducing 
10% gel
Rabbit oc-laminin
Laminin -  component of 
basement membranes.
1 in 1000 Sigma
Reducing 
5 % gel
mAb oc-synaptophysin 
Clone SVP-38
Synaptophysin, a synaptic 
vesicle protein.
1 in 1000 Sigma
Reducing 
10% gel
Rabbit oc-GAP43
Growth associated protein 
expressed by regenerating 
neurons.
1 in 1000 Abeam
Reducing 
10% gel
Rabbit oc-MAP-2
Microtubule associated 
protein 2.
1 in 1000 Santa Cruz
Reducing 
10 % gel
Rabbit oc-Neuroserpin Neuroserpin 1 in 1000
Dr. DA 
Lawrence
Reducing 
10% gel
Goat oc-annexin II Annexin II 1 in 2000 Santa Cruz
Reducing 
10% gel
mAb oc-LRP LRP heavy chain 1 in 1000
Calbiochem,
VWR.
Non-reducing 
5% gel
mAb oc-p-actin 
Clone AC-15
P isoform of actin 
(nonmuscle).
1 in 1000 Sigma N/A
Table 2.5. Antibodies used in Western blotting; their specificity, dilution and conditions for investigation.
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oc goat HRP 2° antibody oc rabbit HRP 2° antibody
—
i
oc mouse HRP 2° antibody
Figure 2.6. Secondary antibody controls for Western blotting. Protein samples were run on 10 % Tris- 
HCL gels under reducing conditions and transferred overnight onto PVDF membranes. The following 
day blots were blocked with 5% Marvel in T-TBS for 1 h at RT. After washing, membranes were 
incubated with an oc-goat, oc-rabbit or oc-mouse secondary antibody conjugate to HRP. Following 
washing, blots were developed using ECL solution and exposed to photographic film under safe light. 
Secondary antibodies bound in a specific manner and produced no non-specific bands.
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2.9. Clot Lysis Assay.
In order to investigate the fibrinolytic capacity of different CNS tissue extracts, 
and if and how this changed during experimental neuroinflammation, a clot lysis assay 
was carried out as previously described (Urano et al., 1996). Spinal cord tissue protein 
extracts were mixed 1:10 with dilution buffer (50 mM Tris, 0.2% Triton X-100, pH 7.4 
with HC1). 40 pi of diluted sample or standard was mixed with 360 pi of dilution buffer 
containing 7.3 pM human fibrinogen (Sigma), 0.25 pM human lys-plasminogen 
(Chromogenix, Milan, Italy), 1.7 mM CaC^, 0.7 mM MgCh and 12.5 mM NaCl. 
Samples were added in duplicate (180 pi per well) to 96-well microtitre plates 
containing 20 pi human thrombin per well (lOOU/ml, Sigma, Dorset, UK) and incubated 
at 37°C. Absorbance was measured at 405 nm in 15/30 min intervals for 4 h and at 17, 
and 24 h for samples from tPA /_ mice. Human recombinant tPA (2 mg/ml; 
Technoclone, Dorking, Surry, UK) mixed with dilution buffer was used as a positive 
control, whilst omission of sample or plasminogen in the buffer was used as a negative 
control.
2.10. Neurofilament enzyme-linked immunosorbant assay (ELISA).
Disruption of neurofilament phosphorylation and transport are common features 
of many neurological conditions. Staining for phosphorylated neurofilaments (SMI34 
or SMB5) is increased in MS, however total neurofilaments are decreased in CREAE 
(Pryce et al., 2003), correlating with neurological impairment. In order to quantify 
phosphorylated neurofilament an ELISA was carried out as described by (Petzold et al, 
2003b). A 96-well microtitre plate (Maxisorp, Nunc, Rochester, NY, USA) was coated 
overnight at 4°C with SMI35 anti-heavy chain neurofilament antibody (1:1000, 
Stemberger Monoclonals Inc., Lutherville, MD, USA) in sodium carbonate buffer 
(0.025M sodium carbonate, 0.025M sodium bicarbonate, pH 9.7 with IN HC1 or IN
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NaOH). After bringing the plate up to RT, non-specific binding was blocked by 
incubation with 200pl of 1% BSA in barbitone buffer (63mM sodium barbital, l lmM 
barbital and 1.2mM EDTA) to each well for 1 h at RT. Following blocking, the plate 
was washed in barbitone buffer containing 0.2% BSA and 0.05% Tween-20. Spinal 
cord protein extracts were serially diluted from neat to 1:100,000 in barbitone buffer 
and a standard curve was prepared from serially diluting porcine neurofilament 
(Chemicon) (0 .16 -10  ng/ml). The final standard concentration was zero, using diluent 
alone to control for background activity. Samples and standards were incubated at RT 
for 2 h under gentle agitation. After washing 4 times as above, the detect antibody 
(rabbit polyclonal anti-neurofilament H antibody, Sigma) was diluted 1:1000 and then 
added at lOOpl per well for 1 h at RT under gentle agitation. Following 4 further 
washes, horseradish peroxidase-conjugated anti-rabbit immunoglobulin (Amersham 
Biosciences) was diluted 1:1000 in diluent as before and 100pl added to each well 
before incubating for 1 h under gentle agitation at RT. Tetramethylbenzidine (TMB) 
chromogenic substrate reagent (R&D Systems UK Ltd., Abingdon, UK) was removed 
from refrigeration and prepared in a light-excluded 50 ml centrifuge tube to allow it to 
rise to room temperature. Following 4 final washes, lOOpl of substrate was added to 
each well before stopping the reaction with 1M phosphoric acid. The plate was read on 
a 96-well spectrophotometer (Anthos Labtec Instruments, Salzburg, Austria) with the 
absorbance set at 450 nm, and a reference reading at 620 nm. All samples were 
analysed in duplicate.
Using Microsoft Excel, an equation representing the standard curve was 
determined, and used to predict the concentration of NF in each sample from the optical 
density reading. This figure was then divided by the total protein for that sample, as 
determined by the Folin phenol method, to give the concentration of NF per mg protein.
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In this way differences in protein concentration caused by non-identical samples were 
normalised, allowing direct comparison of samples.
2.11. ELISAs for PAI-1, tPA and uPA.
In order to investigate levels of tPA, PAI-1 and uPA, under control and 
experimental neuroinflammatory conditions, ELISAs were performed in collaboration 
with Professor Roger Lijnen, Centre for Molecular and Cardiovascular Biology, KU 
Leuven, Belgium. For ELISAs Costar 96-well plates were coated with mouse 
antibodies against PAI-1, tPA or uPA at 4pg/ml for 48h at 4°C (Declerck et al., 1995). 
The wells were blocked with 1% BSA in 1 x PBS overnight at 4°C and plates were then 
washed with 1 x PBS tween 80 (0.004%). Protein extract samples and standards were 
diluted in 1 x PBS containing 0.004% tween 80, 0.1% BSA and 5mM EDTA, and were 
added 180pl/well and incubated overnight at 4°C. Samples were diluted 1 in 7.2 and 
standard curves range from 0.023 - 3 ng/ml (PAI-1), 0.078 - 10 ng/ml (tPA) and 0.156 - 
20ng/ml (uPA). After washing a biotinylated secondary antibody (PAI-1, tPA or uPA) 
was added for 1 hour at 37°C. After addition of the avidin-biotin peroxidase complex 
(ABC; Vector) for 1 hour at room temp, plates were developed using o- 
phenylenediamine, and the reaction was stopped using 4M sulphuric acid. Absorbance 
was read at 490nm with a reference reading at 650nm.
2.12. In situ zymography on fibrin overlay.
In situ zymography was carried out on 10pm cryosections of normal and EAE 
spinal cords as previously described (Lijnen et al., 1998), in order to investigate the in 
situ fibrinolytic capacity of spinal cord tissue from different genotypes of mice at 
various time points of EAE disease. A gel was prepared by clotting a mixture of human 
fibrinogen (final concentration 4 mg/ml), plasminogen (final concentration lOpg/ml),
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and agarose (final concentration 0.5%) with thrombin (final concentration 
0.3NIHU/ml). A thin overlay of gel was added onto cryostat sections of control and 
EAE spinal cord and allowed to set. Zymography was performed in a wet box at 37°C 
for 2 hours. The lysis of substrate was quantified using computer-assisted image 
analysis (Zeiss, Axioplan 2). The lysis area was normalised to the total section area.
2.13. Statistical analysis.
Data was analysed with the GraphPad Prism computer package (GraphPad 
Software, San Diego California, USA). A normality and quality of variance test was 
carried out on all data to determine which test was appropriate. A t-test, for normally 
distributed data sets, or a Mann-Whitney U test, for non-parametric data, was used with 
significance level set at 95 %. If variances of data sets were significantly different, then 
Welch’s correction was applied to correct for this. All values are indicated as the mean 
± standard error of the mean (SEM). P-values were taken as an indicator of statistical 
significance with the following nomenclature: * - P < 0.05, ** - P < 0.01 and *** - P < 
0.001. The parametric Pearson’s correlation test was used for the regression analysis 
and the r value given where appropriate. Individual n-numbers are given in each results 
chapter.
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3. Fibrinolysis and the plasminogen activator system in ABH 
mice during chronic relapsing EAE.
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3.1. Introduction.
Chronic relapsing EAE (CREAE) in Biozzi antibody high (ABH) mice is a well 
established experimental neuroinflammatory disease model, induced by sensitisation to 
CNS homogenate. It is highly reproducible, with pronounced periods of relapse and 
remission. Mice in the acute and relapse stages of disease have a high number of 
inflammatory mononuclear cells present in the spinal cords, but rarely in the brains, 
which resolve during periods of remission (Baker et al., 1990). The histology of 
CREAE in ABH mice, the mononuclear cell trafficking, BBB permeability and cytokine 
profile are all well characterised (Allen et al., 1993; Baker et al., 1990; Butter et al., 
1991). The role of the fibrinolytic system in EAE has been previously investigated in 
BALB/c mice, a strain relatively resistant to EAE induction, where clinical disease is 
typically short, acute and monophasic (Teesalu et al., 2001). In that study, upregulation 
of tPA, PAI-1 and uPAR and accumulation of fibrin correlated to the peak of paralytic 
disease (Teesalu et al., 2001). However, the role of the plasminogen activator system in 
CREAE in ABH mice has not been investigated. It is becoming increasingly evident 
that neuronal and axonal loss are characteristic of MS, thus it was important to utilise a 
model where neurodegeneration is a key feature of disease, to fully elucidate the 
mechanisms and involvement of the PA system during all stages of EAE. Following 
induction of CREAE, spinal cords were taken at different time points, during the acute 
phase of disease, remission and finally in the chronic phase of disease. Levels of tPA, 
PAI-1, uPA, plasminogen and fibrin D-dimer were measured in spinal cord homogenate 
protein extract samples. In addition the fibrinolytic capacity of the tissue was measured 
using a clot lysis assay.
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3.2 Results.
3.2.1. Clinical features o f CREAE disease in ABH mice.
Induction of CREAE in ABH mice by injection with spinal cord homogenate on 
day 0 and day 7 resulted in the development of an acute disease around 14-15 days post 
disease induction (dpi), with peak disease score on 1 8 - 2 0  dpi (Figure 3.1 A). This was 
followed by a period of almost complete remission (26 -  30 dpi). With each subsequent 
relapse, the capacity for recovery diminished due to an accumulation of neurological 
deficit leading to the development of clinical signs of spasticity and tremor. Significant 
weight loss preceded the onset of disease (P < 0.001 versus pre-disease onset weights) 
and persisted for approximately 5 days (Figure 3.1 B). Mean weight of animals prior to 
EAE onset was 23.9g ± 1.1, and mean maximal weight loss was 7.3g ± 0.3 (31%) which 
occurs concurrently with maximum clinical score. It has been found from previous 
studies that Freund’s alone injected ABH mice develop no EAE disease (Allen et al., 
1993).
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Clinical course of CREAE disease in Biozzi ABH mice
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Figure 3.1. CREAE - disease progression and weight loss in ABH mice injected with spinal cord 
homogenate. A. Mice were injected with spinal cord homogenate in IFA supplemented with M. 
tuberculosis and M. butyricum on day 0 and day 7 and disease developed around 14 dpi. Mice were 
scored on a scale of 0 -  5 and the mean clinical score was calculated, n = 18. An acute phase of disease 
was followed by a period of remission and at least two separate relapse phases. Chronic disease 
developed due to an accumulation of deficits and was characterised by incomplete recovery, and the 
development of additional signs such as spasticity and tremor. B. Mice were weighed daily, data 
expressed as mean weights ± SEM. Disease onset was preceded by significant weight loss, n = 18, *** P 
< 0.001 day 7 versus day 19.
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3.2.2. Uprezulation o f the PA system during CREAE in ABH mice.
To investigate the expression of components of the PA system during CREAE, 
mice were killed at various time points throughout the disease (acute -  20 dpi, first 
remission -  30 dpi and chronic - 80 dpi, indicated by the arrows Figure 3.1 A) and 
levels of tPA, PAI-1 and uPA were measured in spinal cord homogenate protein 
extracts by ELISA. Levels of tPA did not change significantly throughout the course of 
EAE, (Figure 3.2 A). uPA antigen was slightly increased in all samples from CREAE
mice (Figure 3.2 B) but this was not significant until 80 dpi of EAE (P < 0.01).
Interestingly, levels of uPA did not return to control values during disease remission at 
30 dpi. PAI-1 was significantly increased during the acute phase of disease at 20 dpi (P 
< 0.01, Figure 3.2 C), correlating with inflammation. Levels of PAI-1 returned to those 
of control animals during EAE disease remission at 30 dpi. Additionally, whilst PAI-1 
was significantly (P < 0.05) increased at 80 dpi during chronic EAE when compared to 
amounts from controls and mice in disease remission, levels were still a third lower than 
during the acute phase at 20 dpi (P < 0.01). To investigate what these changes meant in 
the in vivo situation, calculating ratios of enzyme to inhibitor are useful (Table 3.1).
Under physiological conditions, in control mice the ratio of tPA to PAI-1 was
approximately 56:1, and the ratio of uPA to PAI-1 was approximately 8:1. This ensured 
that at all times enzyme was present in much greater amounts than inhibitor. Ratios of 
enzyme to inhibitor during the acute phase of CREAE, at 20 dpi fell dramatically when 
compared to controls (P < 0.05). This would indicate that levels of PAI-1 were higher 
than uPA or tPA during the inflammatory stages of the disease, thus inhibiting the 
majority of plasminogen activation by these enzymes during acute EAE. Ratios were 
not significantly different during remission at 30 dpi, and were much nearer normal 
levels. Interestingly, the ratio levels of tPA enzyme to inhibitor fell significantly again
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during chronic EAE (P < 0.05), and although ratios o f uPA were decreased, this was not
significant due to increased uPA at 80 dpi.
Ratio (ng/mg) Control 20 dpi 30 dpi 80 dpi
tPA:PAI-l 56.3 ± 19.4 1.7 ±0.3* 34.2 ± 1.6 7.7 ± 1.3*
uPA:PAI-l 8.2 ±2.8 0.5 ±0.1* 8.3 ± 0.4 2.6 ±0.4
Table 3.1. R a tio s o f  tPA a n d  uPA to the inh ibitor PA I-1 durin g  differen t p h a ses  o f  CREAE. Results 
expressed as m ean ±  SEM , * P  <  0 .05 versus control.
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Levels o f tPA, uPA and PAI-1 in spinal cords from ABH mice during CREAE
A- t P A
® 1.0
o> 0.5
B - u P A — 0.4
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Figure 3.2. L evels o f  tPA, uPA a n d  PAI-1 during CREAE in A B H  m ice. L evels o f  tPA, uPA and PAI-1 
were detected in spinal cord hom ogenate sam ples from A B H  m ice at various tim e points during CREAE. 
(A) L evels o f  tPA did not change throughout CREAE disease. (B) A  significant increase in uPA w as  
observed during chronic EAE (80 dpi) and (C ) a dramatic increase in PAI-1 w as seen at 20  dpi o f  
CREAE. Data is presented as the mean ±  SEM , n =  4 or 5 per group. * P  <  0 .05 , ** P  <  0 .01. .
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3.2.3. Plasminogen and fibrin D-dimer are significantly increased in ABH mice during
CREAE.
As levels and therefore activity of tPA and uPA are changed throughout the 
course of CREAE, due to increased PAI-1, it was of interest to investigate how this had 
an effect on levels and activation of plasminogen. Western blotting was performed on 
spinal cord protein extract samples from ABH mice taken at specific time points during 
CREAE, using an antibody against plasminogen. Plasminogen migrated as an 85 kDa 
band which corresponds to cell-bound pre-activation form, called lysine-plasminogen 
(Figure 3.3 A). Plasminogen was significantly increased during the acute phase of 
CREAE at 20 dpi (P < 0.001) when compared to levels in control mice (Figure 3.3 B). 
Levels returned to those in control non-injected mice during disease remission at 30 dpi. 
Whilst lys-plasminogen protein levels were slightly increased again during chronic EAE 
at 80 dpi, these were not significantly different to controls, and were significantly lower 
than levels at 20 dpi (P < 0.001). It is possible to measure activity of plasmin indirectly 
by measuring levels of its substrate fibrin(ogen), and the fibrin degradation product, 
fibrin D-dimer. This was also done by Western blotting. A very small amount of fibrin 
D-dimer was detected in the spinal cords of control mice (Figure 3.4 A), as expected, 
because under physiological conditions the BBB ensures that high molecular weight 
plasma proteins are excluded from the CNS. A significant increase of fibrin D-dimer 
was found in the spinal cords of mice during the acute phase of CREAE (20 dpi) when 
compared to control mice (Figure 3.4 B) and mice at 30 dpi, the remission phase of 
CREAE (P < 0.01 and P < 0.05 respectively). Furthermore, fibrin D-dimer was also 
found to accumulate during the chronic phase, at 80 dpi of CREAE (P < 0.05).
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Figure 3.3. A ccum ulation  o f  p lasm in ogen  in A B H  m ice during the acute p h a se  o f  CREAE. Spinal cords 
from control and CREAE m ice were hom ogenised for protein extraction. A . L evels o f  plasm inogen were  
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Figure 3.4. A ccum ulation o f  fib rin  D -d im er in A B H  m ice during CREAE. Spinal cords from control and 
CREAE m ice were hom ogenised for protein extraction. L evels o f  fibrin D -dim er were detected by 
Western blotting and were quantitatively measured by densitom etry scanning; results are show n as 
arbitrary densitom etry units ±  SEM. Fibrin D-dim er was significantly increased during the acute and 
chronic phase o f  CREAE in A B H  m ice at 20 and 80 dpi respectively, n =  4 or 5 per category, * P  <  0 .05 , 
** P <  0.01 versus control unless indicated by bar.
116
3.2.4. Fibrinolysis in ABH mice during CREAE.
A clot lysis assay was used for spinal cord protein extracts to examine 
fibrinolytic capacity in control and CREAE mice. Over 5 h the clot degradation was 
measured by a decrease in optical density at 405 nm. In samples from control mice, clot 
degradation was complete after 2.5 h of incubation with thrombin to start the reaction 
(Figure 3.5). Protein extracts from mice during the acute phase of CREAE at 20 dpi, 
had a significantly impaired clot lysis, (P < 0.05 at 2 h) when compared to controls and 
clot degradation was complete an hour later than controls at 3.5 h (Figure 3.5). Samples 
from mice during remission or the chronic phase of CREAE (30 dpi or 80 dpi 
respectively) showed no significant difference in clot lysis when compared to controls.
Fibrinolysis in the spinal cords of ABH mice during CREAE
0.CH----------------1---------------1---------------1--------------1------------- 1
0 1 2 3 4 5
Time (hrs)
Control 
EAE 20 dpi 
EAE 30 dpi 
EAE 80 dpi
Figure 3.5. Fibrinolysis in the ABH mouse CNS during CREAE. Spinal cords from control and CREAE 
mice at specific time points were homogenised for protein extraction. The fibrinolytic capacity was 
investigated using a clot lysis assay which measures the degradation of an in vitro formed clot using 
spectrophotometry. Results are presented as the mean clot degradation over time as measured by optical 
density (OD) at 405 nm. Clot degradation was significantly impaired in samples from mice at 20 dpi 
when compared to controls, n = 4 or 5 per category. * P < 0.05.
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3.3. Discussion.
The CREAE model in Biozzi ABH mice was used as an initial tool to 
investigate the changes in the expression of components of the PA system during 
different phases of disease. This model, induced by immunisation with spinal cord 
homogenate, has been well characterised, by pathological investigations (Baker et al., 
1990; Butter et al, 1991; Allen et al, 1993) particularly of the neurodegeneration 
(Petzold et al, 2003a; Pryce et al., 2003). As this model enabled separation of easily- 
recognisable distinct phases of EAE, samples could be taken during the initial acute, 
remission and chronic stages of disease in order to elucidate the involvement of the PA / 
fibrinolytic system during the inflammatory and neurodegenerative components of the 
disease. A significant increase in PAI-1, lys-plasminogen, an accumulation of fibrin D- 
dimer and slower clot lysis points to an involvement of the PA system in the 
pathogenesis of CREAE, and an impairment of fibrinolysis.
Whilst CNS levels of tPA were not altered during CREAE, the significant 
increase in PAI-1, particularly during the acute phase of disease, correlated with the 
peak clinical score and therefore a high degree of inflammation. Studies on post 
mortem MS brain tissue showed that levels of PAI-1 are also significantly increased in 
acute lesions (Gveric et al, 2001). As the ELISAs measure antigen levels, the knock on 
effect of increased PAI-1 on tPA and uPA activity were not directly assessed. 
However, the decreased enzyme:inhibitor ratios during the acute and chronic stages of 
disease, could be an indicator of decreased activity. PAI-1 is an acute phase protein and 
its expression is known to be upregulated in response to pro-inflammatory cytokines 
such as TNF-a and IL-1 (Kasza et al, 2001) thus it is likely that the increases in PAI-1 
and possible decreased tPA and uPA activity are a consequence, rather than the cause, 
of inflammation. A surprising observation was that PAI-1 protein was also increased 
during chronic disease, thus indicating that although the key pathological feature of this
phase of CREAE is neurodegeneration, there was still some ongoing inflammation to 
account for this, as was evidenced in histological assessment of such tissues (Pryce et 
al, 2003; Pryce et al, 2005). Another feature of chronicity was the significantly 
increased levels of uPA, however this would probably be equilibrated by the higher 
levels of PAI-1 as the ratio of uPA:PAI-l was not significantly different to that of 
controls.
Increased amounts of plasminogen in the spinal cord of ABH mice at the peak of 
acute disease reflect its accumulation resulting from decreased activation of the 
zymogen into its active form, plasmin. This reduction in plasminogen activation by tPA 
or uPA, was probably due to increased enzyme-inhibitor complex formation, as a result 
of increased PAI-1, thus reducing enzyme activity. As an indicator of this, lys- 
plasminogen, the pre-activation form of plasmin, and fibrin D-dimer were increased 
during CREAE particularly at the acute stage of disease and impaired fibrin clot lysis 
correlated with these increases. This correlates well with observations in MS tissue. 
Fibrinolysis was markedly reduced in NAWM, acute and chronic lesions due to increase 
complex formation of tPA with PAI-1 and resulting decrease of tPA activity (Gveric et 
al., 2003). Increased PAI-1 and complex formation with tPA is also a key feature of 
disease pathology in rheumatoid arthritis. As a result, fibrinolysis is decreased, which 
correlates with disease severity (Kopeikina et al, 1997).
Fibrin D-dimer is a large molecular weight fibrin degradation product (FDP), 
and its accumulation reflects an impairment of fibrinolysis, as under control conditions, 
fibrinolysis occurs rapidly, thus FDPs are not present in large amounts. Elevated levels 
of fibrinogen and chronically elevated levels of fibrin derivatives are well established 
risk indicators of vascular disease (Koenig et al, 2001; Koenig, 2003), and they may be 
linked to a variety of inflammatory mechanisms as well (Kamath and Lip, 2003). 
Surprisingly increased fibrin D dimer during chronic EAE disease at 80 dpi was not
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accompanied by increased lys-plasminogen levels, nor was a significant impairment of 
fibrinolysis, thus this finding was somewhat puzzling. However during chronic disease, 
the ratio of tPA to PAI-1 is still significantly lower than normal thus there would be less 
tPA activity, which could account for the fibrin accumulation. It appears that this 
system is under tight control and balance, and that slight alterations in the homeostasis 
have significant effects. Perhaps the clot lysis assay was not sensitive enough to detect 
the small reduction in fibrinolysis in samples from mice at 80 dpi of CREAE, even 
though it resulted in a large fibrin deposition in the spinal cords. The observation of 
persisting fibrin during chronic EAE disease follows on from the findings of Claudio et 
al, (1995) who demonstrated that chronic silent MS lesions show persistent BBB 
abnormalities and fibrin deposition even in the absence of active inflammation. 
Additionally, at 80 dpi of CREAE, ABH mice have considerable neurological deficits, 
indicating underlying neurodegeneration Pryce et al., (2003) demonstrated that 
decreased phosphorylated neurofilaments correlated with reduced movement activity of 
ABH mice during CREAE. Increased fibrin during chronic disease also correlates with 
neurological deficits and could point to a role for fibrin in contributing to 
axonal/neuronal loss (Akassoglou et al, 2000; East et al, 2005).
Investigation into the PA system during CREAE has revealed key roles for 
components of this cascade during inflammatory demyelination. Additionally, many 
similarities were found between the CREAE model and that observed in studies using 
MS tissue, thus further supporting the use of SCH-induced CREAE in ABH as a close 
model of MS. Persisting impairment of fibrinolysis, resulting in accumulation of fibrin 
correlates with neurodegeneration and thus could provide a useful target for therapeutic 
intervention.
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4. Characterisation of EAE in tPA and uPAR deficient mice.
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4.1. Introduction.
Components of the plasminogen activator cascade are postulated to have 
detrimental effects contributing to the onset and progression of inflammatory 
demyelination. To investigate the role of tPA and uPAR in experimental 
neuroinflammation, EAE was induced with myelin oligodendrocyte glycoprotein 
(MOG) in tPA ' and uPAR'7' mice and their wildtype (WT) counterparts. Transgenic 
mice on the C57BL/6 background are resistant to CREAE induction with spinal cord 
homogenate, but are susceptible to EAE induced with M O G 3 5 . 5 5  peptide. The clinical 
and histopathological characteristics of the disease were examined in order to identify 
any similarities and differences between the genotypes and to isolate possible 
mechanisms of action.
4.2. Results.
4.2.1. Clinical features o f MOG-EAE disease in tPA~~ and uPAR'f' mice.
To study the role of tPA and uPAR during experimental neuroinflammation
tPA'7' and uPAR'7' mice were used in the M O G 3 5 . 5 5  peptide induced EAE model. After
induction of MOG-EAE, WT animals exhibited signs of disease at 11.0 + 0.5 days post
disease induction (dpi) (Figure 4.1 A; Table 4.1), with peak of disease at 17.6 ± 0.5 dpi.
The acute phase of disease lasted for approximately 15 days with an average mean
maximal score of 2.0 ± 0.2. Animals recovered from the attack with little residual
deficit (Figure 4.1 A) and a mean score at 60 dpi of 0.3 ±0.1. In contrast, tPA'7’ mice
(Figure 4.1 A) had a significantly earlier onset of disease, 8.9 ± 0.4 dpi (Table 4.1; P <
0.01) with a more severe acute phase lasting approximately 22 days reaching a peak
significantly earlier at 14.4 ± 0.7 dpi (P <0.01) than in the WT and with a significantly
higher mean maximal score of 3.3 ± 0.2 (P < 0.001). Disease course in tPA'7" animals
was characterised by an incomplete recovery (Figure 4.1 A) with signs of residual
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deficit including hindlimb paresis (82 %) and occasional tail spasticity (18 %). Mean 
scores at 40 and 60 dpi were 2.2 ± 0.2 and 1.6 ± 0.2 respectively, both significantly 
higher than WT mice (P < 0.001) at comparable time points. Following induction of 
EAE, uPAR'7' mice (Figure 4.1 B), developed signs of disease significantly later than 
WT mice, on 17.4 ± 1.1 dpi (P < 0.001), with peak disease occurring at 34.4 ±3.3 dpi 
(P < 0.001). uPAR'7' mice developed a more chronic disease than WT mice which was 
characterised by incomplete recovery and a significantly higher clinical score at 60 dpi 
than WT (1.9 ± 0.4; P < 0.01).
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Clinical course of MOG-EAE disease in tPA'7', uPAR/_ and WT mice
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Figure 4.1. M O G -E A E  disease  course in tPA", u P A K ' a n d  W T m ice. All mice were injected with 
M O G 3 5 . 5 5  peptide in IFA supplemented with M. tuberculosis  on day 0 and 7 and B. p ertu ss is  toxin on day 
0 and day 2. Adjuvant injected mice (AIC) were used as negative controls and developed no disease. 
Mice were scored daily on a scale of 0 -  5 and the daily mean score was calculated. (A) n = 19 for WT, n 
= 14 for tPA‘/_ and (B) n = 14 for uPAR /‘.
Strain EAEincidence
Onset
(dpi)
Peak of 
disease (dpi)
Mean
Maximal
Score
Mean Score 
at 60 dpi
WT 16/19 11.0 ±0.5 17.6±0.5 2.010.2 0.310.1
tPA"7' 14/14 8.9 ± 0.4" 14.4 ± 0.7** 3.3 10.2*** 1.6 1 0.2***
uPAR'a 14/14 1 7 .4 ± l.r* 34.4 ± 3.3*** 2.4 1 0.3 1.910.4**
Table 4.1. Sum m ary o f  the EAE data  f o r  w ild type (WT), tPAv' a n d  uPAR"  m ice. ** P  < 0.01 and *** p  <  
0.001 versus WT. All values shown as mean ± SEM.
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The incidence and timing of onset of MOG-EAE disease is illustrated in Figure
4.2. Whilst 84% of WT mice developed EAE, the incidence of EAE in tPA'7' and 
uPAR'7' mice was 100%. All tPA"7’ mice showed signs of EAE disease by 12 dpi, 
however by 15 dpi, two WT mice had failed to develop any clinical signs. 100% of 
uPAR‘‘ mice developed EAE by 30 dpi, significantly later than WT or tPA'7" mice (P < 
0 .001).
Following induction of MOG-EAE, mice were weighed daily to check for 
weight loss, (Figure 4.3), which can be an early sign of disease onset in ABH mice 
(Figure 3.1 B). Slight fluctuations in weights were observed over the first 20 days 
following EAE induction, and although weights did not significantly differ at the 
beginning of the experiment, by 18 dpi, mean weights of tPA'7' animals were 
significantly less than WT and uPAR'7' mice (P < 0.001 and P < 0.01 respectively). 
However, as EAE diseased progressed, all three genotypes of mice gained weight and 
there were no differences between the groups.
4.2.2. Adjuvant injected controls developed no EAE disease.
Mice injected with Freund’s adjuvant supplemented with M. tuberculosis, 
without MOG peptide were used as controls. These mice also received an 
intraperitoneal injection of B. pertussis toxin on day 0 and day 2. Adjuvant injected 
mice failed to develop any clinical EAE signs (Figure 4.4 A), and all genotypes had a 
clinical score of 0 for the duration of the experiment. Additionally, there was no 
significant weight loss in any of the three groups of mice (Figure 4.4 B). Upon 
histological examination of the spinal cords from adjuvant injected control (AIC) mice 
taken at different time points, there was no evidence of infiltration of inflammatory 
mononuclear cells in any of the sections (Figure 4.4 C). As a consequence of this result, 
all subsequent controls were taken as normal-non-injected mice from each genotype.
125
Incidence of MOG-EAE in tPA-7', uPAR-7' and WT mice
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Figure 4.2. Incidence and time course o f  MOG-EAE onset in WT, tPA"  and uPAR" mice. All tPA'7' mice 
showed signs o f EAE disease by 12 dpi, however by 15 dpi, two WT mice had failed to develop any 
clinical signs. 100% o f uPA R '' mice developed EAE by 30 dpi, significantly later than WT or tP A '' mice 
(P<  0.001).
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Figure 4.3. Weights o f  WT, tPA'1' and uPAFCA mice during MOG-EAE. Following induction o f EAE, 
mice were weighed daily to check for any significant weight loss. Although weights did not significantly 
differ at the beginning o f the experiment, by 18 dpi, mean weights o f tPA /_ animals were significantly 
less than WT and uPAR"7' mice (P < 0.001 and P < 0.01 respectively). As EAE progressed there were no 
significant differences in weights between the three genotypes.
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Clinical course o f  EAE disease and weights o f  adjuvant injected control mice
A
WTAIC
oo
</)
"Eo
uPAR AIC
'E
o
0 10 20 30
Time (dpi)
B
30-
2  20-
■4-».CO)
©
g
0 10 20 30
W TAIC  
tPA'7' AIC 
uPAR'7' AIC
Time (dpi)
uPAR
Figure 4.4. Adjuvant injected controls (AIC) developed no signs o f  EAE disease, weight loss or CNS 
inflammation. Mice were injected with Freund’s adjuvant supplemented with M. tuberculosis on day 0 
and day 7 and received an intraperitoneal injection of B. pertussis toxin on day 0 and day 2. A. In the 
absence o f MOG, adjuvant injected mice developed no clinical EAE disease. B. There was no significant 
weight loss and C. histological examination revealed no inflammatory infiltrates in the spinal cord of 
these mice (Original magnification xlOO). n = 6 per genotype.
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4.2.3. Activity ofWT, tPAv~ and uPAR''' mice during MOG-EAE.
Movement activity of mice was performed to investigate motor dysfunction and 
the degree of neurological impairment (Pryce et al., 2003). Mice were placed in an 
open field activity chamber and the total distance travelled in 5 min was recorded. 
Control tPA'7' mice were significantly more active than control WT mice (.P < 0.05, 
Table 4.2), thus all data was normalised to the appropriate controls, i.e. WT EAE 
against WT controls, tPA EAE against tPA controls etc. Following EAE induction all 
mice had a significant reduction in activity when compared to the relevant control 
groups (P < 0.001). tPA'7" mice at 35 and 60 dpi were significantly less active than WT 
animals at 35 and 60 dpi of MOG-EAE (P < 0.05; Figure 4.5). Movement of uPAR'/* 
mice at 35 dpi was also significantly reduced compared to WT mice at 35 dpi (P < 
0.001), however by 60 dpi, although uPAR'7' animals had a higher mean score than WT 
(P < 0.05) the activity of the two groups was not significantly different (Figure 4.5).
Baseline activity data
Distanced travelled (cm) in 5 min
WT tPA_/' uPAR'7'
679.3 ± 30.7 928.2 ± 92.6 * 674.1 ±99.9
Table 4.2. Baseline activity data for control WT, tPA~~ and uPAR~~ mice. * P < 0.05. Control tPA"7' mice 
were significantly more active than control WT mice, thus all data was normalised to the appropriate 
controls.
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Activity of tPA"7', uPAR"7' and WT m ice
following induction of MOG-EAE
uPAFT
Control 35 dpi 60 dpi
Figure 4.5. Activity of WT, tPAv' and uPAFf' before and after induction of MOG-EAE. The motor 
function of control and EAE mice (35 and 60 dpi) was assessed using an open field activity chamber, and 
total distance travelled in 5 min was recorded for each mouse. The data represents the average activity of 
each group of mice normalised to the relevant control ± SEM. tPA'7* and uPAR'7' mice were less active 
than WT mice at 35 dpi, and tPA'7" mice were still significantly less active than WT animals at 60 dpi. 
For control groups; WT n = 11, tPA'7' n = 13, uPAR'7' n = 7. For EAE groups; WT n = 19, tPA"7' n = 9, 
uPAR-7- n = 9. * P< 0.05, *** P < 0.001.
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4.2.4. Histological evaluation o f  spinal cords from MOG-EAE mice.
Histological staining, with haematoxylin and eosin, of spinal cord sections taken 
at 20, 35 and 60 dpi, revealed differences in the degree of infiltration of inflammatory 
cells into the CNS between the three genotypes (Figure 4.6). No mononuclear cells 
were found in the spinal cords of control mice (Figure 4.6 A -  C), however a large 
number of perivascular cuffs were evident in sections from WT and tPA'7' mice at 20 
dpi of EAE (Figure 4.6 D and E), but no infiltrating mononuclear cells in the cords of 
uPAR'7' mice (Figure 4.6 F). At 35 dpi, there were fewer perivascular cuffs in sections 
from WT and tPA’7' mice, however a number of perivascular cuffs were identifiable in 
sections from uPAR'7' mice (Figure 4.6 G - I). By 60 dpi, a higher degree of 
inflammation was evident in uPAR'7' mice whilst there appeared to be very few 
infiltrating cells remaining in the spinal cords of WT and tPA'7' (Figure 4.6 J -  L). To 
quantify the amount and degree of mononuclear cell infiltration, cuff counts and scores 
were assessed in the three genotypes of mice at 20, 35 and 60 dpi of EAE. The total 
number of perivascular cuffs was counted in a spinal cord longitudinal section area of 
4cm2, and each cuff was given a score according to the degree of cellular infiltration; 1, 
perivascular inflammation three or fewer cells deep; 2, more than three cells deep; 3, 
parenchymal infiltrate. The average total cuff count and score was taken from a total of 
three slides from three different mice per time point. Cuff count and score were 
significantly higher in tPA'7' mice than WT at 35 dpi (P < 0.01), but at 20 and 60 dpi, 
these were comparable (Figure 4.7). Cuff count and score in uPAR'7' mice at 35 dpi 
were comparable with those at the peak of acute disease in WT and tPA'7- (20 dpi, 
Figure 4.7). Persistent inflammation in uPAR'7' mice at 60 dpi was reflected in high 
numbers of mononuclear cells in perivascular cuffs (Figure 4.6 L), and a higher cuff 
score in comparison with WT and tPA7' mice at 60 dpi (Figure 4.7) in accord with the 
clinical data.
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Figure 4.6. Haematoxylin and eosin staining o f  spinal cord sections from WT, tPA ~ ~ and uPAR~/ mice 
during acute and chronic phases o f  MOG-EAE. Spinal cords were removed from mice at 20 (D -  F), 35 
(G -  I) and 60 (J -  L) dpi o f EAE and cut longitudinally. H & E  was performed on frozen sections to 
detect nuclei distinct from other tissue components. Normal sections (A - C) showed no clustering o f  
nuclei. Whilst perivascular cuffs, indicative of inflammation, were identified in sections from WT (D and 
G) and tPA 7 (E and H) mice during acute EAE, there were few additional nuclei in sections from uPAR'a 
animals before the peak o f disease at 35 dpi (F and I). During chronic EAE there was evidence persistent 
inflammation in uPAR/_ mice (L). Original magnification x 100.
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Histopathological evaluation o f EAE spinal cords from WT, tPA' ' and uPAR'7' mice.
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Figure 4.7. Perivascular cuff counts and scores for WT, tPA" and uPAR" EAE mice. Spinal cords from 
EAE mice at 20, 35 and 60 dpi were sectioned longitudinally and stained with an antibody against CD45. 
The total number of cuffs were counted in a section area of 4cm2, and each cuff was given a score 
according to the degree of infiltration; 1, perivascular inflammation fewer three or fewer cells deep; 2, 
more than three cells deep; 3, parenchymal infiltrate. The total cuff score was calculated for each slide 
and the average of three slides from three different mice per time point was calculated. The data is shown 
as the mean total number of cuffs or mean total cuff score ± SEM; n = 3, * P < 0.05, ** P < 0.01 and *** 
P<  0.001.
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4.2.5. Participation o f macrophases, microglia and T-lvmphocvtes in MOG-EAE.
Immunohistochemical staining was performed on sections of spinal cords 
removed from mice at 20, 35 and 60 dpi, comparing CD45 (Figure 4.8), F4/80 (Figure 
4.9) CD8 and CD4 (Figure 4.10) staining on serial sections. F4/80 is a marker for 
macrophages and microglia, whilst CD45 is a marker for all cells of haematopoietic 
origin including lymphocytes, monocytes and macrophages, and is a general indicator 
of the entry of immune cells, inflammation and microglial activation in the CNS. 
Antibodies against CD8 and CD4 detect CD8+ and CD4+ T-lymphocytes respectively. 
No staining was seen in spinal cord sections from control (non-injected) mice nor 
adjuvant injected animals (Figure 4.4 C) as previously observed (Amor et al., 1993; 
Baker et al., 1990). Staining of serial sections for CD45, F4/80 and T-cells showed that 
both microglia/macrophages and lymphocytes were present in large numbers in the 
perivascular cuffs in all three genotypes of mice, and that microglia/macrophages 
contributed to a high proportion of the CD45 positive cells observed in the CNS. As 
observed with the H & E  histology, high numbers of cuffs were seen in sections from 
WT and tPA'7' mice at 20 dpi (Figures 4.8 and 4.9 A, Ai, B, Bi), but essentially no cells 
or cuffs were observed in sections from uPAR'7' mice (Figures 4.8 and 4.9 C). A few 
perivascular cuffs were evident at 35 dpi in WT and particularly tPA'7* mice (Figures 4.8 
and 4.9 D, E), however the peak of disease in uPAR7' mice at 35 dpi, corresponded to a 
high number of infiltrating mononuclear cells (Figures 4.8 and 4.9 F, Fi). A few 
residual stained microglia/macrophages were still present in tPA'7' mice at 60 dpi, but 
not in the WT animals (Figure 4.9 G and H). Furthermore, inflammation was still 
ongoing at 60 dpi in uPAR'7' mice with a high number of perivascular cuffs and a large 
amount of infiltrating inflammatory cells (Figure 4.8 I).
133
60 
dp
i 
35 
dp
i 
20 
dp
i
CD45
uPAR
Figure 4.8. Total leucocyte population in MOG-EAE. Spinal cords were removed at 20 (A -  C), 35 (D -  
F) and 60 (G -  I) dpi o f MOG-EAE and cut longitudinally. Frozen sections were stained with an 
antibody against CD45 and counterstained with Mayer’s haematoxylin to assess the infiltration/migration 
of inflammatory mononuclear cells. In control animals there were no mononuclear cells in the spinal cord 
tissue (not shown). There was a delay in microglial migration and infiltration o f macrophages and 
lymphocytes in uPA R 7 mice (C) when compared to WT and tPA'7'animals at 20 dpi (A and B). 
However, perivascular cuffs containing mononuclear cells were evident in uPAR"7' mice at the peak o f 
disease, 35 dpi (F). A high degree o f persisting inflammation was evident in uPAR'7' at 60 dpi (I) 
although not in WT animals (G). Ai, Bi and Fi are high power images o f A, B and F respectively. 
Original magnification x 100, inserts (i); original magnification x 400.
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Figure 4.9. Infiltration o f  macrophages/microglia in MOG-EAE. Spinal cords were removed at 20 (A -  
C), 35 (D -  F) and 60 (G - 1) dpi o f MOG EAE and cut longitudinally. Frozen sections were stained with 
an antibody against F4/80 and counterstained with M ayer’s haematoxylin to assess the 
infiltration/migration o f macrophages and microglia. In control animals there were no mononuclear cells 
in the spinal cord tissue (not shown). F4/80 staining on serial sections showed a very similar pattern to 
CD45 (Figure 4.8). Ai, Bi and Fi are high power images o f A, B and F respectively. Original 
magnification x 100, inserts (i); original magnification x 400.
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Immunohistochemical analysis of CD8 and CD4 positive lymphocytes on serial 
sections of spinal cord (Figure 4.10), revealed a high number of both these cell types, 
which showed a similar pattern to the CD45 and F4/80 staining. More staining of CD4 
and CD8 positive cells was seen in the sections from tPA'7' and WT mice than in 
uPAR'7' at 20 dpi (Figure 4.10 A -  C). An interesting observation is that there was a 
high number of CD8 positive cells in all sections (Figure 4.10 J, K and L), which 
suggests that the MOG-induced EAE in these animals has a strong component of 
disease mediated by CD8+ cells in addition to CD4+ cells (Schroeter et al, 2003; Sun et 
al., 2001). To quantify the number of different cell types in perivascular cuffs, the total 
number of CD45+ cells in a cuff were counted, then the total number of CD4+ and CD8+ 
cells were counted in the same cuff on serial sections. A total of three cuffs per section 
were counted, with three slides per time point. The number of CD4+ and CD8+ cells 
were subtracted from the total number of CD45+ cells to give a representation of cells 
which were probably either macrophages/microglia or B lymphocytes; these cells 
accounted for the majority of cells in spinal cords during MOG-EAE. The total number 
of inflammatory cells decreased as EAE disease progressed (Figure 4.11). CD4+ T cells 
were the predominant type of lymphocytes, although CD8+ cells were present in nearly 
equal numbers. Total number of cells (CD45+, CD4+ and CD8+) were significantly 
higher in uPAR'7' mice at 35dpi than WT and tPA'7' mice at the same stage of EAE 
disease (P < 0.01 and P < 0.05 respectively), but were comparable to the number of 
cells in WT and tPA'7’ mice at the peak of disease, 20 dpi (Figure 4.11). Additionally, 
the number of cells at 60 dpi of MOG-EAE in uPAR'7' mice was significantly higher 
than WT at the same stage of EAE (P < 0.01); however there was no significant 
difference between uPAR'7* and tPA*7' mice at 60 dpi (Figure 4.11). Although the total 
number of cells changed throughout the course of MOG-EAE disease, there were no
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apparent differences in different cell types between the genotypes. There were similar 
numbers of CD4+, CD8+ and CD45+ cells at the peak of disease in all groups of mice.
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Figure 4.10. Infiltration o f  CD4+ and CD8+ cells in MOG-EAE. Spinal cords were removed at 20 (A -  
C), 35 (D -  F) and 60 (G -  I) dpi o f EAE and cut longitudinally. Frozen sections were stained with an 
antibody against CD4 and counterstained with Mayer’s haematoxylin to assess the proportion o f CD4+ 
and CD8+ T cells in the perivascular cuffs. In control animals there were no CD4+ or CD8+ cells detected 
in the spinal cord tissue (not shown). There was a delay in infiltration o f lymphocytes in uPA R 7 mice 
(C) when compared to WT and tP A 7'animals at 20 dpi (A and B). However, perivascular cuffs containing 
CD4+ T cells were evident in uPAR'7' mice at the peak o f disease, 35 dpi (F). A high degree o f persisting 
inflammation was evident in uPAR"7' at 60 dpi (I) although not in WT animals (G). CD4 and CD8 
showed similar patterns o f staining; J, K and L are staining for CD8 on serial sections corresponding to 
images A, B and I respectively. Original magnification x 200.
uPAR'’
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Figure 4.11. Proportion o f C D f , CD8+ and CD45+ (CD4'/CD8') cells in perivascular cuffs. The total 
number of CD45+ cells were counted in three cuffs per section. On serial sections, the number of CD4+ 
and CD8+ cells were counted in corresponding perivascular cuffs. A total of three sections were counted 
per time point, per genotype. Results represent the mean ± SEM of CD45+ cells. Statistical analyses for 
each genotype are versus 20 dpi and analyses between different genotypes are indicated by a bar. * P < 
0.05, ** P < 0.01, *** P < 0.001.
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4.2.6. Tight junctional proteins claudin-5 and occludin are unchanged before and
during MOG-EAE disease.
Plasminogen activators are thought to play a role in the opening of the BBB 
through activation of MMPs and via interaction of tPA with LRP (Yepes et al, 2003). 
Endothelial TJs have important roles in BBB regulation during pathological conditions. 
To investigate whether there were disturbances of TJs associated with increased BBB 
permeability, and to investigate whether there were differences between WT, tPA'7' and 
uPAR'7' mice, immunofluorescent staining for two key junctional proteins, claudin-5 
and occludin was performed on sections from mice at different stages of MOG-EAE 
disease. Sections were double stained with an antibody against laminin, a component of 
blood vessel matrix. Changes in BBB permeability are thought to precede the 
infiltration of inflammatory cells and the development of clinical symptoms, thus mice 
were killed at 8 dpi of EAE, before any clinical signs of disease had developed. 
Additionally, sections were also taken from adjuvant injected control (AIC) mice and 
mice at 20 dpi of EAE with a clinical score of 3 or 4, with established inflammation. 
All blood vessels were examined in each section, and photomicrographs of 
representative areas were taken. Staining for claudin-5 and occludin in sections from 
AIC highlighted blood vessels and both proteins were closely localised with laminin in 
the vessel endothelial matrix (Figure 4.12). No differences were observed between the 
genotypes. In addition, there were no apparent differences between staining in sections 
from AIC and sections from mice at 8 and 20 dpi of EAE (Figures 4.13 A and B), and 
again no changes in patterns of staining between WT, tPA'7- and uPAR7' mice. Thus the 
integrity of the TJs appeared intact pre-EAE disease onset, and at 20 dpi of MOG-EAE, 
in sections with a high presence of inflammatory mononuclear cells.
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Figure 4.12. Claudin 5 and occludin are co-localised with laminin at BBB tight junctions. Frozen 
sections from adjuvant injected controls were sectioned and immunofluorescently stained for claudin 5 or 
occludin, and laminin. No differences were observed between the genotypes. Original magnification x 
400.
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A - MOG-EAE pre-disease onset; 8 dpi
uPAR'
Occludin LamininClaudin 5 Laminin
B - MOG-EAE post disease onset; 20 dpi.
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Claudin 5 Laminin Occludin Laminin
Figure 4.13. Claudin 5 and occludin localisation at tight junctions does not change pre-or post MOG- 
EAE onset. Frozen sections from EAE mice at 8 dpi (A), pre EAE onset, and (B) post EAE onset at 20 
dpi, were sectioned and immunofluorescently stained for claudin 5 or occludin, and laminin. No 
differences were observed between the genotypes and controls. Original magnification x 400.
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4 .2 .7. Demvelination in MOG-EAE.
Staining with an antibody against MBP in representative sections of mouse 
spinal cord at specific time points during MOG-EAE development showed that 
demyelination was more pronounced in tPA'7' and uPAR'7" (Figure 4.14i E and F) mice 
than WT animals (Figure 4.14i D). The highest loss of myelin was seen at 60 dpi in 
uPAR'7' mice. Using densitometry scanning, the amount of light transmittance through 
sections stained with MBP was calculated to gain a semi-quantitative measure of myelin 
density. Four random fields per section were studied with three to four sections per 
group. The results were expressed as the amount of light transmittance through a 
stained portion of section normalised to a non-stained area of the slide. The density of 
myelin was decreased in WT and tPA'7' mice at 60 dpi of EAE, although this was not 
significant. Myelin density in uPAR’7’ animals at 60 dpi was significantly reduced when 
compared to control animals (Figure 4.14ii; P < 0.001) and WT and tPA'7' mice at the 
same stage of disease (P < 0.01 and P < 0.05 respectively). Data at other time points of 
EAE showed no significant differences between genotypes.
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Figure 4.14. Demyelination in MOG-EAE. (i). Longitudinal frozen spinal cord sections from normal 
mice (A -  C) and mice at 60 dpi onwards o f EAE (D -  F) were stained for myelin basic protein to assess 
the degree o f demyelination in the CNS during EAE. MBP staining in control untreated mice, A -  C and 
in EAE at 60 dpi, D -  F. Original magnification x 100. (ii). Density o f  MBP staining was assessed using 
a Quantimet image analysis system, 4 random fields o f myelin were assessed per slide, with three slides 
for each control and four slides for EAE groups. Results were normalised to untreated normal mice and 
are expressed as the mean ± SEM. Density o f  MBP staining in uPAR'a mice at 60 dpi was significantly 
less than controls and WT animals at the same stage o f disease. * P < 0.05, ** P < 0.01, *** P < 0.001.
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4.2.8. Axonal pathology in MOG-EAE disease.
Levels of phosphorylated neurofilament have been documented to be increased 
in MS lesions, and other neurodegenerative disorders such as AD and ALS (Petzold, 
2005). However, phosphorylated heavy chain neurofilaments (NfH), measured by 
ELISA are decreased in CREAE, and correlate with the degree of neurological deficit 
(Jackson et al., 2005; Petzold et al., 2003a; Pryce et al., 2003). In control mice, 
immunohistochemical staining for phosphorylated neurofilament (SMI35) showed that 
SMB5 positive axons were clearly visible in the white matter of spinal cord sections 
(Figure 4.15i A -  C). The appearance was uniform with long and straight axons packed 
in high density. In sections from MOG-EAE SMB 5 staining revealed no obvious 
differences (Figure 4.15i D — E). Axons from 60 dpi of EAE showed slight changes in 
morphology, but these alterations were consistent in sections from WT, tPA'" and 
uPAR7' mice. There was no obvious increase or decrease in the number of axons 
stained for SMB 5 between different genotypes and time points. To get a quantitative 
measure of phosphorylated neurofilament heavy chain an ELISA was performed using 
spinal cord protein extracts from MOG-EAE animals, in both the acute (20 dpi for tPA 7" 
and WT, 35 dpi for uPAR7) and chronic phase (60 dpi.), and from normal control mice. 
No significant differences in levels of phosphorylated neurofilament NfH were observed 
between different time points of MOG-EAE and different genotypes of mice (Figure 
4.15 ii).
Staining for non-phosphorylated neurofilament (SMI32) revealed very few 
immunopositive axons in sections from control mice (Figure 4.16i A - C), but large 
numbers of thickened SMI32 positive axons in sections from EAE mice, particularly at 
60 dpi (Figure 4.16i D - F). Axonal pathology was assessed by counting the number of 
SMI32 positive axons in randomly selected areas of spinal cord white matter, from 
control and EAE mice at high magnification (x 400). Four areas were counted by two
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independent observers per section with three sections per group to obtain a quantitative 
measure of axonal pathological changes (Trapp et al., 1998) (Figure 4.16 ii). A 
statistically significant increase in SMI32 positive axons was found in tPA A mice at 20 
dpi when compared to tPA '‘ controls (P < 0.05). Furthermore, significant increases in 
SMI32 immunopositive axons were observed in all genotypes at 60 dpi when compared 
to relevant controls. tPA'7' and uPAR7' mice had higher numbers of SMI32 positive 
axons when compared to WT mice at 60 dpi (P < 0.001 and P < 0.01 respectively).
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Figure 4.15. Levels o f  phosphorylated neurofilament during MOG-EAE. (i) Longitudinal frozen spinal 
cord sections from mice at 60 dpi were stained for SMI35 to assess changes in levels o f phosphorylated 
neurofilament in the CNS during MOG-EAE. SMI35 staining in control untreated mice (A -  C) and in 
EAE at 60 dpi (D -  F). Original magnification x 100. (ii) A modified sandwich ELISA using antibodies 
against neurofilament was carried out on spinal cord homogenates from EAE and compared them with 
those from normal animals, n = 4 for each group, except for control WT and tPA'7' where n=8. Results 
are expressed as the mean NfH in pg per mg o f protein ± SEM. There are no significant changes in levels 
o f NfH in the spinal cords o f WT, tPA'/_ or uPAR'a mice.
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Figure 4.16. Axonal pathology in MOG-EAE. (i) Longitudinal frozen spinal cord sections from mice at 
60 dpi onwards were stained for SMI32 to assess changes in axonal pathology in the CNS during EAE. 
SMI32 staining in control untreated mice (A -  C) and in EAE at 60 dpi (D -  F). Original magnification x 
100. (ii) Four areas o f white matter were counted by two observers per section with three sections per 
group. The number o f SMI32 positive axons was increased in all genotypes at 60 dpi, significantly more 
so in tPA7 and uPA R /_ mice. Results expressed as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 
0.001 versus relevant control and analyses between different genotypes are indicated by a bar.
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4.3. Discussion.
Induction of EAE with MOG peptide produced variable results between the 
tPA'7', uPAR'7' and WT mice, with very different clinical pictures. A more severe and 
prolonged disease course was observed in tPA'7' mice characterised by an incomplete 
recovery and increased neurological deficit when compared to WT mice. In contrast, 
delayed onset and chronicity were major characteristics of EAE in uPAR'7' mice, 
coupled to persisting inflammatory cuffs of mononuclear cells, and a greater degree of 
demyelination. Adjuvant injected controls showed that clinical EAE disease results 
from an autoimmune response against MOG35-55 peptide and that Freund’s adjuvant and 
B. pertussis toxin alone produce no CNS inflammation or demyelination.
We observed similar findings to Lu et al., (2002), who also investigated the role 
of tPA in MOG-EAE using tPA deficient mice; with slight differences in the time of 
onset of disease, which could be accounted for by strain and interbreeding variations. 
The neurological signs in tPA 7' mice are reflected by a significantly higher clinical 
score and decreased motor activity, which was found in previous studies to be closely 
correlated with axonal damage (Pryce et al, 2003). The significantly higher amount of 
non-phosphorylated neurofilament, SMI32, immunoreactivity in sections from tPA 7' 
mice also indicates that these animals had more axonal damage/dysfunction than WT 
mice. Non phosphorylated neurofilament is increased in MS tissue and is used as a 
marker for axonal integrity (Petzold et al., 2003a; Trapp et al., 1998). Whilst decreased 
neurofilament levels may not correlate directly to axonal loss at the early stages of 
disease but reflect a disruption of axonal integrity, neurofilament loss in the chronic 
phase of EAE has been shown to correlate with axonal degeneration (Petzold et al., 
2003a). As tPA"7' mice incur a higher degree of neurological deficit than the WT mice, 
tPA must be acting via a protective mechanism to aid in axonal survival. Additionally, 
WT mice could have a higher threshold for dephosphorylation of neurofilament and
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axonal damage before degeneration occurs. Furthermore, as tPA has major roles in 
synaptic remodelling and plasticity in the brain (Seeds et al., 1996), these results could 
also reflect a reduced ability of tPA'7' mice to remodel synaptic connections and 
functionally recover following neuronal/axonal damage. Remodelling of axonal 
connections has been shown to be an important contributing factor to recovery from 
targeted spinal cord EAE lesions in the rat (Kerschensteiner et al., 2004). There is no 
apparent significant loss of myelin density in sections from tPA'7' mice indicating that 
axonal damage / degeneration can occur independently of demyelination. By activating 
latent TGF-p released from microglia and astrocytes, tPA can down-regulate NO release 
by microglia (Vincent et al., 1998). Nitric oxide can form reactive nitrogen species, 
which can lead to oligodendrocyte damage (Mitrovic et al., 1996), impairment of 
mitochondrial energy metabolism and ATP production, exacerbating demyelination and 
neurodegeneration (Bolanos et al., 1995). Thus activation of TGF-P is another 
mechanism by which tPA could have protective effects during neuroinflammation.
The effect of lack of tPA on mice behaviour is controversial (Yepes and 
Lawrence, 2004), however the observation that normal tPA 7' mice were significantly 
more active than the WT counterparts is interesting in the light of the findings that 
neuroserpin deficiency leads to a decrease in locomotor activity in novel environments 
and in response to anxiety-like situations (Yepes and Lawrence, 2004). This suggests a 
role for the PA system on mouse behaviour and activity, possibly due to its involvement 
in long term potentiation, long term depression, learning and synaptic plasticity (Seeds 
etal., 1996).
The delay in disease development in uPAR'7' mice, and in cell infiltration into 
the spinal cord reflects a reduced adhesion and migration of inflammatory mononuclear 
cells into the CNS coordinated by uPAR through its interactions with integrins and 
vitronectin (Blasi and Carmeliet P., 2002; Chapman, 1997). The importance of uPAR
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has been documented in other in vivo models of infection or inflammation in uPAR'7' 
mice, (Gyetko et al, 2000; Gyetko et a l, 2001; May et a l, 1998; Rijneveld et al,
2002). Perivascular infiltration of mononuclear cells is indicative of the disease 
severity. The cuff count, cuff score and inflammatory histopathology in the CNS of 
uPAR'7' mice by 35 dpi, at the peak of disease, was comparable to that of WT and tPA'7' 
animals at 20 dpi, indicating that cells are migrating through the BBB, by other 
mechanisms, including the production of matrix metalloproteinases (MMPs) and 
upregulation of adhesion molecules (Sellebjerg and Sorensen, 2003). There were no 
changes in the numbers of different cell types between the WT and uPAR'7' mice at the 
peak/acute stages of disease, thus uPAR-mediated cell migration and adhesion appears 
to be important for all leucocytes. Persisting inflammation in the spinal cord of uPAR’7" 
mice, in addition to pronounced axonal impairment and demyelination with significant 
reduction in MBP, may account for chronicity of disease.
No changes were observed in the staining patterns for the tight junction 
associated proteins claudin-5 and occludin, thus cells migrating into the spinal cord do 
not appear to be travelling through this route. If leucocytes were travelling through the 
junctions it is highly likely that some disruption would be seen in the staining for these 
proteins. It is possible that cells were migrating by a transcellular pathway thus leaving 
the junctions intact, a more recent hypothesis which has been documented using brain 
endothelial cell lines (Etienne-Manneville et al, 2000; Wolburg et al., 2005). Although 
abnormalities in staining for these proteins have been observed in MS tissue (Plumb et 
al, 2000), this does not appear to be the case in this model of EAE. Staining for other 
junctional proteins could possibly have yielded different results. In one study 
investigating the patency of the BBB during EAE, a selective loss of claudin-3 was 
observed in blood vessels with associated presence of inflammatory cells, whilst 
staining for claudins 1 and 5, and ZO-1 was comparable with controls (Wolburg et al,
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2003), suggesting that this may not represent a primary pathological hallmark. 
Leucocytes could initially be passing through the endothelial cells but as inflammation 
increases, the number of cells and excessive amounts of proinflammatory cytokines 
could potentially lead to junctional protein disruption being associated with indirect 
secondary damage. However tPA has been documented to be involved in the opening 
of the BBB via interaction with MMP-9 and also with LRP. Infusion of tPA produces a 
dose-dependant increase in cerebrovascular permeability as measured by Evans Blue 
dye extravasation. This effect is inhibited by antibodies to LRP and by the LRP 
antagnoist RAP (Yepes et al., 2003). Whilst it is clear that tPA increases BBB, 
permeability, it appears from this work that this is not due to a direct affect on tight 
junctions, but perhaps an effect at the basement membrane or endothelial cell level.
In this study, the role of tPA and uPAR in MOG-induced EAE, an animal model 
of inflammatory demyelination was investigated, in tPA ' and uPAR' '  mice and their 
WT counterparts. In conclusion, both tPA and uPAR are implicated in the 
inflammation, demyelination and neurodegeneration characteristic of EAE, suggesting a 
major role for PA on modulating the course of neuroinflammatory disease. The effects 
of the PA system are unrelated to changes in BBB permeability via tight junction 
damage, however tPA appears to have a neuroprotective effect and uPAR mediated 
mononuclear cell migration appears to be important for development and progression of 
EAE.
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5. Influence of the plasminogen activator system on 
fibrinolysis during EAE in tPA and uPAR deficient mice.
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5.1. Introduction.
The plasma protein fibrin(ogen) is not normally present in the CNS, however 
under conditions of neuroinflammation, changes in the permeability of the BBB are 
accompanied by entry of serum proteins. As the plasminogen activator cascade is the 
key initiator of plasmin catalysed fibrin degradation, it was of interest to determine how 
changes in fibrinolysis, as a result of gene inactivation (tPA or uPAR) could be linked 
to the differences in clinical picture between the knockouts and WT mice. Impairment 
of fibrinolysis is a feature of MS tissue as a result of increased levels of PAI-1 and a 
subsequent decrease in tPA activity (Gveric et al, 2003). Furthermore, fibrin 
deposition in a peripheral nerve injury model has been shown to hinder axonal 
regeneration, and contribute to demyelination and axonal degeneration (Akassoglou et 
al, 2000).
To investigate the role of fibrinolysis in experimental neuroinflammation, levels 
of tPA, uPA, PAI-1 and plasminogen were measured in the different genotypes at 
different time points throughout the course of MOG-EAE disease. Additionally, the 
fibrinolytic capacity of EAE tissue was quantified and levels of fibrin(ogen) and fibrin 
D-dimer were assessed as a measure of plasminogen activity.
5.2. Results.
5.2.1. Presence o f uPA. uPAR and PAI-1 positive cells in EAE perivascular cuffs.
Immunohistochemical analysis was performed on sections of spinal cords 
removed from mice during the acute phase of MOG-EAE disease and from normal non­
injected control mice. Sections were stained with antibodies raised against uPA, uPAR 
and PAI-1. In sections from control mice there was very little staining for PAI-1, uPAR 
or uPA (Figure 5.1 A -  C). Levels of PAI-1 were clearly increased in sections from 
MOG-EAE mice when compared to normal controls. PAI-1 was mainly located on
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infiltrating inflammatory mononuclear cells in the perivascular cuffs observed in the 
sections of spinal cord from EAE mice, and additionally in some sections appeared to 
be produced locally within the spinal cord parenchyma. Staining patterns were similar 
in sections from WT and tPA'7' mice during MOG-EAE (Figure 5.1 D and G) however, 
increased PAI-1 staining was less obvious in uPAR'7' mice (Figure 5.1 J).
In the normal CNS there were no identifiable cells expressing uPAR (Figure 5.1 
B). In spinal cord sections from WT EAE mice there was a dramatic increase in uPAR 
expressing cells (Figure 5.1 E) during the inflammatory stage of the disease, which were 
located in perivascular cuffs and areas of infiltration of inflammatory cells. In addition, 
an increase in uPAR staining was also observed in sections from tPA 7' EAE mice 
(Figure 5.1 H), however, not all infiltrating cells in these mice were uPAR positive 
(Figure 5.1 Hi). There was no uPAR staining in sections from uPAR'7' mice (Figure 5.1 
K).
In sections from control mice there was some neuronal staining observed with 
the uPA antibody in the GM of spinal cord sections (Figure 5.1 C). However there was 
a marked increase in uPA staining in sections from EAE mice when compared to 
staining in sections from control mice (Figure 5.1 F, I and L). Cells positive for uPA 
could be identified in areas of inflammatory infiltration which were similar for WT, 
tPA'7' and uPAR'7' mice. uPA appeared to be located on inflammatory cells in the 
perivascular region and on cells migrating into the surrounding parenchyma.
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Figure 5.1. PAI-1, uPAR and uPA staining in sections from MOG-EAE mice. Spinal cords were removed 
from mice at the acute phase o f EAE and cut longitundinally. Frozen sections were stained with 
antibodies raised against PAI-1, uPAR or uPA in sections from control (A - C), WT (D -  F), tPA_/ (G - 1) 
and uPAR'7’ (J - L) mice. PAI-1, uPAR and uPA are increased in all mice during MOG-EAE and could 
be located on or surrounding infiltrating mononuclear cells in the spinal cord WM. No uPAR positive 
cells were observed in sections from uPAR /_ mice. Original magnification x 100 (A-C, K), x 400 (D -  J, 
L).
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5.2.2. Increased PAI-1 and uPA levels during M OG-EAE.
Levels of tPA and PAI-1 are increased in the CSF of MS patients (Akenami et 
al, 1996; Akenami et al., 1997) and PAI-1 antigen levels are also increased in MS brain 
tissue. Investigation into levels of tPA in MS and EAE tissue has lead to conflicting 
results (Ahmed et al, 2001; Akenami et al, 1999; Gveric et al., 2001). To investigate 
how the levels of PAI-1, uPA and tPA changed during the course of MOG-EAE 
disease, ELISAs were performed on spinal cord protein extracts. Levels of PAI-1 
showed marked fluctuations and were significantly higher (P < 0.05) at the peak of 
disease (20 dpi for tPA'7' and WT mice and 35 dpi for uPAR'7' animals) in all three 
genotypes (Figure 5.2 A - C). This was especially pronounced in tPA'7' mice in which 
the PAI-1 levels were approximately 10-fold higher in comparison with PAI levels from 
uPAR'7' and WT mice at 35 and 20 dpi respectively, and almost 100-fold higher than the 
appropriate control. An accumulation of uPA was observed during the acute (20 dpi 
and 35 dpi) and particularly chronic phase of EAE (60 dpi) in tPA'7' and uPAR'7" 
animals, which was not seen in WT mice (Figure 5.2 D - F). The increase in uPA was 
significant at 60 dpi in tPA'7' and uPAR’7" mice when compared to the relevant controls 
(P < 0.05). Levels of tPA did not change throughout the course of EAE disease in WT 
and uPAR'7' mice (Figure 5.3 A and B), and no tPA was detected in the spinal cords of 
tPA'7' mice. Ratios of tPA and uPA to PAI-1 are shown in Table 5.1. The ratio of 
tPA:PAI-l was significantly decreased in WT mice at 20 dpi and uPAR'7' mice at 35 dpi 
of MOG-EAE (P < 0.001) when CNS inflammation was greatest, and at 60 dpi in both 
groups of mice (P < 0.001). Amount of uPA:PAI-l was significantly decreased in WT, 
tPA'7' and uPAR'7' mice at the peak of disease (P < 0.001, P < 0.001 and P < 0.05 
respectively). Additionally, the ratio of uPA:PAI-l at 60 dpi in tPA 7 was also 
significantly lower than that in tPA’7' controls and WT and uPAR7 mice at the same 
stage of EAE disease (P < 0.01, P < 0.05 and P < 0.01 respectively).
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Levels o f PAI-1 and uPA in the spinal cord during MOG-EAE
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Figure 5.2. L evels o f  PAI-1 a n d  uPA d u rin g  M O G -E A E  in WT, tP A v' a n d  u P A R " m ice. L evels o f  PAI-1  
(A -  C) and uPA (D  -  F) antigen w ere determ ined in spinal cord hom ogenate sam ples from control and 
EAE m ice by a m odified sandw ich ELISA. R esu lts represent m ean ng antigen /  m g protein ±  SEM . PAI- 
1 w as significantly increased in W T, tPA'7' and uPA R 7' m ice during the acute/peak phase o f  EA E (A  - C). 
L evels o f  uPA were significantly  higher that controls in tPA'/_ and uP A R 7' m ice at 60  dpi o f  M O G -E A E . 
n = 6 -  9  for W T, n =  6  or 7 for tPA 7* and n =  4 -  8 for uPA R 7’. * P  <  0 .05  v s control.
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Levels o f tPA in the spinal cord during MOG-EAE
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Figure 5.3. Levels o f tPA during MOG-EAE in WT and uP A K ' mice. Levels of tPA antigen were 
determined in spinal cord homogenate samples from control and EAE mice by a modified sandwich 
ELISA. Results represent mean ng antigen / mg protein ± SEM. There were no significant changes in 
tPA in WT or uPAR'7' mice during course of EAE. No tPA antigen was detected in samples from tPA'7' 
mice, n = 6 -  9 for WT and n = 4 -  8 for uPAR'7'.
Ratio (ng/mg protein) tPA: PAI-1 uPA:PAI-l
WT control 41.8 ± 4.0 2.4 ± 0.2
WT 20 dpi 4.1 ±0.5 *** 0.6 ±0.2***
WT 60 dpi 17.7 ±2.3 *** 2.0 ±0.4
tPA"7" control - 1.8 ±0.3
tPA'7' 20 dpi - 0.0 ±0 .0***  u
tPA'7' 60 dpi - 0.8 ±0.1** 1 ¥
uPAR 7' control 44.1 ±0.7 3.0 ±0.4
uPAR'7' 20 dpi 45.4 ±6.3 3.9 ±0.6
uPAR*7- 35 dpi 5.5 ±0.7 *** 1.1 ± 0 .4*
uPAR'7' 60 dpi 15.5 ±1.6*** 4.1 ±0.8
Table 5.1. Ratios o f  tPA and uPA to the inhibitor PAI-1 at different time points during MOG-EAE. 
Results expressed as mean ± SEM, * P < 0.05, * * />< 0 .0 1 ,* * * />< 0.001 versus appropriate control, U P 
< 0.05 tPA*7" versus WT at the same stage of disease, ¥ P <  0.01 tPA’7' versus uPAR7 at the same stage of 
disease.
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5.2.3. Neuroserpin is not upremulated during MOG-EAE disease.
Neuroserpin is a serine protease inhibitor (serpin), that reacts preferentially with 
tPA in the CNS. It is expressed in regions of the brain where either tPA message or 
protein are also found (Yepes and Lawrence, 2004). As PAI-1 is markedly upregulated 
in the CNS during experimental inflammatory demyelination, it was of interest to 
determine whether levels of neuroserpin were also altered. Western blotting for 
neuroserpin was performed on spinal cord protein extracts from control and EAE mice 
at different time points of the disease. No differences were observed in levels of 
neuroserpin between control and EAE mice, and additionally there were no differences 
between the genotypes (Figure 5.4).
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Figure 5.4. Levels of neuroserpin do not change throughout the course o f MOG-EAE disease. Levels of 
neuroserpin were measured by Western blotting of spinal cord homogenate protein extract samples from 
control and EAE mice. Using an anti-neuroserpin antibody and a neuroserpin standard, no differences 
were observed between control and EAE samples. The blot was re-probed with anti-actin to ensure for 
equal protein loading onto the gel.
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5.2.4. Plasminogen, fibrin(osen) and fibrin D-dim er are significantly increased in
tPA'A mice during acute EAE.
Activity of tPA and uPA enzymes were likely to change as a result of increased 
PAI-1 levels. To investigate levels of plasminogen and plasmin activity, Western 
blotting was performed on spinal cord protein extracts from control and EAE WT, tPA"7' 
and uPAR'7' mice. Plasminogen migrated as an 85kDa band which corresponds to the 
cell-bound pre-activation form of plasminogen (lysine-plasminogen) (Figure 5.5 A). 
Using densitometry scanning, the highest amount of plasminogen was measured in 
tPA'7' mice at the peak of acute EAE (20 dpi) when compared to normal tPA'7" controls, 
and WT and uPAR'7' mice at the peak of disease (P < 0.01 and P < 0.001 respectively, 
Figure 5.5 B). Slight decreases in levels of plasminogen were observed in WT and 
uPAR'7' mice at 60 dpi of MOG-EAE, compared to levels in control mice and mice at 
the peak of disease, but these were not significantly different.
Using an antibody specific for fibrin(ogen), substantial extravasation and 
deposition of fibrin(ogen) was found surrounding perivascular cuffs in sections from 
EAE animals (Figure 5.6 D - F) when compared to fibrin(ogen) staining in sections 
from control mice (Figure 5.6 A -  C). In WT and uPAR'7’ mice fibrin deposits were 
confined to areas of inflammation, whereas in sections from tPA'7' mice, diffuse 
deposition was observed throughout the spinal cord parenchyma (Figure 5.6 E). 
Western blotting for fibrin(ogen) and the fibrin degradation product D-dimer was 
performed on spinal cord protein extracts from EAE and from control non-injected 
mice. This was to investigate the role of fibrin as a potential plasmin substrate in the 
progression of EAE. All mice were perfused before spinal cords were taken to remove 
any fibrinogen from the vascular sytem. Western blotting on spinal cord protein 
extracts showed that levels of fibrin D-dimer, a large molecular weight fibrin 
degradation product, changed throughout the course of MOG-EAE with a significant
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increase during acute EAE (Figure 5.7 A). Similarly to plasminogen, the highest 
accumulation of fibrin D-dimer was observed in tPA A mice when compared to tPA /_ 
controls and WT animals at the same stage of disease development (Figure 5.7 B, P < 
0.05). Statistical analysis revealed a strong positive correlation of PAI-1 with fibrin D- 
dimer (r = 0.836, P < 0.001), plasminogen levels (r = 0.884, P < 0.001) and clinical 
score (r = 0.452, P < 0.01).
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Figure 5.5. Accummulation o f plasminogen in tPA~~ mice during acute EAE. Spinal cords from control 
and EAE mice were homogenised for protein extraction. A . Levels of plasminogen were detected by 
Western blotting and were quantitatively measured by densitometry scanning and results are shown as 
arbitrary densitometry units ± SEM. Blots were re-probed with anti-actin to ensure equal loading of 
proteins. B. Level of plasminogen were significantly increased during the acute phase of EAE in tPA 7 
mice when compared to control mice and WT mice at the same stage of disease, n = 3, ** P < 0.01, *** 
P<  0.001.
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Figure 5.6. Increasedfibrin(ogen) staining during MOG-EAE in tPA~ ~ mice. Spinal cords were removed 
from mice at 35 dpi o f EAE and cut longitundinally. Frozen sections were stained with an antibody 
raised against fibrinogen in sections from WT, tPA'7 and uP A R '' mice. There was an increase in 
fibrinogen staining in all EAE animals (D -  F) when compared to the relevant controls (A -  C), but 
particularly in sections from tPA7 mice (E). Fibrinogen staining was particularly increased around cuffs 
in sections from WT and uPAR_/" mice (D and F), however a large amount o f  fibrin exudation in tPA 7 
mice meant that it was also deposited throughout the spinal cord parenchyma. Original magnification x 
100.
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Figure 5.7. Accummulation of fibrin D-dimer in tPA^ mice during acute EAE. Spinal cords from control 
and EAE mice were homogenised for protein extraction. A. Levels of fibrin were detected by Western 
blotting using an anti-fibrinogen antibody and were quantitatively measured by densitometry scanning. 
Results are shown as arbitrary densitometry units ± SEM. All animals were perfused before spinal cords 
were removed and fibrin detected is representative of the fibrin deposited in the nervous tissue. B. 
Levels of fibrin D-dimer were significantly increased during the acute phase of MOG-EAE in tPA mice 
when compared to control mice, and WT and uPAR^' mice at the same stage of disease, n = 4, * P < 
0.05.
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5.2.5. Fibrinolysis in WT. tPA v~ and uPAR'f' animals during MOG-EAE.
As fibrin deposition is a known feature of MS (Claudio et al., 1995), it was 
important to determine how the lack of tPA or uPAR would affect fibrin degradation in 
spinal cords from control and EAE animals. A clot lysis assay was used for spinal cord 
protein extracts to examine fibrinolytic capacity in control and knockout mice at 
specific time points during MOG-EAE. Over 5 h the fibrin clot degradation (measured 
as a decrease in OD at 405nm) was comparable in WT and uPAR'7' mice at all time 
points during EAE (Figure 5.8 A and C). In contrast there was no clot degradation in 
samples from tPA'7' mice during the first 5h of incubation (Figure 5.8 B). In order to 
establish whether other enzymes such as uPA can compensate for the lack of tPA, 
samples from tPA'7' mice were incubated up to 24h. A significantly higher clot 
degradation (75.4 % ± 10.0) was found in samples taken at 60 dpi of EAE in 
comparison to tPA'7'controls or samples taken at 20 dpi (31.38 % ± 11.69 and 28.9 % ± 
13.0 respectively) (P < 0.05). Addition of tPA to sample buffer resulted in rapid clot 
degradation within the first hour of incubation, while omission of plasminogen in the 
sample buffer inhibited clot lysis.
Using fibrin overlay in situ zymography, the fibrinolytic capacity of sections of 
spinal cords could be investigated. The lysis of substrate was assessed by measuring 
lysis area and normalising this to total section area (Figure 5.9i). Sections from control 
uPAR'7" mice showed significantly less lysis of fibrin when compared to control WT 
mice (P < 0.05; Figure 5.9ii). Again there was no fibrinolysis in sections from tPA 7' 
animals (Figure 5.9ii) and sections from WT mice during acute and chronic phase of 
EAE showed significantly reduced fibrinolysis (P < 0.05). No differences in 
fibrinolysis between uPAR7" control and EAE sections were observed. This data is in 
agreement with another study whereby all MS tissue, particularly acute lesion sites, 
showed a marked decrease in fibrinolysis (Gveric et al., 2003).
166
Fibrinolysis in the spinal cords o f mice during MOG-EAE
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Figure 5.8. Fibrinolysis in the mouse CNS. Spinal cords from control and EAE mice at specific time 
points were homogenised for protein extraction. The fibrinolytic capacity was investigated using a clot 
lysis assay which measures the degradation of an in vitro formed clot using spectrophotometry. Results 
are presented as the mean clot degradation over time for (A) WT, (B) tPA'7' and (C) uPAR'7' mice. 
Samples from tPA‘/_ mice were incubated for 24 h to detect fibrinolysis initiated by uPA. tPA A mice at 
60 dpi had a significantly faster clot degradation than either control or 20 dpi mice, n = 4* P < 0.05.
167
Clot lysis in situ zymography
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Figure 5.9. Fibrin overlay in situ zymography o f  control and EAE spinal cords, (i) Using frozen sections 
o f spinal cord and overlaying an agarose solution o f fibrinogen, plasminogen and thrombin, fibrin clot 
lysis can be measured in situ. Substrate lysis is identifed by a clear zone surrounding the tissue (arrows) 
which is not seen in sections from tPA A mice (A -  C). The lysis o f  substrate was quantified using 
computer-assisted image analysis. The lysis area was normalised to the total section area, and results are 
presented as mean ± SEM. (ii) No fibrinolysis occurred in sections from tPA7" mice. Spinal cord 
sections from WT EAE mice had a significantly reduced fibrinolytic capacity than control animals during 
the acute and chronic phases o f disease, additionally, control W T mice had a significantly higher substrate 
lysis than control uPAR'7" mice. Statistical analysis versus relevant control and analyses between different 
genotypes are indicated by a bar, n = 3 ,*  P < 0.05.
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5.2.6. Fibrin(ozen) co-localised with non-phosnhorvlated neurofilament on axons in 
tPA~~ mice.
To investigate whether fibrin is deposited on axons and whether it can have an 
effect on axonal pathology, double fluorescent staining was carried out on perfused 
spinal cord sections from WT, tPA'7" and uPAR'7' mice. The two antibodies used were 
SMI32, for non-phosphorylated neurofilament, a measure of axonal integrity, and 
fibrinogen, FITC or a TRITC -  labelled antibody respectively. Single staining with 
each antibody was used as a control. Single staining with SMI32 and fibrinogen (Figure
5.10 A and C) produced clear specific staining with no non-specific background (Figure
5.10 B and D). There were some fine axons stained with SMI32 in sections from 
normal tPA'7' control animals but no fibrinogen staining (Figure 5.10 E and F). Thick 
axons stained with SMI32 were detected in all EAE sections (Figure 5.10 G - I). 
Fibrin(ogen) staining was negligible in sections from WT and uPAR'7' EAE mice, but 
increased in sections from tPA'7' EAE mice (Figure 5.10 J -  L). Double stained 
structures also positive for fibrinogen were largely seen in the tPA'7' animals (Figure
5.10 N), indicating fibrin deposition on damaged axons.
5.2.7. Altered Laminin expression during the course o f  MOG-EAE.
Fluorescent immunohistochemsitry and Western blotting for laminin were 
carried out to investigate the role of laminin as a potential plasmin substrate in the 
progression of MOG-EAE. Laminin is the known substrate of plasmin leading to 
neuronal death under conditions of excitotoxicity. Immunohistochemical staining for 
laminin in sections from EAE mice revealed blood vessel staining in WT and uPAR7 
mice, however in sections from tPA'7" mice, a high degree of laminin matrix was seen 
deposited through the spinal cord (Figure 5.1 li A —C). Western Blotting on spinal cord 
protein extracts taken from acute (20 dpi for WT and tP A 7 mice, and 35 dpi for uPAR
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mice) and chronic phase (60 dpi) of MOG-EAE and from control mice revealed an 
increase in laminin in tPA'7' mice at 20 dpi of EAE and in WT and uPAR' '  mice at 60 
dpi of EAE (Figure 5.1 lii)
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Figure 5.10. Axons in tPA‘A EAE mice doubled stained with fibrin(ogen) and SMI32. Spinal cords were 
removed from mice at 35 dpi for all animals and cut longitundinally. Frozen sections were stained with 
antibodies raised against non-phosphorylated neurofilament (SMI32) and fibrin(ogen) in sections from 
WT (G, J and M), tPA'A (H, K and N) and uPAR /_ (I, L and O) mice. Fluorescent seconday antibodies 
were added to detect double stained cells. Controls include single staining with each antibody (A = 
SMI32 and C = Fibrinogen), and double staining in control tPA (E and F).
171
La
m
in
in
Laminin
(i) WT tPA uPAR'/_
(ii)
p ■& ■£, p -a  ‘a  p ’a  'a
£  T3 T3 T3 T3 £2 T3
O O  § °  ^  § m O
q j  CN VO 5 j « N V O  q C ^ vO
WT tPA'/_ uPAR’''
Laminin
300kd
Figure 5.11. Laminin protein in WT, tPAv and uPAR'~ mice during MOG-EAE. Fluorescence 
immunohistochemistry and Western blotting for laminin were performed on spinal cord sections and 
protein extracts from control and EAE animals in the acute (20 dpi for tPA'7 and WT and 35 dpi for 
uPAR7") and chronic (60 dpi) phase o f disease using an anti-laminin antibody, (i) Immunofluorescence 
staining showed laminin ECM deposition in spinal cord sections from tPA ' mice but not in sections from 
WT or uPAR'7' mice at 20 dpi o f EAE. (ii) By Western blotting, an apparent increase in laminin was seen 
in the acute phase of tPA /_ mice and in the chronic phase o f W T and uPAR a animals.
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5.2.8. A ltered expression o f  tPA receptors during the course o f  MOG-EAE.
Annexin II is a calcium-dependent phospholipid binding protein which is 
expressed at low levels in the adult CNS, but is upregulated in numerous pathological 
conditions. In endothelial cells and macrophages annexin II is expressed on the plasma 
membrane as a tetramer of two annexin II subunits linked by two p l l  subunits. This 
provides a cell surface receptor for tPA and plasminogen interaction, resulting in an ~ 
60 fold increase in plasmin generation, thus it has a direct effect on fibrinolysis. 
Annexin II has been implicated in tPA mediated activation of microglia (Siao and 
Tsirka, 2002), however in MS tissue, upregulation of annexin II and another tPA 
receptor, LRP, are correlated with an impairment of fibrinolysis and could indicate a 
compensatory mechanism in lesions to aid in fibrin degradation (Gveric et al., 2005). 
LRP is a scavenger receptor which binds to a variety of biologically diverse ligands, 
including tPA and uPAR. LRP is expressed in the CNS by neuronal cells, microglia 
and astrocytes and consists of an extracellular ligand binding heavy chain (515 kDa) 
and a transmembrane light chain (85 kDa) (Herz, 2003). Whilst LRP regulates 
extracellular proteolysis by internalising proteases and protease:inhibitor complexes, it 
has also been linked to opening of the BBB through interaction with tPA (Yepes et al,
2003). To investigate whether levels of these two tPA receptors changed throughout the 
course of MOG-EAE in WT, tPA'7' and uPAR'7' mice, Western blots were carried out on 
spinal cord protein extracts.
During MOG-EAE there was an increase in LRP at the acute stage of disease in 
WT, tPA'7' and uPAR'7' mice and at 60 dpi in tPA'7' and uPAR'7' mice (Figure 5.12 B). 
Annexin II (Figure 5.12 A) was also significantly increased during EAE, specifically in 
tPA'7’ mice at 20 dpi and in WT mice at 60 dpi (Figure 5.12 D).
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Figure 5.12. Levels of the tPA receptors, Annexin II and LRP, during MOG-EAE. Spinal cords from 
control and EAE mice were homogenised for protein extraction. Levels of (A) annexin II and (B) LRP 
were detected by Western blotting using an anti-annexin II and an anti-LRP heavy chain antibody. C. 
Blots were re-probed with anti-actin to ensure equal loading of proteins onto the gel. Levels of annexin II 
were quantitatively measured by densitometry scanning. D. Results are shown as arbitrary densitometry 
units ± SEM. Levels of annexin II and LRP were increased during MOG-EAE. Annexin II was 
significantly increased during the acute phase of MOG-EAE in tPA 1 mice when compared to control 
mice, n = 1 for LRP, n = 2 for annexin II, * P <0.05, ** P <0.01.
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5.3. Discussion.
Given the very different clinical pictures resulting from induction of MOG-EAE 
in tPA'7", uPAR'7' and WT mice (Chapter 4), it was of great interest to investigate how 
the known functions of the PA system, i.e., its involvement in fibrinolysis, affected 
disease outcome. The effect of tPA deficiency on fibrinolysis in EAE was a significant 
impairment of in vitro clot degradation confirming tPA as the key fibrinolytic enzyme 
in the mouse CNS. Whilst uPAR'7' mice had comparable levels of fibrinolysis to those 
of the WT, significantly increased levels of uPA could account for the chronicity 
observed in these mice.
The expression of PAI-1, the main inhibitor of tPA and uPA, is upregulated by 
pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor 
alpha (TNF-a) (Gabay and Kushner, 1999; Kasza et al, 2001). The levels of PAI-1 in 
EAE spinal cord correlated strongly with clinical score, being highest at the peak of 
disease in all three genotypes. Additionally, cells positive for uPA, PAI-1 and uPAR, 
were located by immunohistochemistry to inflammatory perivascular cuffs. The 
approximate 10-fold increase in PAI-1 in tPA’7', compared to WT mice, during the acute 
phase of MOG-EAE, was sufficient to completely inhibit fibrinolysis initiated by uPA 
among other proteolytic enzymes, as reflected by the exceptionally high levels of fibrin 
D-dimer at this stage of disease. In addition, increased amounts of plasminogen in the 
spinal cord of tPA'7' mice at the peak of disease reflect its accumulation resulting from 
decreased activation of the zymogen into its active form plasmin. However as levels 
returned to normal, during the chronic stage of disease, increased uPA in tPA'7' spinal 
cord could account for higher turnover of plasminogen and the fibrinolysis. A higher 
degree of clot degradation was observed in tPA"7’ mice at 60 dpi after 17 h incubation 
suggesting that in the chronic phase of disease there was a partial compensation by uPA, 
a slower acting enzyme, initiating fibrinolysis once levels of PAI-1 had decreased. In
addition to upregulation of uPA, increases in expression of the PA receptors annexin II 
and LRP could also represent endogenous compensatory mechanisms to increase local 
fibrinolysis. Binding of tPA to its receptors results in an ~ 60 fold increase in plasmin 
generation, thus by increasing annexin II and LRP, the efficiency of plasminogen 
activation is increased upon binding of tPA that is not complexed with PAI-1. In the 
same way, increased levels of annexin II and LRP are correlated with diminished 
fibrinolysis in MS tissue as increased formation of tPA:PAI-l complexes reduces the 
capability of tPA receptors to generate plasmin (Gveric et al., 2005). Although fibrin 
overlay shows a decrease in fibrinolysis in control uPAR'7' mice compared to control 
WT mice, this did not lead to a significant impairment of clot lysis nor an accumulation 
of fibrin, as tPA was present in sufficient amounts to compensate for this. Dewerchin et 
al., (1996) have also documented decreased fibrin lysis in uPAR7' mice by in situ 
zymography and concluded this was as a result of decreased uPA-mediated 
plasminogen activation. Western blotting did not detect an increase in plasminogen as a 
measure of decreased PA activity in uPAR'7' mice, however again, the tPA in these mice 
would account for the majority of plasminogen activation.
Levels of the CNS-specific tPA inhibitor neuroserpin did not change in the 
various genotypes throughout the course of MOG-EAE, suggesting a minimal role for 
neuroserpin in experimental neuroinflammation. These data agree with a study carried 
out in MS tissue whereby the decrease in fibrinolytic capacity of lesions was due to 
complex formation of tPA with PAI-1, not with neuroserpin (Gveric et al., 2003). 
However in contrast to this study, which revealed a decrease in native neuroserpin, 
possibly a reflection of neuronal damage, no changes in levels of neuroserpin were 
found in spinal cord samples from EAE mice.
uPA, a stress-responsive proteinase upregulated in infiltrating inflammatory 
cells (Blasi and Carmeliet P., 2002; Gabay and Kushner, 1999), was found to be
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significantly increased in the CNS in uPAR"7' mice in the chronic stages of EAE, 
compared to WT and tPA*7' animals. Accumulation of uPA could reflect the absence of 
a clearance mechanism in uPAR"7' animals, as endocytosis of uPA by uPAR, LRP and 
PAI-1 is a mechanism by which uPA is inactivated, cleared from the cell surface and 
degraded intracellularly (Irigoyen et al., 1999). Furthermore, uPA may act 
independently of uPAR as uPA catalysed plasminogen activation during pericellular 
proteolysis is stimulated in vitro by cells that do not express uPAR (Longstaff et al., 
1999). Under normal conditions uPA is expressed at low levels and kept in balance by 
PAI-1. In uPAR'7' mice however, uPA is present at much higher concentrations than 
PAI-1 in chronic stage EAE and plasminogen is decreased at the same time point. Thus 
uncontrolled uPA-generated plasmin proteolysis could lead to myelin and neuronal 
damage in the CNS of these animals (Blasi and Carmeliet P., 2002), which would 
correlate with the greater demyelination and higher numbers of SMI32 positive axons 
detailed in Chapter 4. Plasmin and uPA are also able to cleave laminin (Chen and 
Strickland, 1997) and fibronectin (Gold et al., 1992) respectively and possibly other 
axon-supporting ECM components. In addition, uPA-generated plasmin can activate 
MMPs (Carmeliet P. et al., 1997), which are known to have detrimental effects under 
neuroinflammatory conditions (Cuzner and Opdenakker, 1999), particularly MMP-9 
which can break down myelin. Furthermore, uPA can directly activate MMP-9 (Liu et 
al., 2005), thus is a potential important pathogenic mechanism involved in 
inflammatory demyelination.
A key feature of neuroinflammation is increased BBB permeability and 
subsequent entry of fibrin into the CNS. Impairment of fibrinolysis due to increased 
PAI-1, as observed in MS tissue (Gveric et al., 2003), and in the tPA'7" mice, leads to 
accumulation of fibrin which has important effects in the CNS, contributing to disease 
progression. Fibrin deposits frequently accompany inflammatory responses,
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(Akassoglou and Strickland, 2002) and fibrin(ogen) has the ability to intensify 
inflammation, acting through signalling molecules, such as ICAM-1 (CD54) and Mac-1 
(CDllb), to modulate cell adhesion and migration, (Flick et al., 2004; Languino et al., 
1995) and increase expression of cytokines, including IL-lp (Perez et al., 1999; Smiley 
et al., 2001). Additionally, fibrin is a potent mediator and activator of macrophages, 
and stimulates them to secrete pro-inflammatory cytokines and chemokines 
(Akassoglou et al., 2004). Low molecular weight degradation products of fibrin can 
enhance vascular permeability and have chemotactic activities (Sueishi et al., 1981), 
thus potentially exacerbating BBB breakdown and promoting migration of leucocytes 
into the CNS. Genetic or pharmacological depletion of fibrin(ogen) in a tumour 
necrosis factor (TNF) transgenic mouse model of MS increases the lifespan of the 
animals as a result of decreased inflammation and a delay in demyelination (Akassoglou 
et al., 2004). Previous studies have shown that fibrin deposition coincides with areas of 
demyelination (Kwon and Prineas, 1994), implicating a role for fibrin in regulating 
myelin breakdown (Akassoglou et al., 2004). However fibrin deposition does not 
correlate well with demyelination in tPA"7' mice, although it correlates very well with a 
marker of neurofilament dephosphorylation, SMI32 (data from Chapter 4), indicating 
that in this study the effect of fibrin on axonal pathology is likely to be via a direct 
mechanism, rather than as a secondary result of demyelination.
Fibrin(ogen), which enters the CNS during the acute phase of disease, 
accumulated over time and was co-localised with SMI32 on axons in the spinal cords of 
tPA'/_ mice. Lack of tPA and resultant fibrin deposition have been shown to exacerbate 
axonal damage in a model of peripheral nerve injury (Akassoglou et al., 2000), 
suggesting similar conditions may influence inflammatory injury to CNS axons. 
Furthermore, inhibition of fibrin formation by attenuation of thrombin activity is 
neuroprotective in the injured optic nerve (Friedmann et al, 2001). Following sciatic
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nerve injury, it was revealed that fibrin can downregulate myelin gene expression in 
Schwann cells via the phosphorylation of extracellular signal regulated kinases 1 and 2 
(Akassoglou et al., 2002), which maintains Schwann cells in a proliferating, non­
differentiated, non-myelinating form. Fibrin could have similar effects on 
oligodendrocytes, the myelinating cells of the CNS, thus inhibiting remyelination and 
functional recovery.
Laminin is a major functional component of basement membranes and is crucial 
for neuronal survival (Chen et al, 2003; Indyk et al, 2003; Jones et al., 2003). It is a 
substrate for plasmin and its degradation is detrimental to neuronal survival in response 
to excitoxic challenge (Chen et al., 2003). However, an increase in laminin was seen in 
tPA'7' mice during the acute phase of disease and during the chronic phase in WT and 
uPAR7' animals. The expression of certain laminin isoforms are increased in response 
to IL-1 (Sixt et al., 2003), thus this could represent an increase in laminin expression in 
response to pro-inflammatory cytokines during acute EAE. In addition, increases in 
laminin expression are seen in response to inflammation and certain laminin isoforms 
have roles assisting the adhesion and migration of T-cells (Sixt et al., 2003). An 
increase in laminin in uPAR'7' mice could provide an alternative mechanism by which 
inflammatory cells can enter the CNS. In the PNS, laminin is a positive regulator of 
Schwann cell migration and differentiation and can induce myelination in vitro 
(Eldridge et al., 1989). Following spinal cord injury, re-growth of axons is 
accompanied by an increase in extra vascular laminin (Ma et al, 2004), and during 
sciatic nerve regeneration, laminin expression is also increased (Akassoglou et al., 
2002). Thus similar mechanisms could be occuring the CNS, whereby laminin is 
increased as a safety mechanism, providing additional support to injured neurons, and 
providing a matrix along which oligodendrocyte precursors can migrate.
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This study has suggested a major role for tPA in CNS fibrinolysis and 
highlighted the inhibitor PAI-1 as a potential target for disease modifying treatment. 
Similar to findings in MS tissue, fibrin removal in lesion sites appears to be important 
for a more favourable outcome. Investigation into the role of tPA and uPAR during 
neuroinflammation has revealed potential sites for therapeutic intervention such as the 
inhibition of uPAR-mediated cell migration and targeting PAI-1 to promote fibrinolysis.
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6. Characterisation of EAE in PAI-1 deficient mice.
181
6.1. Introduction.
Mice deficient for PAI-1 were generated by homologous recombination in 
embryonic stem cells resulting in the deletion of the entire coding region of PAI-1 
(Carmeliet P. et al, 1993). These mice were then backcrossed for three generations 
onto the C57BL/6 background. Resulting offspring were of a different genetic 
background to the tPA'7' and uPAR’7’ mice so had different wildtypes, which were 
genetically matched controls. Although these WT controls were genetically similar to 
PAI-1'7' mice, they were not derived from the same breeding pairs thus were not true 
WT littermates. Induction of MOG-EAE in PAI-1'7' and corresponding WT mice on the 
C57BL/6 background revealed a very low incidence of disease (36 % and 25 % 
respectively). As it was important to have a better comparison of knockouts with WT 
littermates, mice deficient for PAI-1 were backcrossed for 4 generations into the ABH 
strain of mice to increase EAE susceptibility. This yielded PAI-1'7' and appropriate WT 
littermates (PAI-1+7+). These mice were susceptible to CREAE induction with spinal 
cord homogenate.
6.2. Results.
6.2.1. Clinical features o f CREAE disease in PAI-1~7~ and PAI-1+/+ WT littermate mice.
Following immunisation with spinal cord, PAI-1+7+ mice developed clinical 
signs of disease on day 13.9 ± 0.3 (Figure 6.1 A). Peak of EAE disease occurred on day 
16.1 ± 0.3 with a mean maximal score of 2.7 ± 0.3 (Table 6.1). Clinical remission from 
EAE occurred between 25 and 30 dpi. Reimmunisation of mice can precipitate disease 
in the ABH strain or induce a relapse (Pryce et al., 2003). This can be used as an 
additional priming agent when full susceptibility may not occur. Following re­
immunisation on 28 dpi, PAI-1+7+ mice suffered an induced relapse of disease beginning 
at 34 dpi, and mean clinical score at 40 dpi was 1.6 ± 0.4. Onset of CREAE in PAI-1
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mice was significantly later than the PAI-1+/+ at 16.2 ± 0.6 (P < 0.001) (Figure 6.1 A, 
Table 6.1). Peak of disease was also significantly delayed and occurred at 17.9 ± 0.5 {P 
< 0.01), with a significantly lower mean maximal score (1.5 ± 0.4; P < 0.05). 
Following re-immunisation at 28 dpi, no PAI-1'7' mice developed a clinical relapse, and 
mean score at 40 dpi was 0.2 ±0.1, significantly lower than PAI-1+/+ mice (P < 0.05). 
Incidence and time course of EAE onset is illustrated in figure 6.1 B. Whilst 77 % of 
PAI-1+/+ mice developed EAE by 17 dpi, onset of EAE in PAI-1'7' mice was 
significantly later. In addition, incidence of EAE was lower, with 48% of PAI-1'7' mice 
developing clinical signs of EAE by 22 dpi.
Strain
EAE
Incidence
Onset
(dpi)
Peak of 
disease (dpi)
Mean
Maximal
Score
Mean 
Score at 40 
dpi
PAI-1+7+ 20/26 13.9 ±0.3 16.1 ±0.3 2.7 ±0.3 1.6 ±0.4
PAI-1'7' 11/23 16.2 ± 0.6*** 17.9 ±0.5** 1.5 ±0.4* 0.2 ±0.1*
Table 6.1. Summary o f the EAE data for PAI - 1and  PAI-1+/+ (WT) littermate mice. All values shown 
as mean ± SEM, * P < 0.05, ** P < 0.01 and *** P < 0.001 compared to PAI-1+/+.
Weights of all mice were monitored daily as significant weight loss precedes 
CREAE disease onset. Weights of PAI-1'7' mice at 11 dpi were significantly higher than 
the PAI-1+/+ group (P < 0.01) before EAE onset (Figure 6.2). Furthermore, whilst 
PAI-1'7' mice that developed clinical disease suffered significant weight loss, as a group, 
this weight loss was not significant because 52 % failed to develop EAE disease. 
Weight loss in PAI-1+7+ mice was observed from 13 dpi and by 17 dpi was significantly 
lower than weights at 11 dpi (P < 0.01). PAI-1+/+ mice gained weight and by 21 dpi, 
had comparable weights to those before EAE onset. However, following re­
immunisation of all mice at 28 dpi, weight loss was observed in PAI-1+,+ mice before
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onset of a relapse. AT 36 dpi, weights of PAI-1+/+ mice were significantly lower than 
PAI-1'7' mice (P<  0.001).
6.2.2. Movement activity is significantly reduced following CREAE disease.
Movement activity of mice was performed to investigate motor dysfunction and 
the degree of neurological impairment (Pryce et al., 2003). All data was normalised to 
the appropriate controls as control non-injected PAI-1'7' mice were slightly more active 
than control PAI-1+/+ littermates. Following CREAE induction, all mice had a 
significant reduction in activity (Figure 6.3, P < 0.05). There was a 50 % reduction in 
activity of PAI-1'7' mice compared to PAI-1'7' control, and a 75 % reduction in activity 
of PAI-1++ mice compared to the PAI-1+7+ control group. Furthermore, PAI-1+l+ 
littermates were significantly less active than PAI-1'7' mice at 35 dpi of EAE (P < 0.05). 
Mice which failed to develop clinical CREAE disease had comparable levels of activity 
to that of controls.
Baseline activity data
Distanced travelled (cm) in 5 min
ABH.PAI-1w
577.6 ±122.0
ABH.PAI-1
668.7 ± 94.9
Table 6.2. Baseline activity data for control PAI-J+/+ WT and PAI-1mice.  Control PAI-1'7' mice were 
more active than control PAI-1+/+ mice.
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Clinical course of CREAE disease in PAI-1 ^  and PAI-1+/+ littermates
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Figure 6.1. Disease course, time o f  onset and incidence o f  CREAE in PAT ' mice and PAI-1+4 
littermates. A. All mice were injected with spinal cord homogenate in IFA supplemented with M. 
tuberculosis and M  butyricum on day 0, 7 and 28. Mice were scored daily on a scale o f 0 -  5 and the 
daily mean score was calculated for PAI-1+/+ (n = 26) and PAT7' (n = 23). B. 77% o f PAI-1+/+ mice 
showed signs o f EAE disease by 17 dpi, however only 48% o f PAI-1"" mice developed clinical EAE signs 
by 22dpi.
185
Weights of PAI-1'7' and PAI-1+/+ mice during CREAE
3 0 -
a>
<->
. c 2 5 -
O)
*a>
£
2 0 -
1 5 -
A B H . P A I -1 +/+ 
A B H .P A I - 1 '7'
10
"i-----------------1----
2 0  3 0
Time (days p.i.)
— i —
4 0
Figure 6.2. Weights o f P A I - 1 a n d  PAI-1 4 littermates during CREAE. Following induction of EAE, 
mice were weighed daily to check for any significant weight loss. Data is expressed as the mean daily 
weights ± SEM for PAI-1+/+ (n = 26) and PAI"7' (n = 23). ** P < 0.01 and *** p  < 0.001.
Activity of PAI-1'7' and PAI-1+/+ mice following 
induction of CREAE
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Figure 6.3. Activity o f PAP ' mice and PAI-1+/+ littermates before and after CREAE onset. The motor 
function of control and EAE mice (35 dpi) was assessed using an open field activity chamber, and total 
distance travelled in 5 min was recorded for each mouse. The data represents the average activity of each 
group of mice normalised to the relevant control ± SEM. PAI-1'7' mice are more active than PAI-1+/+ 
littermates at 35 dpi. n = 6 for control groups, n = 14 - 16 for EAE groups, * P < 0.05
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6.2.3. Histological evaluation o f  spinal cords from CREAE m ice.
Histological staining with haematoxylin and eosin of spinal cord sections, taken 
at 15, 20, 30 and 40 dpi, revealed differences in the degree of infiltration of 
inflammatory mononuclear cells into the CNS. No mononuclear cells were found in the 
spinal cords of control mice (Figure 6.4 A and B). Sections taken from mice at 15 dpi 
of CREAE revealed a high degree of inflammation in PAI-1+/+ littermates (Figure 6.4 C 
and E), but very few cells were seen in sections from PAI-1'7' mice (Figure 6.4 D) 
indicating that disease onset may have been delayed compared to WT controls. At the 
peak of disease in PAI-1'7' mice at 20 dpi there were large number of perivascular cuffs 
in the spinal cord and comparable levels of inflammatory mononuclear cells to sections 
from PAI-1+/+ mice (Figure 6.4 F). Sections from mice in disease remission at 30 dpi, 
revealed some evidence of ongoing inflammation in PAI-1'7' mice but very few 
infiltrating cells remained in spinal cords of PAI-1+7+ mice (Figure 6.4 G and H), 
however at 40 dpi of CREAE, there was an increase in the number of inflammatory 
cells in the spinal cords of PAI-1+/+ mice corresponding with disease relapse (Figure 6.4 
I). The absence of mononuclear cells in sections from PAI-1'7' mice at 40 dpi (Figure
6.4 J) mirrored the clinical picture where animals remained in disease remission.
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Figure 6.4. Haematoxylin and eosin staining o f  spinal cord sections from  PAI-fr' and PAI-1+/+ mice 
during acute and remission stages o f  CREAE. Spinal cords were removed from mice at 15, 20, 30 and 40 
dpi o f CREAE and cut longitudinally. H & E was performed on frozen sections to detect nuclei distinct 
from other tissue components. Sections from control mice (A and B) and PAI-1'7' mice at 15 and 40 dpi 
(D and J) showed no clustering o f nuclei indicative o f cuffing. Perivascular cuffs were identifiable in 
sections from PAI-1+/+ and PAI-1"7' mice during acute EAE (C, E and F) and in PAI-1+/+ mice during 
relapse (I) indicative o f inflammation. Samples from mice in remission (G and H) revealed some 
evidence o f ongoing inflammation. Original magnification x 100 (A -  D, F - J), x 400 (E).
H & E ABH . PAI-1+/+ ABH.PAI-1 A
6.2.4. Infiltration o f  macrophages, microglia and lymphocytes in CREAE.
Immunohistochemical staining was carried out on sections of spinal cords 
removed from mice during the acute phase of CREAE, 15 dpi for PAI-1+/+ and 20 dpi 
for PAI-17', comparing CD45, F4/80, CD4 and CD8 staining on serial sections (Figure 
6.5). No staining was observed in sections from control mice (not shown). Staining on 
serial sections for CD45, F4/80, CD4 and CD8 and showed that both 
macrophages/microglia and lymphocytes were present in large numbers in perivascular 
cuffs in PAI-17' mice and PAI-1+/+ littermates. Additionally, microglia and 
macrophages contributed to a high proportion of CD45 positive cells observed 
infiltrating into the CNS. A high number of perivascular cuffs were observed in PAI-17' 
and PAI-1+/+ mice at the peak of disease (15 dpi for PAI-1+/+ and 20 dpi for knockouts) 
which corresponded to high clinical disease scores (Figures 6.5 A and G). Although 
there were similar numbers of CD45 positive cells surrounding blood vessels in sections 
from both genotypes (Figure 6.5 B and H), there were less microglia/macrophages in 
the perivascular cuffs in PAI-17' mice when compared to sections from PAI-1+/+ (Figure
6.5 E and K). No CD4 or CD8 positive cells are present in sections from control mice 
(not shown). Immunohistochemical analysis of CD4 and CD8 positive lymphocytes on 
serial sections of EAE spinal cord revealed the presence of both of these cell types in 
the inflammatory infiltrates of perivascular cuffs. Numbers of these cells were 
comparable between PAI-17' mice and PAI-1+/+ littermates during active disease, 
however in both groups of mice, the numbers of CD4+ cells (Figure 6.5 C and I) were 
greater than the number of CD8+ lymphocytes (Figure 6.5 F and L), consistent with 
previous findings (Allen et al., 1993; Baker et al., 1990).
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Figure 6.5. CD45, F4/80, CD4 and CD8 staining in PAI-1+/+ and knockout mice during acute CREAE. 
Spinal cords were removed at the acute stage o f CREAE and cut longitudinally. Frozen sections were 
stained with an antibody against CD45 (A, B, G and H), F4/80 (D, E, J and K), CD4 (C and I) or CD8 (F 
and L) and counterstained with Mayer’s haematoxylin to assess the infiltration/migration o f inflammatory 
mononuclear cells. In control animals there were no mononuclear cells in the spinal cord tissue (not 
shown). CD45 (A and G) and F4/80 (D and J) showed very similar patterns o f staining. Perivascular 
cuffs containing CD4+ and CD8+ cells were evident in PA I-17 and PAI-1+/+ mice at the peak o f EAE 
disease, but no differences were observed between the two genotypes. In all corresponding serial sections 
there were more CD4+ cells (C and I) than CD8+ lymphocytes (F and L) Original magnification; x 100 
(A, D, G, and J), x 400 (B, C, E, F, H, I, K and L).
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6.2.5. Demyelination after induction o f  CREAE in PAI-1~A mice and PAI-1+/+
littermates.
Staining with an antibody against MBP in representative sections of mouse 
spinal cord at different time points during CREAE progression was used to assess 
demyelination. In control mice myelin staining was dense and complete in the white 
matter of the spinal cord (Figure 6.6 A and D) and no differences were observed 
between PAI-1+/+ and PAI-1"7' mice. In sections from EAE mice during the peak of 
disease (15 dpi for PAI-1+/+ and 20 dpi for PAI-1'7' mice), the appearance of myelin 
density was altered with the presence of perivascular cuffs, which contained 
macrophages, and hence active demyelination (Figure 6.6 B, C, E and F). Following 
disease remission at 30 dpi there were obvious patches of demyelination in the white 
matter appearing as changes in myelin density (Figure 6.6 G and I). At 40 dpi of 
CREAE, PAI-1'7' mice were still in disease remission and had normal appearing myelin 
staining (Figure 6.6 J), whilst PAI-1+7+ littermates were relapsing, and had further 
evidence of demyelination in the spinal cord, specifically in areas of perivascular 
inflammation (Figure 6.6 H and Hi).
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Figure 6.6. MBP staining in PAI-1+/+ and knockout mice during acute, remission and relapse stages o f  
CREAE. Spinal cords were removed at different stages o f EAE and cut longitudinally. Frozen sections 
were stained with an antibody against MBP to assess the degree and location o f demyelination. MBP 
staining in control (A and D) and EAE mice (B, C, E, F, G - I). Loss o f myelin appeared to be restricted 
to areas o f perivascular cuffing. Hi and Ii are high magnification images o f H and I respectively. 
Original magnification; x 100 (A -  H, I and J), x 400 (Hi and Ii).
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6.2.6. Axonal pathology in CREAE in PAI-1'A mice and PAI-1+/+ litterm ates.
Changes in axonal pathology were assessed by staining for phosphorylated 
(SMI35) and non-phosphorylated (SMI32) neurofilaments on sections from 30 and 40 
dpi of CREAE. There was no obvious increase or decrease in the number of axons 
stained for SMI35 between different genotypes and time points (Figure 6.7i). In control 
mice, SMI35 positive axons were clearly visible in the white matter of spinal cord 
sections (Figure 6.7i A and D). The appearance was uniform with long and straight 
axons packed in high density. In sections from PAI-1+/+ and PAI-1'7' CREAE mice, 
there were slight changes in axonal appearance; with some thickened, non-uniform 
axons visible surrounding perivascular cuffs (Figure 6.7i B and E). In areas of 
infiltration there was a paucity of axons (Figure 6.7i B and E) consistent with the lack of 
myelin in these areas (Figure 6.6 B and E). This suggests that the infiltrating 
inflammatory cells may have changed the path of axons around the lesion. Following 
remission of clinical EAE disease, axons appeared most normal in sections from 
PAI-1'7' mice, with some larger thicker axons still present (Figure 6.7i F). However in 
PAI-1+7+ littermate mice, with on-going inflammation, varicose axons were still visible, 
with the appearance of bulbs or ovoids indicating possible axonal transection (Figure 
6.7i C). In sections from control PAI-1'7' and PAI-1+/+ mice there were very few axons 
stained for SMI32 (Figure 6.7ii G and J). Following induction of CREAE at disease 
remission, 30 dpi, there was an increase in the number of axons stained for SMI32 
(Figure 6.7ii H and K), although there were no apparent differences between the two 
genotypes. However at 40 dpi of CREAE, there were much higher numbers of axons 
stained for SMI32 in sections from PAI-1+/+ WT mice, which were undergoing disease 
relapse, than in sections from PAI-1’7’ mice, still in clinical remission (Figure 6.7ii I and 
L).
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Figure 6.7. L e v e ls  o f  p h o s p h o r y la te d  a n d  n o n -p h o s p h o r y la te d  n e u ro fila m e n t d u r in g  C R E A E  in  P A I - 1 7 
a n d  P A I-1 +/+ lit te rm a te s .  Longitudinal spinal cord sections from control animals and mice in the 
remission and relapse stages o f EAE were stained for (i) SMI35 and (ii) SMI32 to assess changes in 
levels o f phosphorylated and non-phosphorylated neurofilament in the CNS. SM B 5 in control mice (A 
and D) and in EAE (B, C, E and F). SMI32 in control mice (G and I) and at 30 and 40 dpi o f  CREAE (H, 
I, K and J). Original magnification xlOO (A, D, G and J), x 200 (B, C, E, F, H, I, K and L).
Control
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6.2.7. Levels oftPA , uPA and PAI-1 in PAI-1v' and PAI-1+/+ mice during CREAE.
To investigate how the levels of tPA, uPA and PAI-1 change during the course 
of CREAE disease, in the absence of PAI-1, ELISAs were performed on spinal cord 
protein extracts. Levels of tPA did not change throughout the course of CREAE disease 
in PAI-1+/+ littermate mice (Figure 6.8 A). However in samples from PAI-1'7' mice, 
levels of tPA were significantly increased at all stages of CREAE, when compared to 
PAI-1'7' controls, particularly during the acute and remission phases (P < 0.01; Figure 
6.8 B). uPA protein did not change significantly during the acute phase of CREAE in 
either PAI-1'7' or PAI-1+7+ WT mice, however levels were significantly increased during 
disease remission in PAI-1'7' mice at 30 dpi (.P < 0.05) and during disease relapse in 
samples from PAI-1+7+ littermates (.P <0.01) (Figure 6.8 C and D). As predicated no 
PAI-1 protein was detected by ELISA in samples from PAI-1'7' mice, however in WT 
littermates, PAI-1 was increased during the acute and relapse stages of CREAE, 
corresponding to inflammation (P < 0.05) (Figure 6.8 E). To investigate what these 
changes meant in the in vivo situation, calculating ratios of enzyme to inhibitor are 
useful (Table 6.3). Under physiological conditions, in control PAI-1+7+ mice the ratio of 
tPA to PAI-1 was approximately 36:1, and the ratio of uPA to PAI-1 was approximately 
5:1. This ensured that at all times enzyme was present in much greater amounts than 
inhibitor. Ratios of tPA and uPA enzyme to inhibitor during the acute phase of 
CREAE, at 15 dpi fell dramatically when compared to controls (P < 0.05 and P < 0.01 
respectively). This would indicate that levels of PAI-1 were higher than uPA or tPA 
during the inflammatory stages of the disease, thus inhibiting the majority of 
plasminogen activation by these enzymes during acute EAE. Ratios were not 
significantly different during remission at 30 dpi, and were much nearer physiological 
levels. Interestingly, ratio levels of tPA and uPA enzyme to inhibitor fell significantly 
again during disease relapse at 40 dpi (P < 0.05). Ratios in PAI-1'7' mice could not be
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calculated as there was no PAI-1, thus it could be assumed that the majority of tPA and 
uPA detected are free, un-complexed enzymes.
Ratio (ng/mg) Control
Acute 
20 dpi
Remission 
30 dpi
Relapse 
40 dpi
tPA:PAI-l 36.1 ±19.2 2.0 ± 0.2* 41.6 ±4.2 0.5 ±0.1*
uPA:PAI-l 4.5 ±0.6 0.2 ±0.4** 15.4 ±7.8 0.2 ±0.0*
Table 6.3. Ratios o f tPA and uPA to the inhibitor PAI-1 during different phases o f CREAE in PAI-1* + 
WTmice. Results expressed as mean ± SEM, * P < 0.05, ** P < 0.01 versus control.
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Levels o f  tPA, uPA and PAI-1 in spinal cords during SCH-CREAE
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Figure 6.8. Levels o f tPA, uPA and PAI-1 in ABH backcross mice during CREAE. Levels of tPA (A and 
B), uPA (C and D) and PAI-1 (E) were measured in spinal cord homogenate protein extracts from control 
animals and mice at different stages of CREAE. tPA and uPA were increased in samples from PAI-l'7' 
mice, particularly during disease remission. No PAI-1 was detected in samples from PA I-l7’ mice. uPA 
and PAI-1 were significantly increased in PAI-1+/+ mice during EAE relapse. All data presented as mean 
± SEM, n = 3 per time point. * P < 0.05, ** P < 0.01, versus control unless indicated by a bar.
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6.2.8. Levels o f  neuroserpin during CREAE disease.
Although levels of neuroserpin, the CNS specific serpin, did not change 
significantly in tPA'7', uPAR'7' and WT mice during MOG-EAE (Chapter 5), differing 
results may be obtained in mice following CREAE induction with SCH. Additionally, 
as PAI-1 is usually upregulated in the CNS during experimental inflammatory 
demyelination, it was of interest to determine whether levels of neuroserpin were altered 
in the absence of PAI-1. Western blotting for neuroserpin was carried out on spinal 
cord protein extracts from normal control and CREAE mice at different time points of 
the disease (Figure 6.9). A higher, but not statistically significant level of neuroserpin 
was found in spinal cords from control PAI-1'7' mice compared to PAI-1+7+ littermates. 
During the acute phase of CREAE in both PAI-1+7+ and PAI-1'7' mice there was a 
decrease in levels of neuroserpin, however this was not significant. A decrease in 
neuroserpin levels in samples from PAI-1'7' mice during CREAE remission were also 
lower than levels in samples from control, pre-onset and acute mice, but again this was 
not statistically significant.
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Figure 6.9. Levels o f neuroserpin do not change significantly throughout the course o f CREAE disease. 
Spinal cords from control and CREAE mice were homogenised for protein extraction. A. Levels of 
neuroserpin were detected by Western blotting and were quantitatively measured by densitometry 
scanning and results are shown as arbitrary densitometry units ± SEM. B. Using an anti-neuroserpin 
antibody, no significant differences were observed between control and EAE samples. The blot was re­
probed with anti-actin to control for protein loading onto the gel. n = 3.
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6.2.9. Plasmino2en. fibrinfosen) and fibrin D-dimer are significantly increased during
CREAE.
Activity of tPA and uPA was likely to change as a result of lack of PAI-1 in the 
knockouts. To investigate levels of plasminogen and plasmin activity, Western blotting 
was performed on spinal cord protein extracts from control and CREAE PAI-1+/+ and 
PAI-1'7' mice. Plasminogen migrated as an 85kDa band which corresponds to the cell- 
bound pre-activation form of plasminogen (lysine-plasminogen) (Figure 6.10 A). Using 
densitometry scanning, the highest amount of plasminogen was measured in PAI-1'7' 
mice before the onset of CREAE (15 dpi) when compared to PAI'7' controls (Figure 6.10 
B, P < 0.05). Increases in levels of plasminogen were observed in PAI-1+/+ and PAI-1'7' 
mice at the acute and remission phases of CREAE (15 dpi, 20 dpi and 30 dpi), 
compared to levels in control mice but these were not significant. However during 
relapse at 40 dpi, PAI-1+/+ mice had a significant increase in plasminogen when 
compared to levels in PAI-1+/+ control mice (P < 0.01).
Using an antibody specific for fibrin(ogen), extravasation and deposition of 
fibrin(ogen) was assessed in sections of spinal cord from PAI-1'7' and PAI-1+/+ WT mice 
before and after induction of CREAE, during different time points of disease 
progression. In control mice there was no fibrin(ogen) in the CNS of either PAI-1+/+ or 
PAI-1'7' mice (Figure 6.1 li A and D). An increase in staining for fibrin(ogen) was seen 
in all sections from EAE mice. Fibrin(ogen) was particularly high in sections from the 
acute phase of EAE (15 dpi for PAI-1+/+ and 20 dpi for PAI-1'7') and fibrin deposits 
were located to areas of inflammatory infiltration (Figure 6.1 li B and E). In sections 
from PAI-1+/+ mice more diffuse deposition was observed throughout the spinal cord 
parenchyma (Figure 6.1 li B). During CREAE disease remission in PAI-1'7' mice, 
staining for fibrin(ogen) was reduced and was limited to small areas of heightened BBB 
permeability (Figure 6.1 li F). At 40 dpi of CREAE, when PAI-1'7’ mice were still in
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disease remission, PAI-1+/+ mice were relapsing with accompanying increases in BBB 
permeability and fibrin(ogen) deposition (Figure 6.1 li C).
Western blotting for fibrin(ogen) and the fibrin degradation product D-dimer 
was performed on spinal cord protein extracts from CREAE and from control non­
injected mice (Figure 6.11ii). This was to investigate the role of fibrin as a potential 
plasmin substrate in the progression of CREAE. All mice were perfused before spinal 
cords were taken to remove any fibrinogen from the vascular sytem, thus fibrin detected 
is representative of that deposited in the nervous tissue. Western blotting on spinal cord 
protein extracts showed that levels of fibrin D-dimer, a large molecular weight fibrin 
degradation product, change throughout the course of CREAE. In PAI-1'7' mice a 
significant increase in fibrin was observed at 15 dpi which was before clinical signs of 
EAE disease had developed in this genotype, (Figure 6.11 iii, P < 0.01 versus PAI-17' 
controls). However levels of fibrin D-dimer at other stages of CREAE disease in 
PAI-1'7' mice were not significantly different to controls. A significant increase in fibrin 
D-dimer was observed during acute and relapse (15 and 40 dpi) phases of CREAE in 
samples from PAI-1+7+ mice when compared to controls (Figure 6.11 iii, P < 0.05 and P 
< 0.05 respectively). The highest levels of fibrin D-dimer were observed in samples 
from PAI-1+7+ mice during CREAE relapse, and this was significantly higher than the 
highest levels found in samples from PAI-1'7' mice at 15 dpi (P < 0.01). Statistical 
analysis revealed a strong correlation of PAI-1 with fibrin D-dimer (r = 0.836, P < 
0.01), and plasminogen levels (r = 0.884, P < 0.01). In addition there was a significant 
negative correlation between plasminogen and tPA (r = -0.556, P < 0.05).
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Figure 6.10. Increased levels o f plasminogen in PAI-I+/+ and PAI-1V~ mice during CREAE. Spinal cords 
from control and EAE mice were homogenised for protein extraction. A. Levels of plasminogen were 
detected by Western blotting and were quantitatively measured by densitometry scanning and results are 
shown as arbitrary densitometry units ± SEM. Blots were re-probed with anti-actin to control for loading 
of proteins onto the gel. B. Levels of plasminogen were increased pre onset of EAE in PAL7' mice, and 
during the acute phase of EAE in both PAI-l'7' and PAI-1+/+ mice, n = 3, * P < 0.05, ** P < 0.01.
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Figure 6.11. Fibrin(ogen) deposition in the spinal cords o f  PAI-1'' and PAI-1+/+ mice during CREAE. (i) 
Spinal cords were removed from mice during different stages o f  EAE and cut longitundinally. Frozen 
sections were stained with an antibody raised against fibrin(ogen) in sections from PAI-1+/+ (A — C) and 
PA I-17' (D -  F) mice. Original magnification xlOO. (ii) Levels o f  fibrin were detected by Western 
blotting using an anti-fibrin(ogen) antibody and (iii) were quantitatively measured by densitometry 
scanning. Results are shown as arbitrary densitometry units ± SEM. n = 3, * P < 0.05, ** P < 0.01 
versus appropriate control and analysis between genotypes is indicated by a bar.
6.2.10. Fibrinolysis in PAI-1~7~ mice and PAI-1+/+ littermates during CREAE.
As fibrin deposition is a known feature of MS (Claudio et al., 1995), it was 
important to determine how the lack of PAI-1 would affect fibrin degradation in spinal 
cords from control and CREAE animals. A clot lysis assay was used for spinal cord 
protein extracts to examine fibrinolytic capacity in control and knockout mice at 
specific time points during CREAE. Over 5 h the fibrin clot degradation (measured as a 
decrease in OD at 405nm) was comparable in PAI-1+/+ and PAI-17' control mice. 
(Figure 6.12 A and B). In samples from PAI-1+/+ mice during acute and relapse stages 
of CREAE, clot lysis was significantly impaired (P < 0.01). In control PAI-1+/+ mice, 
fibrin clot degradation was complete at 2 h, however in samples from PAI-1+/+ mice 
during the acute phase of CREAE, clot lysis was not complete till 4 h. Furthermore, 
samples from PAI-1+/+ WT mice during CREAE relapse failed to degrade the in vitro 
formed clot within the 5 h time frame of the experiment. Protein extract samples from 
PAI-1+/+ mice in remission, did appear to have a slower rate of fibrinolysis, however 
this was not significant. Samples from PAI-17' mice during acute and remission stages 
of CREAE had comparable clot lysis to PAI-17' controls (Figure 6.12 B), however, at 
15 dpi, before clinical signs had developed in these mice, clot lysis at 2 h was 
significantly slower compared to control mice, however was complete within 3.5 h. 
Addition of tPA to sample buffer resulted in rapid clot degradation within the first hour 
of incubation, while omission of plasminogen in the sample buffer inhibited clot lysis.
Using fibrin overlay in situ zymography, the fibrinolytic capacity of sections of 
spinal cords could be investigated. The lysis of substrate was assessed by measuring 
lysis area and normalising this to total section area. Sections from PAI-1+/+ mice 
showed no significant differences in fibrin lysis at any stage of CREAE when compared 
to controls, although there was a slight decrease in sections from mice during acute 
CREAE (Figure 6.13). There was a very low level of fibrin(ogen) lysis in sections from
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control PAI-1'7' mice, and fibrinolysis was increased significantly in sections from mice 
at all stages of CREAE. Lysis of fibrin substrate was increased in sections from PAI-1'7' 
mice pre EAE onset (P < 0.05) and in sections from mice during the acute phase of 
CREAE at 20 dpi (P < 0.05). Although during CREAE remission in PAI-17' mice, 
levels of fibrinolysis had decreased, they were still significantly higher than PAI-1'7' 
control (P < 0.01).
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Figure 6.12. Clot lysis in PAI-1"  and wildtype littermates before and during CREAE disease onset. 
Spinal cords from control and EAE mice at specific time points were homogenised for protein extraction. 
The fibrinolytic capacity was investigated using a clot lysis assay which measures the degradation o f  an 
in vitro formed clot using spectrophotometry. Results are presented as the mean clot degradation over 
time for PAI-1+/+ (A) and PAI-1' ' (B) mice. Clot lysis in samples from acute and relapse stages o f  EAE 
in PAI-1+/+ mice were significanly slower than control. Furthermore, pre EAE onset, fibrinolysis was 
impaired in PA I-17' mice, n = 3, * P  < 0.05, ** P< 0.01.
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Fibrin overlay on spinal cord sections from
PAI-1'7' and PAI-1+/+ mice during CREAE
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Figure 6.13. Fibrin overlay in situ zymography of control and CREAE spinal cords. Using frozen 
sections of spinal cord and overlaying an agarose solution of fibrinogen, plasminogen and thrombin, 
fibrin clot lysis can be measured in situ. The lysis of substrate was quantified using computer-assisted 
image analysis. The lysis area was normalised to the total section area. The fibrinolytic capacity in WT 
littermate mice does not significantly change throughout the course of CREAE. However, fibrinolysis 
significantly increases in spinal cord sections from PAI-1*7' EAE mice, n = 4 ,* P < 0.05, ** P < 0.01.
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6.3. Discussion
Induction of CREAE in PAI-17' and PAI-1+/+ mice on the ABH background led 
to a less severe clinical course of disease, and less marked pathophysiological features 
than in tPA'7' and uPAR'7' mice. PAI-1+/+ littermates had a very similar disease to mice 
of the pure ABH strain with significant inflammation, impairment of fibrinolysis, and 
evidence of demyelination and axonal degeneration. CREAE in PAI-1'7' mice resulted 
in a lower incidence of disease, with mice developing signs of EAE significantly later 
than WTs. A delay in cellular entry into the CNS accompanied by a higher capacity for 
fibrinolysis resulted in a milder disease in PAI-1'7' mice with no clinical relapses and 
less axonal damage.
The delayed disease onset and inflammation in the spinal cord of PAI-1'7' mice 
support a role for PAI-1 in promoting cell adhesion and migration. A key modulatory 
effect of PAI-1 is its capacity to bind the adhesive glycoprotein, vitronectin (VN), a 
component of the ECM (Hertig and Rondeau, 2004). The VN meshwork is detected in 
the blood vessel walls of active MS lesions (Gveric et al., 2001; Sobel et al., 1995). In 
solution, VN-bound PAI-1 is twice as stable as unbound PAI-1, and the half life can 
exceed 24 h (Binder et al, 2002). PAI-1 acts as a “molecular switch” interfering with 
the adhesive uPAR-VN link, leading to detachment of cells from the substrate (Deng et 
al, 1996) and by promoting detachment of uPAR bearing cells from VN, PAI-1 
increases cellular migration on this matrix (Waltz et al., 1997). Thus in PAI-1'7' mice, 
there would be no interference with the adhesive uPAR-VN link, so detachment and 
migration of cells into the CNS is interrupted. The effect of PAI-1 on cell migration is 
particularly evident in cancer whereby high levels of this inhibitor are associated with 
tumour metastasis and a poor prognosis (Dellas and Loskutoff, 2005). Furthermore, in 
an antigen-induced mouse model of rheumatoid arthritis, PAI-1 deficiency attenuated 
joint inflammation, thus proving that PAI-1 has an important role in inflammation
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through promoting leucocyte adhesion and migration (Van Ness et a l, 2002). This 
effect was also due to increased synovial fibrinolysis and a reduced accumulation of 
fibrin.
In ABH.PAI-1+/+ littermates, a significant impairment of fibrinolysis was 
observed during acute and relapse stages of CREAE, associated with increased PAI-1 
and decreased plasminogen activation, leading to lys-plasminogen and fibrin D-dimer 
accumulation. These finding are very similar to those observed in ABH mice, detailed 
in Chapter 3. An increase in SMI32 staining and a decrease in motor activity point to a 
significant degree of axonal damage and neurological impairment in the PAI-1+/+ 
littermates, when compared to the PAI-1'7' mice. Again these findings correlated 
particularly well with fibrin accumulation, indicating a role for fibrin on axonal 
pathology (Akassoglou et al., 2000; East et al, 2005). Furthermore, decreased fibrin 
deposition provides a more favourable environment for regeneration (Akassoglou et al, 
2000; Akassoglou et al, 2002).
Lack of PAI-1 in the knockout mice may ensure that fibrin entering through the 
BBB in CREAE is quickly removed, due to the absence of the key fibrinolytic inhibitor. 
The clot lysis assay and fibrin overlay in situ zymography showed that fibrinolysis was 
much more efficient in PAI-1'7' mice than in the PAI-1+7+ littermates, and actually 
increased during CREAE disease, due to raised levels of plasminogen activators. Even 
though CREAE disease was clinically silent at 40 dpi in PAI-1'7' mice, significant 
accumulation of tPA and uPA during remission showed that there was still some 
ongoing pathology, underlying these changes. Accumulation of tPA and uPA in 
PAI-1'7' mice, not seen in PAI-1+7+ mice, could represent a regulatory effect of PAI-1 on 
these enzymes. This could be at the gene expression, mRNA level or protein level. 
Additionally, PAI-1 is responsible for termination of tPA and uPA activity by their 
removal from the circulation through interaction with LRP and subsequent cellular
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internalisation (Strickland and Ranganathan, 2003). Lack of PAI-1 means that this key 
clearance mechanism is lacking, thus ineffective elimination could explain the high 
levels of PAs in this genotype. Such high levels of these plasminogen activators, in the 
absence of an inhibitor could have potentially detrimental effects. Via plasmin, tPA and 
uPA have the ability to activate MMPs, which are known to degrade the BBB, and 
exacerbate myelin breakdown in MS. Additionally, tPA can mediate microglial 
activation (Rogove et al, 1999), and play a key role in neuronal cell death following 
excitotoxic injury through proteolytic degradation of laminin (Chen and Strickland, 
1997; Tsirka et al, 1995; Tsirka et al, 1997a). However as there was little evidence of 
neurodegeneration in PAI-1'7' mice, it appears that tPA and uPA were not acting via 
these potentially damaging mechanisms. Alternatively, other PA inhibitors could be 
compensating for loss of PAI-1. Neuroserpin, the CNS-specific tPA inhibitor was not 
upregulated during CREAE, however levels of this protein did decrease at 20 and 30 dpi 
in PAI-1'7' mice, which could correspond to increased complex formation of neuroserpin 
with tPA. Furthermore, PAI-2, which is synthesised by monocytes and macrophages in 
response to TNF-a (Dobrovolsky and Titaeva, 2002; Irigoyen et al., 1999), could play a 
role in inhibiting excessive PA activity. It was not logistically possibly to continue with 
this experiment beyond 40 days due to low n-numbers rendering the data statistically 
non-viable. Although if the CREAE experiment had been continued, it is possible that 
with continuing increases in tPA and uPA, there might have been some further evidence 
of demyelination and axonal degeneration. In uPAR'7' mice, high levels of uPA during 
disease chronicity lead to a high degree of myelin loss and an increase in neuronal 
damage (Chapters 4 and 5).
Mice deficient for PAI-1’7’ did not undergo a clinical relapse following re­
immunisation. Thus, fibrinolysis appears to have a major influence in 
neuroinflammation, possibly by contributing to disease relapse. Inefficient fibrin
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removal in PAI-1+/+ littermate mice during CREAE could contribute to exacerbation of 
disease and clinical relapse as fibrin is known to have a key role in inflammation. 
Fibrin(ogen) participates in a variety of cellular responses associated with inflammation 
through binding with different types of integrin and non-integrin receptors. Binding to 
CX5P1, (Xm|32 (Mac-1 or CDllb/CD18) and ocyfb, which are expressed on leucocytes, 
macrophages and monocytes, can lead to different effects depending on the cell type 
and the intracellular signalling pathways elicited (Adams et al., 2004). Through 
interaction with ICAM-1, fibrin(ogen) binding to vascular cell receptors can initiate 
increased leucocyte adhesion to endothelium and leucocyte transendothelial migration 
(Languino et al., 1995). Additionally the fibrin(ogen):ICAM-1 complex can lead to an 
anti-apoptotic state of cells through activation of the MAP kinase pathway (Pluskota 
and D'Souza, 2000). Apoptosis of T-cells is thought to be an important contributory 
factor to disease remission during EAE and MS (Pender and Rist, 2001), and 
suppression of T-cell apoptosis in EAE increases the severity of the disease (Okuda et 
al., 2002). Akassoglou et al., (2004) demonstrated that fibrin can exacerbate 
inflammation in a model of MS. Genetically or pharmacologically fibrin depleted mice 
demonstrated reduced neuroinflammation, decreased demyelination and as a result a 
lengthened lifespan compared to wildtype or vehicle injected animals (Akassoglou et 
al., 2004). Additionally it was found that fibrinogen can stimulate secretion of pro- 
inflammatory cytokines and chemokines, and is a potent stimulator of macrophage 
activation (Akassoglou et al., 2004). As fibrin is capable of modulating inflammation 
via a number of different mechanisms, it is clear that removal of this plasma protein, by 
enhancing fibrinolysis, can produce extremely beneficial results.
In summary, inhibition of PAI-1 could be therapeutically beneficial in treating 
MS. This would provide a dual palliative approach whereby leucocyte migration and 
inflammation are reduced, allowing efficient removal of fibrin, which could potentially
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decrease axonal/neuronal damage, and reduce frequency of disease relapses in MS 
patients.
212
7. Synaptic and dendritic proteins as markers of axonal
pathology in EAE.
213
7.1. Introduction.
Many studies have focused on the degree and timing of axonal injury in MS 
(Bjartmar and Trapp, 2001), and by using various axonal/neuronal markers, such as 
APP and SMI32, neuronal injury and degeneration can be assessed (discussed in section 
1.5) (Ferguson et al, 1997; Trapp et al, 1998). Recently a study by Zhu and collegues 
(Zhu et al., 2003) discovered that various synaptic and dendritic proteins may provide 
useful markers and tools to investigate early changes during inflammatory 
demyelination. Additionally, as dendrites are very susceptible to excitotoxicity 
(Hasbani et al, 2001), dendritic markers can provide clues about the role of excessive 
glutamate in neuroinflammation. Excitotoxicity is thought to be one of the underlying 
pathogenic mechanisms involved in EAE and MS (Groom et a l, 2003). Additionally, 
tPA is known to play a role in excitotoxicity through enhancement of NMDA receptor 
signalling, possibly by cleavage of the NR1 subunit of the NMDA receptor (Nicole et 
al, 2001; Vivien et al, 2003). It was therefore of interest to investigate how these 
synaptic and dendritic proteins changed in tPA 7', uPAR7', PAI-1'7" and their respective 
WT mice throughout the course of EAE disease. This would allow further investigation 
into these proteins as markers for changes in synaptic and dendritic pathology in 
relation to measures of neuronal damage. Although MAP-2, synaptophysin, GAP-43 
and PSD-95 have been investigated previously in acute Lewis rat EAE (Zhu et al., 
2003), this model is largely monophasic and inflammatory in nature, lacking clear 
demyelination and axonal pathology (Ahmed et a l, 2001). Therefore levels of these 
proteins were investigated in the MOG-EAE and ABH chronic relapsing EAE model. 
The SCH-induced CREAE model shows more notable nerve pathology than the Lewis 
rat model (Baker et al, 1990; Jackson et al, 2005), as animals in the chronic phase of 
disease fail to relapse, but have accumulating neurological deficit and axonal pathology 
(Pryce et a l, 2003).
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7.2 Results.
7.2.1. Expression ofP SD -95 in the spinal cord  during EAE.
Immunohistochemical staining for the synaptic protein PSD-95 revealed some 
neuronal structures in the GM of control spinal cord sections, but very little staining in 
WM (Figure 7.1 A -  C and Figure 7.2 A and D). Following induction of MOG-EAE 
there was an increase in PSD-95 staining in the WM of sections from WT, tPA'7' and 
uPAR'7' mice at the acute stage of disease (20 dpi for WT and tPA'7' and 35 dpi for 
uPAR'7' mice). Following SCH induced CREAE there was also an increase in PSD-95 
staining in the WM of sections from ABH.PAI-1+/+ and ABH.PAI-1'7' mice at the acute 
stage of disease (15 dpi for PAI-1+7+ and 20 dpi for PAI-1'7' mice). PSD-95 was 
specifically localised in EAE tissue and the antibody against this protein reproducibly 
stained axons running through or around perivascular cuffs (Figure 7.1 D -  L and 
Figure 7.2 B, C, E -  G and J). . During the chronic phase of MOG-EAE at 60 dpi, 
there was little PSD-95 staining in sections from WT and tPA'7' mice (Figure 7.1 M and 
N), but there were still some axons stained surrounding perivascular cuffs in sections 
from uPAR'7' mice as a result of on-going inflammation (Figure 7.1 O). During the 
remission phase of CREAE at 30 dpi, there was little PSD-95 staining in sections from 
PAI-1+/+ mice (Figure 7.2 H) consistent with the relative lack of mononuclear cell 
infiltration, but there were still some axons stained surrounding perivascular cuffs in 
sections from PAI'7' mice in perivascular cuffs underlying ongoing inflammation 
(Figure 7.2 K). At 40 dpi in PAI-1+/+ mice undergoing a relapse, there was a further 
increase in PSD-95 staining on axons in the perivascular cuffs, however there was no 
axons visible in sections from PAI-1'7’ mice (Figure 7.2 I and L), which were not 
relapsing at the time of sampling.
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Figure 7.1. PSD-95 is localised to axons in perivascular cuffs in MOG-EAE tissue. Spinal cords 
removed from control and EAE mice were sectioned longitudinally. Frozen sections were stained with an 
antibody against PSD-95. Staining in sections from control mice revealed very little PSD-95 positive 
structures (A -  C), however in sections from EAE mice (D -  O), axons within perivascular infiltration 
were consistently strongly immunopositive for PSD-95. There were no differences between the 
genotypes. Original magnification xlOO (A -  C, M and N) and x 200 (D -  L and O).
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Figure 7.2. PSD-95 is localised to axons in perivascular cuffs in CREAE tissue. Spinal cords removed 
from control and CREAE mice were sectioned longitudinally. Frozen sections were stained with an 
antibody against PSD-95. Staining in sections from control mice revealed very little PSD-95 positive 
structures (A and D), however in sections from CREAE mice (B, C, E, F, G -  L), axons within 
perivascular cuffs were consistently strongly immunopositive for PSD-95. There were no differences 
between the genotypes. Original magnification xlOO (A, D, H and L) and x 200 (B, C, E, F, G, I - K).
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7.2.2. Expression o f  M AP-2 in the spinal cord  during EAE.
Western blotting for MAP-2 was performed using spinal cord protein extracts 
from normal control ABH mice, and mice during acute, remission and chronic stages of 
CREAE in ABH mice (at 20, 30 and 80 dpi respectively) (Figure 7.3 A). MAP-2 
protein was decreased significantly during the acute phase of CREAE at 20 dpi (P < 
0.01), however during disease remission at 30 dpi, levels of MAP-2 were not 
significantly different from controls but were significantly higher than levels at 20 dpi 
(P < 0.01; Figure 7.3 B). During the chronic stage of EAE, at 80 dpi, MAP-2 was lost 
again, and levels in the spinal cord were significantly lower than those in the CNS of 
control ABH mice (P < 0.05).
Immunocytochemistry for MAP-2 on spinal cord sections from control WT, 
tPA'7' and uPAR'7' mice on a C57BL/6 background showed staining of neuronal cell 
bodies in the GM, similarly in the different genotypes (Figure 7.4 A -  F). In sections 
from the acute phase of MOG-EAE, there was a reduction in density of staining, with 
fewer neuronal cell bodies (Figure 7.4 G -L), particularly in sections from tPA'7' mice 
(Figure 7.4 H). At 60 dpi of MOG-EAE, there was more staining in sections from 
u P A R m i c e  and WT mice when compared to that in sections from tPA'7' mice (Figure 
7.4 J -  L). Additionally there were hypertrophic neuronal cell bodies in the grey matter 
in sections from tPA'7’ and uPAR'7' mice, which were not observed in WT spinal cord 
sections. Western blotting on spinal cord protein extracts was used to quantitatively 
measure levels of MAP-2 in the CNS at different time points of MOG-EAE disease in 
the different genotypes (Figure 7.5 A). Levels of MAP-2 protein were comparable in 
control WT, tPA 7' and uPAR'7' mice. Following MOG-EAE induction, MAP-2 was 
significantly decreased in WT and tPA'7’ mice at 20 dpi (P < 0.01), such that no MAP-2 
could be detected in samples from mice at this time point (Figure 7.5 B). At 35 dpi, the 
peak of disease in uPAR’7" mice, levels of MAP-2 were also decreased, although this
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was not significantly different when compared to relevant controls. At 60 dpi, MAP-2 
levels had recovered slightly in WT and tPA'7' mice, however the amount of MAP-2 
protein was still significantly lower than those of control (P < 0.01). No MAP-2 was 
detected in the spinal cords of uPAR'7' mice at 60 dpi, (.P < 0.01 versus control). No 
significant differences were observed between the different genotypes at any of the time 
points.
Staining for MAP-2 protein in sections of spinal cord from ABH.PAI-1'7' and 
ABH.PAI-1+/+ control mice also revealed neuronal cell bodies in the GM (Figure 7.6i A 
and D). Following induction of CREAE, staining for MAP-2 was reduced particularly 
in sections from PAI-1+/+ mice at the peak of disease (15 dpi) and during relapse (40 
dpi) (Figure 7.6i B and C). At 20 and 40 dpi, staining for MAP-2 in sections from PAI- 
l '7' mice did not appear significantly different to that in controls (Figure 7.6i E and F). 
Western blotting on spinal cord protein extracts was used to quantitatively measure 
levels of MAP-2 in the CNS at different time points of CREAE disease in the different 
genotypes (Figure 7.6 ii). Levels of MAP-2 protein were comparable in control PAI- 
1+/+ and PAT7' mice (Figure 7.6 ii). At 15 dpi of CREAE, when PAI-1+/+ mice were in 
the peak acute phase of disease there was a decrease in MAP-2 in these mice although 
this was not significant. There were no changes in MAP-2 in PAI-1'7’ mice before 
disease onset, although during acute CREAE, there appeared to be a decrease but this 
failed to reach statistical significance. When both groups of mice were in disease 
remission, there was a subsequent increase in MAP-2 to levels that were comparable to 
controls. Following disease relapse in PAI-1+7+ mice there was a significant decrease in 
MAP-2 when compared to PAI-1+7+ controls {P < 0.05).
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Figure 7.4. MAP-2 staining is reduced in sections from MOG-EAE mice. Spinal cords removed from 
control and EAE mice were sectioned longitudinally. Frozen sections were stained with an antibody 
against MAP-2. Staining in sections from control mice revealed MAP-2 positive structures in the grey 
matter o f spinal cords (A -  F). In sections from EAE mice (G -  L), staining was reduced, particularly in 
sections from tPA /_ mice. Original magnification xlOO (A -  C) and x 400 (D -  L).
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Figure 7.5. Levels o f MAP-2 during MOG-EAE. A. Western blotting for MAP2 was performed on 
spinal cord protein extracts from normal non-injected and EAE animals using an anti-MAP-2 antibody. 
Blots were quantitatively measured by densitometry scanning and were re-probed with anti-actin to 
control for loading of proteins onto the gel. B. A significant loss of MAP-2 was seen in the acute phase 
of EAE particularly in WT and tPA'/_ mice. Levels of MAP-2 recovered slightly in WT and tPA'7' animals 
by 60 dpi but not in uPAR'/_ mice. Results are expressed as the mean ± SEM, n = 3 -  5, ** P < 0.01.
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Figure 7.6. Levels o f  MAP-2 during SCH-CREAE in ABH.PAI-1A and PAI-1+/+ mice, (i) Spinal cords 
removed from control (A and D) and EAE (B, C, E and F) mice were sectioned longitudinally. Frozen 
sections were stained with an antibody against MAP-2. In sections from CREAE mice, GM staining was 
reduced at 20 and 40 dpi in sections from PAI-1+/+ mice. Original magnification x 400. (ii) Western 
blotting for MAP2 was performed on spinal cord protein extracts from control and EAE animals. Blots 
were quantitatively measured by densitometry scanning. A loss o f MAP-2 was seen in the acute phase o f 
CREAE in both PAI-1'7 and PAI-1+/+ mice. Levels o f MAP-2 in recovered to near those o f controls 
during disease remission, however MAP-2 was significanlty decreased during relapse in PAI-1+/+ mice. 
Results are expressed as the mean ± SEM, n = 3. * P < 0.05.
7.2.3. Expression o f  synaptophysin in the spinal cord during EAE.
Western blotting for synaptophysin (Figure 7.7 A) revealed that there was a 
decrease in all samples from ABH mice during CREAE; however none of these changes 
were statistically significant (Figure 7.7 B).
Immunohistochemical staining for synaptophysin in sections from control 
C57BL/6 mice stained mostly GM in the spinal cord (Figure 7.8 A -  F), with some 
immunopositive neuronal cell bodies. In sections from WT, tPA'7' and uPAR'7' mice, on 
the C57BL/6 background, at the acute and chronic stages of MOG-EAE disease there 
were no apparent differences between staining in the genotypes at different time points 
(Figure 7.8 G -  L), although in sections from tPA'7' and uPAR'7' mice at 60 dpi, there 
were noticeable changes in the morphology of neuronal bodies, which appeared 
enlarged and hypertrophic when compared to those in sections from WT mice (Figure 
7.8 J -  L). Whilst Western blotting for synaptophysin revealed slight fluctuations in 
levels of the protein at different time points of MOG-EAE disease (Figure 7.9 A), there 
were no significant increases or decreases during MOG-EAE compared with controls, 
nor between the different genotypes (Figure 7.9 B).
Synaptophysin staining in sections from control ABH.PAI-1+/+ and ABH.PAI-1' 
7' mice stained GM neuronal cell bodies in the spinal cord (Figure 7.1 Oi A and D). In 
sections from PAI-1+/+ and PAI-1'7' mice at the acute, remission and relapse stages of 
CREAE disease there were no apparent differences between staining in the different 
genotypes at the different time points (Figure 7.1 Oi B, C, E and F). Western blotting for 
synaptophysin revealed no significant differences during CREAE compared with 
controls, nor between the different genotypes (Figure 7.10 ii).
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Figure 7.7. Western blotting o f synaptophysin during SCH-CREAE in ABH mice. A . Western blotting 
for synaptophysin was performed on spinal cord protein extracts from normal non-injected and CREAE 
animals using an anti-synaptophysin antibody. Blots were quantitatively measured by densitometry 
scanning and were re-probed with anti-actin to control for loading of proteins onto the gel. B . 
Synaptophysin protein did not change significantly throughout the course of CREAE disease. Results are 
expressed as the mean ± SEM, n = 3 - 5.
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Figure 7.8. Synaptophysin staining in sections from MOG-EAE mice. Spinal cords removed from control 
and EAE mice were sectioned longitudinally. Frozen sections were stained with an antibody against 
synaptophysin. Staining in sections from control mice revealed synaptophysin positive structures, 
localised in the grey matter (A -  F). In sections from EAE mice (G -  L), there were changes in the 
morphology o f cells with neuronal bodies appearing hypertrophic in tPA 7 and uPAR A mice. Original 
magnification x 100 (A -  C) and x 400 (D -  L).
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Figure 7.9. Levels o f synaptophysin during MOG-EAE. A. Western blotting for synaptophysin was 
performed on spinal cord protein extracts from normal non-injected and EAE animals using an anti- 
synaptophysin antibody. Blots were quantitatively measured by densitometry scanning and were re­
probed with anti-actin to control for loading of proteins onto the gel. B. No significant differences were 
seen in synaptophysin levels in WT, tPA'7' or uPAR/7’ mice following induction of MOG-EAE. Results 
are expressed as the mean ± SEM, n = 3.
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Figure 7.10. Levels o f  synaptophysin during SCH-CREAE in ABH PAI-Ta and WT mice, (i) Spinal cords 
removed from control and EAE mice were sectioned longitudinally. Frozen sections were stained with an 
antibody against synaptophysin. There were no obvious changes in synaptophysin staining and no 
apparent differences between the genotypes. Original magnification xlOO (A and D) and x 400 (B, C, E 
and F). (ii) Western blotting for synaptophysin was performed on spinal cord protein extracts from 
normal non-injected and CREAE animals using an anti-synaptophysin antibody. Blots were 
quantitatively measured by densitometry scanning. No significant differences were seen in synaptophysin 
levels in the acute, remission or relapse stages o f CREAE disease. Results are expressed as the mean ± 
SEM, n = 3.
7.2.4. Expression o f  GAP-43 in the spinal cord during EAE.
GAP-43 protein decreased over time in ABH mice as CREAE disease 
progressed (Figure 7.11 A and B). During the acute and remission phases of disease, at 
20 and 30 dpi respectively, GAP-43 was significantly decreased (P < 0.05) when 
compared to control. During remission, levels of GAP-43 were slightly lower than 
those during acute CREAE, however this was not significant. A highly significant 
decrease of GAP-43 was observed in samples from the spinal cords of mice at 80 dpi of 
CREAE, the chronic phase (P < 0.001). Additionally, this was also significantly lower 
than levels of GAP-43 during disease remission (P < 0.05).
There was a high density of immunohistochemical staining for GAP-43 in 
sections from control C57BL/6 mice, which could be largely located to axons in the 
WM of the spinal cord (Figure 7.12 A -  F). During acute EAE, at 20 dpi for WT and 
tPA'7' and 35 dpi for uPARv'mice, there was a decrease in GAP-43 staining in the spinal 
cord (Figure 7.12 G -  I), however it did not appear that there were any differences 
between the genotypes. Furthermore at 60 dpi, there were no apparent differences in 
GAP-43 staining between the genotypes (Figure 7.12 J -  L). To quantitatively measure 
levels of GAP-43, Western blotting was performed on spinal cord homogenates (Figure 
7.13 A). GAP-43 was significantly decreased in samples from WT and tPA’7' mice at 20 
dpi of MOG-EAE when compared to the relevant controls (Figure 7.13 B; P < 0.05). In 
WT mice at 60 dpi, levels of GAP-43 returned to amounts that were comparable to 
those of controls; however there was still a significant decrease in GAP-43 in tPA'7 
mice at 60 dpi which was significantly lower (P < 0.05) than levels in tPA'7' controls 
and significantly lower (P < 0.05) than levels in WT mice at 60 dpi. Although there 
were decreases in the level of GAP-43 in samples from uPAR"7’ mice at 35 and 60 dpi of 
EAE, these were not statistically significantly different to uPAR7 controls.
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Staining for GAP-43 in spinal cords from control and CREAE ABH.PAI-1+7+ 
and ABH.PAI-1'7' mice revealed no striking differences at different time points between 
the genotypes (Figure 7.14i A and D). There was a high density of 
immunohistochemical staining in all sections, which was located to axons in the WM of 
the spinal cord. During acute CREAE at 15 dpi for PAI-1+/+ and 20 dpi for PAI-1'7', 
there were apparent decreases in GAP-43 staining, particularly surrounding perivascular 
cuffs (Figure 7.14i B and E). At 40 dpi, there was evidence of increased GAP-43 
expression in PAI-1'7' mice, however GAP-43 staining in PAI-1+7+ mice was still 
reduced compared to that in sections from control mice (Figure 7.14i C and F). To 
quantitatively measure levels of GAP-43, Western blotting was performed on spinal 
cord homogenates. GAP-43 was lower in samples from control PAI-1'7' mice than 
control PAI-1+/+ mice, however this was not statistically significant (Figure 7.14 ii). 
There were no significant changes in levels of GAP-43 in PAI-1+7+ littermates at any 
stage during CREAE, although the trend suggested a decrease during acute and relapse 
stages with a slight recovery during disease remission. In samples from PAI-1'7' mice 
there was increases in GAP-43 pre-CREAE disease onset (15 dpi) and during disease 
remission. During the acute phase of disease there was a decrease in GAP-43 protein, 
which was similar to levels in control mice, but significantly lower than levels in mice 
from CREAE remission (P < 0.05).
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Figure 7.11. Western blotting o f GAP-43 during SCH-CREAE in ABH mice. A. Western blotting for 
GAP-43 was performed on spinal cord protein extracts from normal non-injected and CREAE animals 
using an anti-GAP-43 antibody. Blots were quantitatively measured by densitometry scanning and were 
re-probed with anti-actin to control for loading of proteins onto the gel. B. Levels of GAP-43 decreased 
over time as EAE progressed and levels during the chronic stages of CREAE were approximately a third 
of that of control mice. Results are expressed and the mean ± SEM, n = 3 - 5. * P < 0.05, *** P < 0.001 
versus control unless indicated by a bar.
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Figure 7.12. GAP-43 staining in sections from MOG-EAE mice. Spinal cords removed from control and 
EAE mice were sectioned longitudinally. Frozen sections were stained with an antibody against GAP-43. 
Staining in sections from control mice revealed GAP-43 positive structures, particularly in white matter 
(A -  F), however in sections from EAE mice, staining was reduced, although no apparent differences 
were obvious between the different genotypes. Original magnification xlOO (A -  C, J - L) and x 400 (D -
I).
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Figure 7.13. Levels o f GAP-43 during MOG-EAE. A. Western blotting for GAP-43 was performed on 
spinal cord protein extracts from normal non-injected and EAE animals using an anti-GAP-43 antibody. 
Blots were quantitatively measured by densitometry scanning and were re-probed with anti-actin to 
control for loading of proteins onto the gel. B. A significant loss of GAP-43 was seen in the acute phase 
of EAE in all three groups of mice. In WT mice at 60 dpi, levels of GAP-43 recovered to those of control 
mice however tPA'/_ and uPAR'/_ mice had sustained GAP-43 loss by 60 dpi. Results are expressed and 
the mean ± SEM, n = 3 - 5. * P < 0.05 against appropriate control unless indicated by a bar.
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Figure 7.14. Levels o f  GAP-43 during SCH-CREAE in ABH PAI-1^' and PAI-1+/+ WT mice, (i) Spinal 
cords removed from control and EAE mice were sectioned longitudinally. Frozen sections were stained 
with an antibody against GAP-43. In sections from CREAE mice, WM staining was slightly reduced, 
although no apparent differences were obvious between the different genotypes. Original magnification 
xlOO (A and D) and x 400 (B, C, E and F). (ii) Western blotting for GAP-43 was performed on spinal 
cord protein extracts from normal non-injected and EAE animals. Blots were quantitatively measured by 
densitometry scanning. Levels o f  GAP-43 decreased during acute and relapse stages o f  CREAE. A 
significanlt increase in GAP-43 was seen following disease remission in PAI-1 / mice compared to
levels during the acute phase o f  CREAE. Results are expressed and the mean ± SEM, n = 3. * P < 0.05.
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7.3. Discussion.
Expression of different synaptic and dendritic proteins has provided very useful 
tools to investigate axonal, neuronal and dendritic pathology in the CNS during EAE. 
During neuroinflammation notable changes were observed in axonal and dendritic 
proteins, which are primarily located in the white matter (WM), whilst grey matter 
(GM) synapses were relatively unaffected. Dendrites appear to be the one of the first 
structures affected by the inflammatory attack. Although this is initially reversible, a 
more permanent loss of dendritic proteins was observed following chronic disease. The 
capacity for axonal regeneration and plasticity decreased as EAE disease progressed, 
possibly reflecting neuronal loss and degeneration.
Specific upregulation of PSD-95 on axons in lesion areas indicates a role for this 
protein in WM axonal functioning, in addition to its role at the post-synaptic density. In 
contrast, no striking changes in the staining pattern for PSD-95 in the GM were 
observed here in MOG-EAE or CREAE tissue. Previous work has revealed a 
physiological role for PSD-95 showing that this protein can play a decisive role in 
controlling synaptic strength and activity-dependant plasticity (Beique and Andrade, 
2003; Migaud et al., 1998), thus upregulation of PSD-95 could be a mechanism to 
increase plasticity and remodelling around lesion areas. However Zhu et al, (2003) 
found a clear decrease in PSD-95 staining in the GM and WM of rat EAE spinal cord 
sections, which reportedly represented excessive NMDA receptor activation under 
excitotoxic conditions. One key difference in these experiments was the way in which 
the sections were prepared. In order to gain a semi-quantitative measurement of PSD- 
95 levels Western blotting would need to be carried out, but the antibody used here was 
not suitable for this application. Upregulation of PSD-95 could also reflect potentially 
damaging effects of this protein. PSD-95 promotes functional localisation of NMDA 
receptors by clustering at synapses, increasing their stability and glutamate signalling
(Kim and Sheng, 2004). Additionally PSD-95 couples NMDA receptors to neuronal 
nitric oxide synthase (nNOS), and excessive NO can have detrimental effects on axonal 
conductance (Kapoor et al., 2003).
PSD-95, in addition to clustering of NMDA receptors, also induces clustering of 
Kvl type potassium channels (Jugloff et al., 2000). Specific redistribution of Kvl 
potassium channels on neurons is a feature of axons in MS lesions and is observed 
during remyelination (Jugloff et al., 2000). Injured axons have increased expression of 
Kvl channels, and their distribution is changed to a more dispersed pattern along 
demyelinated axons (Nashmi and Fehlings, 2001). Specific expression of PSD-95 on 
axons in the area of perivascular cuffs during EAE could represent a mechanism for 
clustering of K+ channels, thus stabilising them by reducing their rate of 
intemalisation/endocytosis (Jugloff et al, 2000). In this way PSD-95 might aid in 
neuronal functioning by helping the axon maintain an action potential. However whilst 
this might help in the short term as an endogenous response to demyelination and 
axonal damage, K+ in the long term can be potentially harmful. Increased activity of K+ 
channels holds the membrane potential close to the equilibrium potential of K+ and 
results in axonal conduction block (Nashmi and Fehlings, 2001), and 4-aminopyridine 
(4-AP) a broad K+ channel blocker, has shown therapeutic potential in EAE and is 
currently in clinical trials for treatment of MS (Nashmi and Fehlings, 2001). Thus 
disruption of the PSD-95 interaction with K+ channels could provide a potentially 
therapeutic effect. Furthermore perturbation of the PSD-95-NMDA receptor link has 
proved to be beneficial in a model of ischaemic brain injury, by preventing downstream 
neurotoxic signalling (Aarts et al., 2002).
GAP-43 is a major constituent of the growth cone where it modulates the 
formation of new connections as well as in guiding the growth of axons. It is expressed 
by developing or regenerating axons and can serve as a marker for axonal sprouting thus
236
is considered to be an intrinsic determinant of the growth state of neurons (Benowitz 
and Routtenberg, 1997). GAP-43 expression is important for re-connectivity following 
a targeted EAE lesion in the spinal cord (Kerschensteiner et al, 2004). A decrease in 
GAP-43 over time in ABH mice during CREAE indicates that the environment was not 
conducive for regeneration or repair. From previous work, it is clear that ABH mice at 
80 dpi of CREAE have substantial neuronal loss (Jackson et al., 2005; Pryce et al., 
2003), thus significant loss of GAP-43 may also represented a decrease in plasticity and 
regeneration of axons. In the MOG-EAE model, a significant decrease in GAP-43 was 
only seen in tPA' '  mice at 60 dpi. Akassoglou et al., (2002) found that fibrin deposition 
and depletion did not affect axonal sprouting and elongation (as measured by GAP-43), 
and that the inhibitory effect of fibrin was on regeneration of the nerve. However in the 
CNS under neuroinflammatory conditions, GAP-43 expression was reduced in tPA'7' 
mice correlating with fibrin deposition and SMI32 staining, which could indicate that 
fibrin was creating a hostile environment for axonal sprouting and regeneration. Local 
reorganisation of synaptic connections can occur spontaneously in the CNS after injury 
(Kerschensteiner et a l, 2004). As tPA plays a key role in synaptic plasticity (Seeds et 
al., 1996), decreased GAP-43 in tPA'/_ mice could represent a decrease in levels of 
remodelling around lesion areas.
Demyelination would usually be associated with a reduced effect of myelin 
inhibition on neurite outgrowth in and around lesion areas by molecules such a Nogo-A, 
leading to an increase in GAP-43 expression (Kerschensteiner et al., 2004; Pot et al., 
2002). However, the negative correlation that should exist between GAP-43 and myelin 
did not appear in this study. This was probably as a result of significant axonal damage 
and degeneration, reducing the numbers of axons capable of sprouting new processes 
for reconnection and plasticity surrounding lesion areas.
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Dendrites are particularly susceptible to excitotoxic damage as they receive most 
of the synaptic inputs (Harris and Kater, 1994; Zhu et al, 2003). The dendritic marker 
MAP-2 was primarily located in the grey matter of sections in neuronal cell bodies 
whilst white matter dendrites were not clearly visible. Although some MAP-2 was lost 
in the GM, it is more likely that the loss seen in Western blotting was that lost in the 
WM and dendritic tree as this was the site of inflammation, demyelination and axonal 
damage. This suggests that excitotoxic mechanisms are playing a role in dendritic 
pathology in the MOG and CREAE models of neuroinflammation. However as there 
was no significant difference between the genotypes, it is unlikely that the PA system 
has a direct effect here on NMDA receptor function and signalling. Although MAP-2 
loss may be induced by excitotoxicity (Zhu et al., 2003), it remains to be determined 
whether fibrin, and exposure to other neurotoxic factors such as inflammatory 
cytokines, reactive oxygen species or proteases could also result in a decrease of this 
protein.
Similar to findings by Zhu et al., (2003), decreased levels of MAP-2 correlated 
with inflammation, and subsequently increased following disease recovery/remission. 
In ABH mice, loss of MAP-2 at 80 dpi, where mice had significant neurological deficit 
and movement impairment (Jackson et al., 2005; Pryce et al., 2003), eludes to a more 
permanent loss of MAP-2 as a result of dendritic degeneration. Frequent episodes of 
CNS inflammatory demyelinating attacks result in cumulative synaptic damage and 
transmission failure in WM dendrites and could possibly contribute to the movement 
dysfunction in EAE (Zhu et al, 2003). Additionally loss of MAP-2 may be an early 
indicator of neuronal dysfunction, and may precede neurodegeneration (Matesic and 
Lin, 1994). The total loss of MAP-2 protein in WT, tPA /_ and uPAR’ ' mice detected by 
Western blotting was a somewhat puzzling observation. This could not represent a total 
loss of spinal cord MAP-2 as the mice wouldn’t be able to survive. Additionally
238
staining for MAP2 was still seen in spinal cord sections by immunohistochemistry. 
However it could represent loss of the particular epitope of MAP-2 which the antibody 
detects. MAP-2 also contributes to dendritic remodelling and postsynaptic alterations 
that occur after specific lesions, and increased MAP-2 immunoreactivity during CREAE 
remission could be associated with axonal sprouting (Johnson and Jope, 1992).
No changes in levels of synaptophysin indicate that induction of CREAE or 
MOG-EAE does not significantly affect neurons at the synaptic level. Since most 
synapses are present in the GM, this is not entirely surprising as most EAE pathology is 
observed in the WM. These results contrast with findings by Zhu et al, (2003) who 
found a significant loss of synaptophysin, and another synaptic marker synapsin 1, with 
more significant reductions in the GM than WM. Although no changes were observed 
in mice during MOG-EAE, staining with the synaptophysin antibody in sections did 
reveal some hypertrophic neuronal cell bodies particularly in sections from t P A m i c e .  
Upon closer examination these cells showed signs of nuclei condensation, a sign of 
apoptosis, thus this could be a possible indicator of neuronal apoptosis.
In summary, whilst there is no definitive marker for axonal and neuronal 
degeneration, the synaptic and dendritic proteins investigated here could provide useful 
information on pathological changes in MS. This work supports the findings that 
neuronal/axonal dysfunction occurs early on during EAE, and is not just a feature of 
chronicity (Onuki et al, 2001). Additionally synaptic proteins are relatively unchanged 
revealing that CNS pathology in EAE mice affects preferentially the WM axons, with 
relative sparing of the GM and synaptic functioning. Finally, in the midst of looking for 
better, more accurate predicators of disease outcome, a potential therapeutic target has 
been revealed in PSD-95.
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8. Conclusions and Future work.
8.1. Conclusions.
The findings from the studies in this thesis have highlighted that manipulation of 
the PA system can affect outcome of neuroinflammatory disease. CREAE-induction in 
the ABH mouse has been previously characterised as a robust model of inflammatory 
demyelination. Investigation into the involvement of the PA system using this model 
revealed some important pathological similarities to MS, with increased PAI-1 synthesis 
and impairment of fibrinolysis as key features of disease. Fibrin deposition was 
associated with inflammation and persisted over time correlating with chronicity and 
neuronal degeneration. Additionally, analysis of dendritic proteins supported evidence 
that neuronal / axonal dysfunction occurs early in EAE disease, and is not just a feature 
of chronicity.
Induction of EAE with MOG peptide in tPA'7" mice led to a more severe clinical 
disease than wildtype mice thus revealing a protective and beneficial role for this 
enzyme during neuroinflammation. This contrasts with ischaemia and excitotoxicity 
where tPA has a detrimental effect on outcome. After further investigation, the 
protective role of tPA seems to occur through its ability to initiate plasmin-catalysed 
removal of CNS and axonal fibrin deposits. This also highlights the potentially 
damaging influence of fibrin, which could have a direct effect on axonal pathology, in 
addition to indirect actions via exacerbation of inflammation.
EAE induction in uPAR7' and PAI-17' revealed an involvement of these 
molecules in regulating cell migration and adhesion of leucocytes. Any interference of 
this unique system interrupts cell migration in the CNS, and delays disease onset. 
Another feature of EAE disease in PAI-1'7' mice was an enhanced fibrinolytic potential, 
which contributed to a reduction in disease severity and improved outcome in these 
mice.
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In conclusion, all three of these components of the PA cascade are implicated in 
the inflammation, demyelination and neurodegeneration characteristic of EAE and are 
capable of modulating clinical progression. Investigation into the role of tPA, uPAR 
and PAI-1 during neuroinflammation has revealed potential sites for therapeutic 
intervention. This study has suggested a major role for tPA in CNS fibrinolysis and 
highlighted the inhibitor PAI-1 as a potential target for disease modifying treatment. 
Interruption of the uPAR-PAI-l-VN link could prove to be another method of targeting 
and reducing cell migration into the CNS. Inhibition of PAI-1 could be therapeutically 
beneficial in treating MS. This would provide a dual palliative approach whereby 
leucocyte migration and inflammation are reduced, allowing efficient removal of fibrin, 
which could potentially decrease axonal/neuronal damage, and reduce frequency of 
disease relapses in MS patients.
8.2. Future work.
The work presented here is a step towards elucidating the role of the PA system 
during neuroinflammation, and highlights potential sites for therapeutic intervention. 
Additional experimental studies are needed to fully clarify to role of fibrin on axonal 
pathology and to further investigate the findings from this work.
Previous work by Inoue et al., (1996) and Akassoglou et al, (2004) has found 
that pharmacological and genetic depletion of fibrin is beneficial under experimental 
neuroinflammatory conditions. Additionally, removal of fibrin by ancrod aids neuronal 
regeneration and demyelination in a model of peripheral nerve injury (Akassoglou et al., 
2000). This has not however been investigated in the MOG or CREAE model, nor has 
it been looked at in tPA'7' mice. Treating tPA'7' mice with ancrod would determine 
whether removing fibrin could rescue these mice from the more severe disease and what 
effect it would have in CREAE in ABH mice.
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To confirm the localisation and deposition of fibrin on axons in lesions, electron 
microscopial studies are required. Investigation into whether fibrin(ogen), fibrin or 
FDPs has a direct or indirect toxic effect on neurons and whether is it capable of 
activating microglia in the same way that it can activate macrophages (Akassoglou et 
al., 2004) could be done by in vitro studies. Adding fibrin to microglial cultures would 
assess its affect on microglial activation, and adding the conditioned medium to 
neuronal cultures would assess a potential indirect toxic effect. Additionally by using 
these techniques in cultures derived from the different knockout mice, it could be 
revealed whether neurons from tPA'7' mice are more susceptible to fibrin induced 
toxicity. Furthermore, it would be of interest to determine whether fibrin(ogen), fibrin 
matrix or FDPs affect the migration and remyelinating properties of oligodendrocyte 
precursors cells as in the PNS with Schwann cells (Akassoglou et al., 2002).
To further investigate the mechanisms involved in uPAR mediated cell 
migration, and to determine which cell types are particularly affected by lack of uPAR, 
a series of experiments could be carried out. Using a transfer EAE protocol, 
encephalitogenic T cells from uPAR'7' mice, either from sensitised animals or 
propagated in vitro, could be injected into WT recipients. This would determine 
whether uPAR was affecting T lymphocyte migration/adhesion into the CNS and if this 
accounted for the differences in clinical pictures observed between the WT and uPAR'7' 
mice. It would be interesting to see if cells from uPAR'7' mice injected into WT mice 
would produce a disease similar to that in uPAR'7' mice and whether T-cells from WT 
mice, would produce a WT-like disease course in uPAR7' mice. Additionally cell 
migration and adhesion assays could be carried out to determine which cells are affected 
by the absence of uPAR or PAI-1. For example T-lymphocytes, peritoneal 
macrophages, and microglia could be isolated from the different genotypes and the cell 
migration capabilities of these different cells compared.
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The plasminogen activator system is linked with the MMP cascade as plasmin 
can activate several of the enzymes. In the absence of tPA, with a reduction in 
plasminogen activation there could potentially be a reduction in MMP-3 activation. 
Furthermore, in PAI-1'7' mice, there is a higher degree of plasminogen activation, 
possibly leading to excessive MMP activation, which could ultimately have detrimental 
effects during inflammatory demyelination. Investigation into levels of different MMP 
enzymes, particularly MMPs 3, 7 and 9 in the different knockout mice would determine 
how the link between these two systems is changed during EAE in the different 
knockout mice. This could be done by western blotting, using non-reducing conditions 
to identify native and complexed enzymes. Additionally, activity assays could be 
carried out to further characterise this.
To clarify and expand on the findings in the PAI-1'7' mice, there are several 
experiments that could be carried out. Firstly a tPA activity assay could be performed 
in order to confirm that increased tPA during EAE is reflected by an increase in activity 
due the absence of PAI-1. Furthermore, by investigating levels of PAI-2, it could be 
determined whether this serpin is compensating for lack of PAI-1. This could be done 
by Western blotting. Additionally levels of the plasmin inhibitor, ot2-AP could be 
investigated, to establish whether enhanced tPA activity is controlled at the level of 
plasmin activity.
Investigations into the staining for other TJ proteins including claudin-3 would 
clarify whether these junctions are kept intact during CREAE and MOG-EAE, or if the 
proteins already examined, i.e. claudin-5 and occludin, are specifically unaffected 
during infiltration of inflammatory mononuclear cells into the CNS. Additionally, the 
localisation and expression of these proteins during CREAE in ABH mice have not 
previously been investigated. This would also enable more detailed investigation to 
how these proteins change over time, as EAE progresses, and would aid in determining
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whether TJ disruption, if it occurs, happens during the primary inflammatory attack, or 
whether it occurs following secondary damage. Looking at staining for ZO-1, a TJ 
accessory protein might provide additional information on mechanisms of TJ disruption, 
as ZO-1 is a ligand for MMP-9 (Harkness et al., 2000).
Further characterisation of the findings with PSD-95 is necessary to confirm the 
axonal localisation. Double staining of PSD-95 with SMI-32 or myelin would allow 
identification of which subset of axons in the perivascular cuff region are stained. PSD- 
95 might only be upregulated on demyelinated, damaged axons. Additionally, Western 
blotting and densitometry analysis would enable a semi-quantitative analysis of the 
levels of PSD-95 and how they change over the course of EAE disease progression. 
Glutamate antagonists acting at the NMDA receptors have been shown to be beneficial 
in EAE, however are associated with severe side effects in the clinic (Paul and Bolton, 
2002). Thus new and different ways to disrupt NMDA receptor mediated neurotoxicity 
without interfering with normal receptor functioning are being sought. An interesting 
experiment would be to disrupt the PSD-95-NMDA receptor link by injection with a 
specific peptide to see how this would affect onset and development of EAE disease. 
This strategy has been shown to be protective in a model of ischaemia (Aarts et al, 
2002), and could be beneficial in treating neuroinflammatory conditions.
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